EDGAR 10-K Filing

Company CIK: 1575295
Filing Year: 2024
Filename: 1575295_10-K_2024_0001477932-24-008119.json

---

ITEM 1. BUSINESS
Item 1. Business.
Our Company
Allied Corp. is an international cannabis company with its main production center in Colombia, is one of the few companies that has exported from Colombia internationally, and among the first company to export commercial cannabis flower from Colombia. By leveraging the Colombian advantages and its Canadian cannabis cultivation expertise, Allied offers consistent supply of premium cannabis product at scale and attractive prices, while meeting high quality standards, thus significantly de-risking its partners supply chain.
Our mission is to be a consistent and reliable supplier of high-quality medical cannabis to pharmaceutical companies globally. We aim to make cannabis a primary source of medicine accessible to all and improve patient lives throughout the world.
Historical Company Information
We were incorporated in the State of Nevada on February 3, 2013 under the name “Cosmo Ventures, Inc.” On July 1, 2019 the Company filed a Certificate of Amendment with Nevada changing the name to Allied Corp.
Effective July 25, 2019 the Company entered into a Stock Purchase and Reorganization Agreement with AM (Advanced Micro) Biosciences, Inc., a British Columbia Canada corporation. Upon completion of the closing effective September 10, 2019, AM (Advanced Micro) Biosciences became a wholly-owned operating subsidiary of the Company.
References in this Offering Circular to “Allied” or the “Company” may include references to the operations of our subsidiaries AM (Advanced Micro) Biosciences, Inc., Allied Corp Colombia S.A.S., and Allied US Products, LLC. All of these entities are 100% wholly owned subsidiaries of Allied.
The Company’s principal corporate office is located at 200-460 Doyle Ave, Kelowna, British Columbia, Canada, V1Y OC2. Our telephone number is (877) 255-4337. Our email is ir@allied.health.
Our Opportunity
We focus on the development of Colombian produced medicinal cannabis for patients with conditions potentially suitable for treatment therewith. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI).
Our objective is to be a company that controls its own international vertically integrated supply chain, in order to maximize cash flow and profit margins. Our management team believes that having control over our supply chain should enable us to provide a consistent, rolling-harvest supply to the global cannabis community.
Based on our historical cannabis production and on the production of other companies in the same region, our anticipated direct agricultural cost of raw flower is estimated to be in the range of $0.05 to $0.12 per gram. Given the average cost of production in North America is approximately $1.00 to $2.00 per gram, we believe our low production costs provide us with a competitive advantage.
In addition to what we consider as our demonstrated ability to cultivate low-cost and high margin cannabis in Colombia primarily for international distribution, we have received commercial approval for sale of medical cannabis being produced in Colombia for export internationally. Our commitment to building and maintaining strong relationships with its partners and customers around the world has been a driving force behind its recent successes. The Company is dedicated to meeting the evolving needs of patients and healthcare professionals with its high-quality medical cannabis products, underpinned by rigorous quality standards and ethical cultivation & processing practices.
We intend for our clients to access superior cannabis-related products developed with a high level of quality control. The Company believes that it is fortunate to have assembled a team of industry veterans and management professionals with the background and experience to enable the Company to build, manage and grow such systems.
Key Strategic Objectives
Scale cannabis production in Colombia
We believe our Bucaramanga, Colombia development and cultivation facility gives us a significant competitive advantage in our production of cannabis. In fact, Allied has established a track-record of producing high-quality product with consistent supply year-round at scale, while meeting European quality assurance. Most importantly, Allied has successfully executed on several shipments from Colombia. Notable achievements include:
·
We have constructed a one-hectare greenhouse, with 5 hectares of space under production. Of these five hectares, we have approximately 3 in production and 2 hectares for working and cannabis processing space and storage. We have the ability to expand to an additional 20 hectares if and when it is needed.
·
We are licensed to produce, extract, import and export psychoactive and non-psychoactive strains of cannabis.
·
Each of our ten non-psychoactive CBD seed strains, and our ten THC seed strains submitted to ICA have been approved over a course of a process that began in October 2019.
·
We obtained commercial approval for production of non-psychoactive cannabis in October 2020, and commercial approval for production of psychoactive cannabis in February 2021.
·
We completed our first harvest in July 2020 for the Colombian Ministry of Agriculture (“ICA”).
·
We were approved to export cannabis derivatives by the Colombian government in April 2021.
·
In April 2022, Colombia opened the opportunity for companies to export dried cannabis flower. Up until this date, only cannabis derivatives were allowed. Allied immediately applied for the first export. We only sell and ship Colombia produced cannabis flower to countries where it is legal to do so.
·
In September 2022, we harvested our first psychoactive THC harvest of 2,200 plants. In October 2023, we harvested an additional 6,100 plants. These have been dried and cured and are to be tested before being offered to sale and export. The production pipeline has additional work packages of approximately 6,000 plants every three weeks.
·
We applied for a psychoactive quota for the equivalent of 8,000 kgs of psychoactive flower in 2021. Non- psychoactive production and sales are limitless under current Colombian law.
·
Allied has demonstrated its ability to harvest up to 1000 kgs per month of high-quality cannabis flower. Since June 2023, it has scaled down production to approximately 600-800 flowers per month as it was reaching the end of its quota.
·
In late August 2023, Allied was granted an increase of its THC cannabis flower quota, expanding from 8,000kgs to 50,000 kgs of THC cannabis flower; of which 5,000kgs will be used for THC derivatives production.
·
Allied has access to scalable land holdings in what it considers to be one of Colombia’s best suited climates for Cannabis production in the order of 200 acres.
·
On November 3, 2023, Allied successfully shipped THC based medical cannabis flower from its cultivation and processing facilities located in Colombia pursuant to Forward Purchasing Agreements with Australian purchasers.
·
On November 9, 2023, Allied entered into a Term Sheet for Contract Manufacturing Services with Blossom Pharmaceuticals, a EU-GMP certified partner in Portugal that will enable Allied to be able to offer Colombia produced flower with the EU-GMP (good manufacturing practices) approved certifications. As this partner is located in Portugal this flower will be positioned to be offered in European countries, as well as Australia.
·
In late May 2024, Allied successfully completed an international shipment of 180 kilograms of medical cannabis from Colombia, split between THC and CBD. This shipment, which cleared customs, fulfills a purchase order with an EU-GMP manufacturer and establishes a proven route for future transactions.
·
On September 24, 2024, Allied released its first GMP-certified medical cannabis batch into the European market. Allied’s Colombian-grown cannabis flower is now available in Switzerland through PhytoXtract SA as a magistral medicinal product.
·
On September 26, 2024, Allied entered into a Forward Purchase Agreement with CanPoland Spolka Akeyina and Blossom Genetics Lda pursuant to which the Company will sell THC and CBD medical grade cannabis and related products, manufactured by Blossom Genetics Lda, to CanPoland for sale in Poland.
·
In late November 2024, Allied completed the successful shipment of 30kgs of THC-based medical cannabis to Blossom Pharmaceuticals. This shipment marks the start of fulfilling a 3-year supply agreement with a UK licensed medical cannabis distributor, expected to generate at least €360,000 annually starting Q1 2025. Additionally, Allied secured a €15.3 million, 5-year agreement with Canpoland, committing to supply 1.05 tons of cannabis flower annually to Poland.
Since we received cultivation approval from ICA, we have developed what we consider to be competitive advantages of Yield, Cannabinoid Potency, Quality, Cost, Frequency of Harvests, and, notably have:
·
Yield-Continually increased our yields per hectare.
·
Potency-Increased and replicated the THC and CBD yields of our plant/seed strains.
·
Cost-Reduced our direct agricultural cost of raw flower production to as little as $0.05 - $0.075 per gram based on historical production of ours and other companies in the same region. This is favorably compared to the estimated North American production costs of between $1.00 and $2.00 per gram that we have observed.
·
Quality-Met or Exceeded European Pharmacopeia Standards.
·
Frequency of Harvest - We currently have rolling harvests, with ten to twelve harvests per year in order to maximize our production footprint. Consequently, each hectare at our Colombian cultivation site is expected to produce the equivalent of ten to twelve hectares of cannabis on a mono-crop yearly cycle. (See-Cannabis Production-Colombia).
Allied’s recent successes are underpinned by what we consider to be one of Colombia’s leading agricultural genetics teams for cannabis production, combined with a strong pharmaceutical background. In fact, Allied’s production team is led by Canadian cultivation and genetics experts with over 30 years of production expertise. The Canadian cultivation team is joined by an existing Colombian agronomical science team who managed 8,000 hectares of rice plantations in Colombia, bringing an unmatched advantage and experience in understanding local growing conditions and best agronomy practices. Moreover, the cultivation team is supported by a strong pharmaceutical background, with Allied’s CEO having over 10 years of experience managing hospital quality assurance programs. The aim is to bring the hospital and pharma background to the standard operating procedures and quality assurance of its Colombian based production.
Allied has now executed on Part 1 (site identification and setup) and Part 2 (cultivation and export) of its plan. With this strong foundation, it is now implementing Part 3 of its journey: while continuing to leverage its Colombian cost advantages, cultivation know-how and pharma expertise, Allied is now focusing on distribution and commercialization to become the most reliable global wholesale cannabis supplier.
Establish Relationships with Multi State Operators in the United States for if/when federally legalized
At Allied Corp, our strategic vision extends far beyond geographical boundaries, as we proudly direct our focus towards the international burgeoning cannabis industry. While the United States cannabis market undoubtedly holds immense potential, the Board of Directors have strategically made the decision to allocate all our financial and human resources to the expansive fields of Colombia, where we are dedicated to the large-scale production of premium cannabis for international markets. By leveraging the favorable legal landscape in Colombia, we position ourselves as key players in the global cannabis trade, ensuring that our products reach regions where their sale is legally sanctioned. Our commitment to excellence in cultivation, coupled with our dedication to navigating international legal frameworks, defines Allied Corp as a trailblazer in the ever-evolving landscape of the cannabis industry.
Our wholly owned subsidiary, Allied US Products LLC, a Nevada limited liability company, intends to lease land and acquire licenses for production upon on the occurrence or waiver of the changes in U.S. federal law to permit the general cultivation, distribution and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States. We will only conduct business activities related to growing or processing cannabis in jurisdictions, including the United States, when it is federally permissible to do so. While we have several arrangements with United States based companies that may themselves participate in the United States cannabis market, these relationships do not violate the federal laws of the United States respecting cannabis and in no manner involve us in any activities in the United States respecting cannabis.
The Company is now focusing its efforts on its cultivation in Colombia and as such, United States production is currently not an area of priority to the business and little progress has been made on this front.
Generate Revenues from Natural Health Products containing Hemp-based CBD
In a decisive move aimed at maximizing our global impact, the Board of Directors at Allied Corp has strategically chosen to channel all available resources into the vibrant landscape of Colombia. This pivotal decision reflects our commitment to positioning Allied Corp as a major player in the international cannabis market. By concentrating our financial and human resources on large-scale commercial cannabis production in Colombia, we align ourselves with a jurisdiction that not only offers a conducive environment for cultivation but also presents opportunities to cater to the growing demand for cannabis products in regions where legality supports its trade. This strategic reallocation underscores our dedication to fostering sustainable growth and global prominence in the dynamic cannabis industry.
The Company is now focusing its efforts on its cultivation in Colombia and as such, it is not an area of priority to the business and little progress has been made on this front.
Complete trials of ALID 11, 11 and Psilonex™ Prescription Medications
In response to fiscal constraints, Allied Corp has taken a proactive approach by temporarily pausing our ongoing clinical trials for ALID-11, 11 and Psilonex. This strategic decision allows us to reallocate all available resources towards the large-scale production of cannabis in Colombia. While clinical trials are invaluable for advancing our understanding of cannabis's medicinal potential, we recognize the importance of adapting to current financial circumstances. By focusing on the cultivation and production of high-quality cannabis in Colombia, we aim to capitalize on the robust international market demand while addressing fiscal challenges. This temporary shift underscores our commitment to flexibility and resilience, ensuring that Allied Corp remains at the forefront of the global cannabis industry despite current constraints on clinical trial endeavors.
We completed our clinical Phase 1 pharma trials in 2021, eventually leading to a drug indication for PTSD. However, the Company is now focusing its efforts on its cultivation in Colombia and as such, these clinical trials are not an area of priority to the business and little progress has been made on this front.
Commercial Expansion and Distribution
Our goal is to become a market leader and reliable partner in the cultivation and processing of medicinal-grade cannabis oil and high-quality cannabis derived medical products for large channel distributors. The Board of Directors has made a conscious decision to prioritize and direct all available resources toward the success of our Colombian production and operations, as well as commercialization of our high-quality Colombian cannabis. Once profitability is realized and our position in the market is strengthened, Allied Corp, at the discretion of the Board of Directors, will seamlessly transition to capitalize on the previously developed brands and products, expand its geographic footprint, continue to explore strategic partnerships and pursue accretive acquisitions to supplement our organic growth. For the time being, the key focus is on Commercial expansion and distribution.
Allied has already successfully executed on Part 1 (Site Set up) and Part 2 (Cultivation / Export) of its plan. On this strong foundation, we are entering Part 3: Distribution to accelerate market entry and become a global leader in the supply of wholesale cannabis. Since 2022 and throughout 2024, the Company has been focusing its efforts on building the baseline partnerships and infrastructure to enable its commercial efforts by focusing on the following segments:
·
Partnerships: Secure partnerships across the supply chain (cultivators, manufacturers and distributors) to accelerate product sale and market entry, as well as enable Allied’s product lines in key jurisdictions. For instance, Allied announced in April 2023, a joint venture with Blueberries Medical in Colombia to expand its product offering into extracts and enable sale of derivative products in new markets. Similarly, in May 2023, the Company announced a new partnership with a GMP manufacturer in Switzerland allowing for the sale of both flower and extracts into countries like Germany and UK, among others.
·
Certification: Allied has identified the need to secure CUMCS (including Euro GACP) and IMC GAP Audits and licensing to enter countries such as Israel, as well as facilitate its supply chain going forward. Throughout 2023 and 2024, the Company has begun pre-audit work and is in the process of planning an audit date for the near future.
·
Commercial team expansion: In September 2023, the Company has made strategic additions to its commercial team with the appointment of a new Chief Business Development Officer and a VP of Global Sales. Allied Corp has also Contracted a Cannabis Sales and Go-To-Market Consulting Group set to equip and guide Allied Corp’s sales efforts while validating and extending its go-to-market strategy for an appropriate targeted approach.
·
Sales Pipeline: Allied has continued to develop its sales pipeline in key markets of Germany, Poland, UK, Australia and Latam.
These efforts have culminated in the announcement of two commercial shipments of THC based medical cannabis from Colombia to Australia in November 2023. This achievement is a testament to the Company’s ability to comply with one of the world’s most stringent quality standards set by the Australian Therapeutics Goods Association (TGA) and unwavering commitment to providing high-quality medical cannabis products worldwide.
With demonstrated success’ in cultivation, meeting pharmaceutical requirements and now a strong commercial foundation, Allied has entered an exciting phase of commercialization since the start of 2024, where the focus has been on closing long-term recurrent contracts with minimum yearly commitments to secure its cash flow. Notable contracts that have been closed include :
·
Polish Distributor (Sep-24) : Allied signed a 5-year exclusive forward purchase agreement with Canpoland, a leading Polish distributor, worth 15m EUR. Allied will deliver 1,05 Tons of premium Colombian-grown cannabis flower annually to Poland through its EU-GMP manufacturing partner in Portugal, Blossom Genetics. The first delivery is expected Q3 2025.
·
UK - Distributor (Feb-24) : Allied has executed a three-year sales and distribution agreement for the UK market with yearly minimum of 200kg and MOQs expected to generate 360,000 EUR per annum.
·
Australian Manufacturer (Mar-24) : Master Agreement with an EU-GMP manufacturer with leading distribution capabilities in its territories including telehealth clinics and pharmaceutical distributors, that sets the terms and conditions for cannabis sales. The first Purchase Order was signed and executed on for 180kg of medical cannabis from Colombia, equally split between THC and CBD.
·
International Distributor (Feb-24) :Allied has signed a forward purchase agreement to supply an international distributor with THC flower, across 3 years. Allied had already completed a test shipment for this same partner in Q4 2023 and this contract is a testament of customer satisfaction. The buyer has since failed on his obligations towards the contract and both parties have decided to terminate the agreement.
Since, the company has also announced several shipments to channel partners and end clients to execute on its commercial contracts and initiate new supply chains :
·
80kg to PhytoXtract (Mar-24) : Shipment to Allied’s Swiss-GMP manufacturer for further flower and extract sale into Switzerland and Europe, which require GMP manufacturing. Allied’s first GMP smokeable flower batch has since been manufactured and approved for sale in Switzerland, marking a significant milestone for the business.
·
180kg to Australian Manufacturer (May-24) :Allied has successfully shipped to Australia, fulfilling the previously announced purchase order of 180kgs. The client has since received permits for further imports from Allied, paving the way for a future order.
·
30kg to Portuguese Channel Partner (Nov-24) : Allied has completed a shipment of 30kgs of THC-based medical cannabis to Blossom Pharmaceuticals, its EU-GMP Manufacturing Partner in Portugal. The product, which has started to be manufactured by Blossom, is destined to begin satisfying a sales agreement announced in early 2024 with a UK licensed medical cannabis distributor. The first product is expected to be delivered in Q1 2025.
The successful passing of audits and the commencement of commercial shipments reflect Allied's commitment to excellence, compliance, and reliability in meeting the demands of its international clientele. Most importantly, the business is demonstrating that it can not only sign commercial agreements, but also execute on delivery and be a reliable partner to navigate the complex medical cannabis supply chain.
Eventually explore strategic partnerships
Following the attainment of company profitability through the successful production and sales of Colombian-grown cannabis, Allied Corp is poised to strategically resume its focus on natural health products and brands. This phased approach reflects our commitment to diversification and innovation within the evolving landscape of the cannabis industry. Having established a strong foundation through the lucrative Colombian cannabis market, we plan to integrate natural health products seamlessly into our portfolio, leveraging the knowledge and expertise gained from our initial successes. This complementary strategy aligns with our vision to not only contribute significantly to the international cannabis market but also to broaden our offerings to cater to a broader spectrum of health and wellness needs. As Allied Corp continues to navigate and thrive in dynamic market conditions, our dedication to excellence and adaptability remains unwavering.
Because we offer a variety of cannabis related products, including beauty and skincare products, foods and beverages, we believe that we can create a competitive advantage by partnering with national and multinational companies, across various product categories to jointly develop and market branded cannabis offerings.
Pursue accretive acquisitions
We believe that our deal-making capabilities and experience will allow us to successfully identify, consummate and integrate acquisitions. The cannabis industry is highly fragmented and as it continues to evolve, we expect significant industry consolidation in existing and new markets. Our deal-making capabilities and experience may allow us to successfully identify, consummate and integrate acquisitions. As a public company, we could have greater ability to finance acquisitions, including through using our equity as consideration and accessing the capital markets.
Due to the competitive and dynamic nature of the emerging cannabis products market and rapid changes in the regulatory environment, we recognize the need to remain flexible, so we can react to opportunities and risks as they develop. We will continue to re-evaluate and re-prioritize our strategies to respond to these developments. We are actively fostering a culture of continued agility and exploration since the ability to pivot depending on market dynamics will deliver competitive advantage.
Our CBD Brands and Products
While the extensive brand and product development initiatives undertaken by Allied Corp remain invaluable, the Company is strategically deferring the pursuit of these opportunities until after achieving profitability from the sale of its Colombia-produced cannabis. The Board of Directors has made a conscious decision to prioritize and direct all available resources toward the success of our Colombian operations. This focused approach underscores our commitment to establishing a solid foundation in the global cannabis market through the large-scale production and sale of high-quality Colombian cannabis. Once profitability is realized and our position in the market is strengthened, Allied Corp will seamlessly transition to capitalize on the previously developed brands and products, leveraging the groundwork laid during this strategic phase. This approach reflects our dedication to a methodical and phased growth strategy, ensuring sustained success and longevity in the ever-evolving cannabis industry.
Over the past years we have developed, manufactured and test marketed all of our hemp derived CBD products for sale in the United States. Under the Farm Bill of December 2018, the use and sale of hemp derived CBD products in the United States is legal.
The Company is now focusing its efforts on its cultivation in Colombia and as such, the development and commercialization of Allied’s brands described above is not an area of priority and little progress has been made on this front.
Pharmacologic Products
While the development and licensing of pharmaceutical products presents a compelling avenue with significant future revenue potential for Allied Corp, the Company has made a strategic decision to temporarily direct all resources toward the production and sales of Colombian cannabis. This focused approach is aimed at capitalizing on the immediate opportunities in the rapidly growing cannabis market, particularly in Colombia. Once Allied achieves profitability from its Colombian cannabis operations, the Company intends to transition its attention back to advancing its work in pharmaceutical development. This strategic sequencing reflects Allied Corp's commitment to a phased and adaptable business strategy, ensuring that resources are deployed efficiently to address immediate market demands while maintaining a long-term vision for diversified revenue streams through pharmaceutical ventures. The temporary shift in focus underscores our dedication to strategic agility and the overarching goal of establishing Allied Corp as a formidable player in both the cannabis and pharmaceutical sectors. As such, this is no longer an area of focus to the business and very little progress has been made.
Allied was organized because our founders believed veterans and first responders suffering from Post-Traumatic Stress Disorder (“PTSD”) could have their underlying symptoms better addressed with targeted cannabinoid pharmacologic solutions. We entered into an agreement to purchase all common shares of Pacific Sun Fungi Inc. on January 24, 2021 which was subsequently amended and the acquisition later closed in March 2021. The primary business plan for acquiring Pacific Sun Fungi Inc. was to develop psilocybin-based solutions, including both potential pharmaceutical and natural health products, for those suffering from PTSD. At the direction of the Board of Directors we are currently focusing our business plan on development in Colombia and this project is on hold pending further company financing and/or success.
Products in Potential Development
Psilonex™
On March 25, 2021 we announced that we filed for trademark protection with the United States Patent Office for our pharmaceutical product Psilonex™. Psilonex™ is a proprietary formulation prescribed within a treatment path that involves both a pharmaceutical psilocybin-based formulation, followed by a daily cannabinoid maintenance period. Psilonex™ is intended to be prescribed by a physician, followed by the cannabinoid daily therapy that can be purchased by the consumer in regions where it is legal to do so as “Psilonex™ Daily,” Continued development of these projects is currently delayed while the Company focuses on development of our Colombia cannabis business.
The filed trademark protects our intellectual property for Psilonex™ covering: chemical preparations for pharmaceutical or medical purposes, namely, for treating depression, anxiety, and PTSD, and for improving mental health; nutraceuticals for the treatment of mental health disorders and conditions, including depression, anxiety, and PTSD; nutraceuticals for use as a dietary supplement; Nutraceuticals for use as a dietary supplement for improving mental health; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for the treatment and prevention of mental health disorders; Pharmaceuticals, namely, psychotropics; dietary and nutritional supplements; fungal extracts sold as a component ingredient of nutritional supplements and vitamins, and; related websites.
ALID 10 and ALID 11
ALID 10 and ALID 11 target the treatment of Post-Traumatic Stress Disorder and related mental health conditions through the targeted function of the 5-HT2 receptor and physiological pathways. Following the completion of the pre-clinical research phase, when we are financially capable we intend to bring ALID 10 and ALID 11 through human clinical trials through its relationships with the University of Haifa, Israel and MGC Pharma in Europe.
In 2020, we filed a United States provisional patent application entitled “Compositions and Methods for Modulating Endocannabinoid Systems Activity and Treating Mental Health Disorders”. The patent application covers ALID-10 and ALID-11, as well as other cannabis derived compounds designed for superior pharmaceutical properties for treatment of PTSD and other mental disorders.
In October 2019, we signed a Master Services Agreement with the University of Haifa, Israel. This academic research center gives us access to a proprietary pre-clinical animal model that is owned by Carmel. Carmel is the business unit that manages the University of Haifa center for Research in Israel. Specifically, we will use this proprietary animal model for the purposes of specialized pharmaceutical cannabinoid research and pharmaceutical product development. Through our agreement, we have access to the University of Haifa’s leading-edge facilities, proprietary animal model, pharmaceutical development, academic laboratory and associated scientists and investigators. This should enable us to conduct the pre-clinical phase of the development of a proprietary pharmaceutical product for ALID-10 and ALID-11.
In the second quarter of 2020, we expanded our ALID-10 and ALID-11 research activities, as well as entered into a manufacturing and sales agreement with MGC Pharmaceuticals of Australia (“MGC”). Under the terms of these agreements, MGC will manufacture our pharmaceutical products within their GMP (Good Manufacturing Practices) certified factory in Slovenia (which is in the European Union, or EU), which should enable us to have our pharmacological products produced under procedures and methods that meet those high-quality standards. In addition, the MGC sales and distribution agreement should provide us a channel to sell our products following the completion of a PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe, and. Moreover, we believe it has demonstrated a proven ability to commercialize cannabis based pharmaceutical products. We also announced the initiation of a pharmaceutical human clinical PHASE I research trial with MGC, but COVID-19 had an operational impact on the progression of this research trial.
Under the terms of our agreements with MGC, it will provide what we consider to be a comprehensive suite of pharmaceutical services to advance our pharmaceutical products into human clinical PHASE 1. This trial is expected to test the efficacy and pharmacodynamics of our pipeline of proprietary cannabis derived drug candidates targeting PTSD. The scope of MGC Pharma’s services is to cover clinical research, Investigational Medicinal Product (IMP) registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an IMP numbers that are needed in order for pharmaceutical products to be sold.
The Company is now focusing its efforts on its cultivation in Colombia and as such, the products in development described above are not an area of priority to the business and little progress has been made on this front.
Cannabis Production
Colombia
We believe our Bucaramanga, Colombia development and cultivation facility gives us a significant competitive advantage in our production and sales of cannabis. Allied has established a track-record of producing high-quality products with consistent supply year-round at scale, while meeting European quality assurance. Most importantly, the Company has successfully executed on several shipments from Colombia. Notable achievements include:
●
We are licensed to produce, extract, as well as both import and export psychoactive and non-psychoactive strains of cannabis.
●
We were approved to export cannabis by the Colombian government in April 2021.
●
We have constructed a one-hectare greenhouse, with 5 hectares of space under production. Of these five hectares, we have approximately 3 in production and 2 hectares for working and cannabis processing space and storage. We have the ability to expand to an additional 20 hectares if and when it is needed.
●
We completed our first harvest in July 2020 as part of the approval process for the Colombian Ministry of Agriculture (“ICA”).
●
We obtained commercial approval for production of non-psychoactive cannabis in October 2020, and commercial approval for production of psychoactive cannabis in February 2021.
●
Each of our ten non-psychoactive CBD seed strains, and our ten THC seed strains submitted to ICA have been approved over a course of a process that began in October 2019.
●
Lower production cost: Our anticipated direct agricultural cost of raw flower production is approximately $0.05 - $0.075 per gram based on historical production of ours and other companies in the same region, as favorably compared to the North American production costs of as opposed to most production between $1.00 and $2.00 per gram that we have observed.
●
Access to scalable land holdings in what we consider to be one of Colombia’s best suited climates for cannabis production in the order of 200 acres.
●
We have applied for a psychoactive quota for the equivalent of 8,000 kgs of psychoactive flower for 2021. Non psychoactive production and sales are limitless under current Colombian law.
●
We have engaged what we consider to be one of Colombia’s leading agricultural genetics teams for cannabis production.
●
In September 2022 we harvested our first psychoactive THC harvest of 2,200 plants. In October 2022, we harvested an additional 6,100 plants. These have been dried, cured and tested before being offered to sale and export. The production pipeline has additional work packages of approximately 6,000 plants every two to three weeks. We only sell and ship Colombia produced cannabis flower to countries where it is legal to do so.
●
Allied has demonstrated its ability to harvest up to 1000 kgs per month of high-quality cannabis flower. Since June 2023, it has scaled down production to 650 flowers per month as it was reaching the end of its quota.
●
In late August 2023, Allied was granted an increase of its THC cannabis flower quota, expanding from 8,000kgs to an impressive 50,000 kgs of THC cannabis flower; of which 5,000kgs will be used for THC derivatives production.
In the 2020 fiscal year, we activated our Colombian licenses that are required to produce, extract, import and export psychoactive and non-psychoactive cannabis. This has been a year-long process that began with the registration of our ten (10) novel strains with the national cultivar registry. Each strain was then germinated into plantlets in our cultivation center in Colombia. Following germination, the plants entered into five (5) months of field trials that included rigorous data collection, analysis and phenotyping of the strains while in the vegetation life cycle. During this time, the strains were provided with proprietary nutrients, handled with standard operating procedures and guided towards the plant flowering phase. Proprietary nutrients and procedures were also adhered to during the flowering phase and detailed batch record audit data were diligently collected during every day of the plant life cycle. Following flowering, the plants were harvested and tested for cannabinoid profiles and quality assurance testing parameters. The harvested material was then sent to several accredited testing laboratories and tested by high performance liquid chromatography testing methods. Testing was carried out in several labs for validation of the results regarding the accuracy of the cannabinoid profiles.
The lab results from the testing of the cannabis showed a higher cannabinoid profile from being grown in the Colombian climate when compared to the same strains grown in North American climate. The lab results, batch records and procedural archives were also submitted to the Colombian Institute of Agriculture and a day-long presentation was provided by our team. As a result of this process, we received approval for twenty novel strains (ten psychoactive, ten non-psychoactive) from the technical directorate of the Colombian Ministry of Agriculture, representing a diverse range of chemotypes with novel cannabinoid profiles.
Our production approach is designed according to the European Pharmacopeia, Good Agricultural Collection Practices (GACP) and Buenas Prácticas Agrícolas (BPA) standards. These standards meet South American, European, US and Canadian quality assurance standards for production of commercialization of cannabis.
In addition, in order to adhere to Canadian production regulations with respect to seed approval and strain-acclimatization, in Canada we have created research and development environments (under personal production licenses approved by the Canada Regulators) that mimic the micro-climates in Suesca, Ibague and Bucaramanga. We found Bucaramanga to have the best microclimate for production of our plant strains, and accordingly located our Colombian production there. We have stressed the strains with high temperatures and humidity levels to mimic the natural weather patterns in the areas in which we will be cultivating. This is designed to mitigate the acclimatization risk that we believe many peer companies are experiencing in Colombia.
Our Colombian Cultivation Results
On April 15, 2021 we shared an analysis of our Colombian production harvests. Over this period, we continued to harvest every 6-7 weeks, while adding to our inventory and expanding our analytic data set.
We have now cultivated several successive Colombian harvests with what we consider to be consistent results. The results showed increased production yield, higher cannabinoid percentages, high quality as measured by cannabinoid potency, as well and as low cost per gram production cost relative to North American production. Our lab results showed a higher cannabinoid profile from being grown in the Colombian climate when compared to similar genotypes of strains grown in North American climate. These lab results, batch records and procedural archives, were submitted to the Colombian Ministry of Agriculture during a day-long presentation by our team, which, in turn, resulted in the approval by the technical directorate of the Colombian Ministry of Agriculture for the ten THC (i.e., psychoactive) strains tested. We believe these THC strains represent a diverse range of chemotypes with novel psychoactive cannabinoid profiles.
In addition to the increase in grams produced per square meter, the cannabinoid percentages showed an increase when produced in Colombia when compared to North America. We have now cultivated several successive harvests with repeatable results. We believe these results suggest we have competitive advantages that we describe as Yield, Cannabinoid Potency, Quality, Cost, Frequency of Harvests.
Increased yield - Approaching One kilogram per Square Meter
We believe we have a proprietary approach to cultivation which fosters high yield production. Our first Colombian harvest yielded 424 grams per square meter of production space. The second harvest, 612 grams per square meter and third and fourth harvest resulted in yields of 684 grams and 893 grams per square meter respectively. The fifth and sixth harvest yielded 894 and 905 grams per square meter respectively. This has continued with this trend since 2022. We have started to enter into our production pipeline new genetics that have been registered and brought forth to first harvest in 2024. We believe this data shows that our team, is approaching its goal of one kilogram per square meter goal of production output.
Potency-Cannabinoid Production
In Colombia, per our internal testing we have achieved repeatable THC cannabinoid percentages of 29.08% in the psychoactive varieties and CBD percentages of 24.64%. With our continuous quality improvement program, these percentages have continued to increase. The data collected showed that these strain profiles showed a significant increase in cannabinoid content when comparing the output from our Colombian cultivation to our North American cultivation environments.
Direct Agricultural Costs - Approximately $0.05 - $0.075 per Gram
Our direct agricultural cost of raw flower production is anticipated to be $0.05 - $0.075 cents per gram based on historical production of ours and other companies in the same region. This presents a potential increased margin advantage to multi-state operators within the United States if and when we are able to sell cannabis to the United States, and potentially for wholesale buyers internationally. We believe we can reduce the cost of supply and improve margin for distributors in markets with costs of production between $1.00 - $2.00.
Quality - Meeting European Pharmacopeia (International) Standards
Our cultivation and production processes meet European Pharmacopeia, Good Agricultural Collection Practices (GACP) and Buenas Prácticas Agrícolas (BPA) standards with zero pesticide use, as they were designed from inception. These standards meet South American, European, US and Canadian quality assurance standards for production of commercialization of cannabis. Every cannabis plant is counted and audited during every day of its life cycle. Data collected includes temperature, humidity, pest and disease management indicators. All harvested material is tested for physical identity, aflatoxins, foreign body count, total aerobic plate count, total yeast, e coli, salmonella, bile tolerant gram-negative bacteria, cannabinoids, cadmium, lead, arsenic, mercury, terpenes and pesticides. All product is analyzed and approved based upon meeting thresholds for each of the testing parameters.
Frequency of Harvests: We Have Maintained Consistent Production with Consecutive Harvests every 6-7 weeks
Given the advantages that the equatorial climate of Colombia offers, we have been harvesting every 6-7 weeks, suggesting we should be able to offer reliably consistent supplies in large volumes to multiple markets simultaneously.
Success at Quality Assurance and Customer Vendor Qualification
Allied Corp takes pride in its proven track record of success, having successfully navigated the vendor qualification process with approximately a dozen different international cannabis and pharmaceutical companies. This rigorous process has involved thorough desktop audits of our Standard Operating Procedures (SOPs), virtual farm tours, in-person third-party neutral audits, and various other assessments-all of which Allied has passed. The meticulous scrutiny of our operations has been instrumental in establishing a high level of trust and credibility in the industry. The successful completion of these qualification processes play a preliminary role prior to discussing sales contracts. Allied Corp's commitment to transparency, quality, and compliance is reflected in these achievements, underscoring our dedication to maintaining the highest standards in the cannabis industry and fostering long-term partnerships with discerning companies.
Our Focused Cultivation and Cannabis Plant Development Approach
We received approval from the Colombian Ministry of Agriculture (“ICA”) for 100% compliance, or 20 out of 20 plant strains (10 CBD and 10 THC). ICA reported to us in February 2021 that we were the first company to do so. Our strains have both non-psychoactive and psychoactive varieties that have been legally cultivated both in North America and now in the South America. As a result, we have activated our Colombian licenses for production, extraction, importation and exportation of psychoactive and non-psychoactive cannabis.
This is the culmination of a year-long process that began with the registration of what, in our opinion, are our novel strains with the Colombian national cultivar registry. Each strain was then germinated into plantlets in our cultivation center in Colombia. Following germination, the plants were tested in field trials over five months of field trials that included data collection, analysis and phenotyping of the strains during the vegetation life cycle. These strains were given proprietary nutrients, handled with standard operating procedures guided towards the plant flowering phase, while detailed batch record audit data was collected every day of the plant life cycle. Following flowering, the plants were harvested and tested for cannabinoid profiles and quality assurance testing parameters. The harvested material was then sent to several (accredited testing laboratories and tested by liquid chromatography testing methods for validation of the accuracy of the cannabinoid profiles.
It should be noted that production is divided into two key types of products: (i) “non-psychoactive” means the strains and genetics with THC levels of less than 1% by weight (ii) “psychoactive” means the strains that have more than 1% THC by weight. Approval of psychoactive cultivation is much more complex than the non-psychoactive approvals in Colombia. In order for a Colombian licensed producer to gain approval to sell and export, the producer must first register their genetics, then go forth and cultivate a limited number of plants as a test harvest. Following the harvest, drying and extraction processing, the product is analyzed and presented to the Colombian Ministry of Agriculture; we have received the requisite approvals from the Colombian Government for each phase of its cannabis development and cultivation.
Our Path from Testing to Approved Cannabis Exports from Colombia
In October 2020 we were granted from the Colombian Ministry of Agriculture approval to begin the seed evaluation process for our ten non-psychoactive CBD strains. In addition, on April 29, 2021, the Ministry of Justice signed a resolution authorizing us to evaluate our Company’s proprietary strains in order for us to select THC psychoactive cannabis strains with the best commercial production characteristics. Along with our previous approval for non-psychoactive evaluation, our subsidiary Allied Colombia S.A.S. (“Allied Colombia”) could then evaluate all twenty of our psychoactive and non-psychoactive strains.
On October 15, 2020, we received approval from the Colombian Institute of Agriculture (“ICA”) for the cultivation and commercialization of each of our ten proprietary CBD non-psychoactive strains submitted within seed evaluation process which commenced a year earlier. Such enabled us to process and sell our Colombian CBD non-psychoactive production.
On March 9, 2021, we announced that we received ICA approval for the commercialization of its our proprietary THC psychoactive cannabis strains, which was the culmination of the evaluation process for which permission was granted in late April 2020. Each of our ten psychoactive strains were approved and we have passed all of the ICA requirements to be able to cultivate the resultant plants. As a result, we have has applied for a psychoactive export quota for both 2021 and 2022 under the Colombian regulatory regime. In late August 2023, Allied was granted an increase of its THC cannabis flower quota, expanding from 8,000kgs to an impressive 50,000 kgs of THC cannabis flower; of which 5,000kgs will be used for THC derivatives production.
On April 20, 2021 we received clearance from the Colombian authorities to export our derivative non- psychoactive cannabis-based products from our first harvest. This milestone was achieved after having undergone the testing and cultivation activities described immediately above herein, and having received the ICA and Colombian Ministry of Justice approvals and licenses described below. Moreover, on April 26, 2021, we received approval to export cannabis-based products to a second international market.
In a groundbreaking development in April 2022, Colombia announced its authorization for the export of locally produced cannabis flower, opening new horizons for the industry. Allied Corp promptly submitted an application, aiming to be at the forefront of this significant milestone. Allied emerged as the pioneer in June 2022 by successfully executing the first-ever export of dried Colombian cannabis flower. This accomplishment not only positions Allied as an industry trailblazer but also underscores our commitment to capitalizing on emerging opportunities in the dynamic global cannabis market.
Throughout the entirety of 2022, Allied Corp maintained a steadfast focus on cultivating and nurturing customer relationships, embarking on long international sales cycles to establish a strong market presence. This dedication extended into the early part of 2023, during which Allied underwent several audits and customer due diligence visits. Demonstrating the robustness of our operations, Allied successfully passed these assessments, garnering approvals that further solidify our credibility in the industry.
Building on these accomplishments, Allied has successfully exported and shipped the first commercial shipments. This marks a pivotal moment as the Company transitions from relationship-building and due diligence through to the ability to export and ship, and now will position itself to scale and enter into sales agreements. With these initial commercial shipments, Allied is poised to scale its operations, leveraging the groundwork laid in 2022 and early 2023 to make a lasting impact on the global cannabis market. The successful passing of audits and the commencement of shipments reflect Allied's commitment to excellence, compliance, and reliability in meeting the demands of its international clientele. For more information on Distribution, which occurred thereafter, please refer to section “Commercial Expansion and Distribution”.
Regulatory Matters
Colombia
Our cultivation operations are in Colombia and are conducted by Allied Colombia S.A.S., a wholly-owned subsidiary. As a cultivator of cannabis, the Company is substantially dependent on the licenses for cultivation, production and other regulatory activities, granted to Allied Colombia by Colombian governmental and regulatory bodies.
The following table summarizes regulations applicable to the cultivation, fabrication, import, export and use of cannabis in Colombia.
Regulation:
Regulates:
Law 1787 of 2016
Legalizes the use of Cannabis for medical and scientific purposes
Decree 613 of 2017 modifies Decree 780 of 2016
Regulates law 1787 establishing a licensing system and process. Defines psychoactive and non-psychoactive cannabis and the quota system for psychoactive cannabis in accordance with Single Convention of Narcotics of 1961 and amendments
Resolution 577 of 2017 from the Ministry of Justice
Regulates the evaluation and control of the following licenses:
a. Seed Use
b. Cultivation of psychoactive plants (High-THC cultivation license)
c. Cultivation of non-psychoactive plants (Low-THC cultivation license)
Creates requirement for security protocol
Resolution 578 of 2017 from the Ministry of Justice
Resolution 578 of 2017 from the Ministry of Justice Regulates the cost of the following licenses:
a. Seed Use
b. Cultivation of psychoactive plants (High-THC cultivation license)
c. Cultivation of non-psychoactive plants (Low-THC cultivation license)
Resolution 579 of 2017 from the Ministry of Justice
Establishes that growers that cultivate on a half a hectare area (5,000 square meters) or less are considered small and medium growers and, therefore, may access technical advice, priority allocation of quotas and purchase of their production by the processor and requires that 10 percent of the total production of the processor must come from small and medium producers.
Resolution 2892 of 2017 from the Ministry of Health
Regulates the evaluation and control of the Fabrication of Cannabis derivatives (High-THC Production License) Provides guidelines for appropriate security protocols for manufacturing cannabis derivatives including physical security, monitoring, detection, and incident reporting to authorities.
Resolution 2891 of 2017 from the Ministry of Health
Regulates the cost of the High-THC production License
Resolution 1478 of 2006 from the Ministry of Health modified by Resolution 315 of 2020.
Regulation of the control, monitoring and surveillance of the import, export, processing, synthesis, manufacture, distribution, dispensing, purchase, sale, destruction and use of controlled substances, medicines or products containing them and on those which are State Monopoly
Decree 2200 of 2005 from the Ministry of Health
Regulates pharmaceutical services including the Magistral Preparations
Guidelines for the GEP certification for Magistral Preparations with Cannabis issued the 25 of October 2019 by INVIMA
Establishes the requirements for labs to obtain the GEP certification for the fabrication of Magistral Preparations with Cannabis derivatives
Licenses
The Ministries of Health, Justice and Agriculture issued Decree 613 of 2017 to define the licenses that can be granted with respect to permissible activities related to medical cannabis that include: (i) the production of cannabis derivatives; (ii) use of seeds for sowing; (iii) planting of psychoactive cannabis plants; and (iv) planting non-psychoactive cannabis plants.
Apart from a psychoactive cannabis license, Allied Colombia has obtained licenses in each of the above categories, necessary to carry out its operations. Licenses are not transferable, interchangeable, or assignable and are valid for five years and can be renewed for additional five-year periods upon request. Each of the Licenses is current and has not expired. None of the Licenses are subject to current, pending, or compromised regulatory action.
In addition to its efforts in customer relationships and international sales cycles, Allied Corp. has proactively engaged with regulatory bodies and authorities by hosting a series of both announced and unannounced audits. These comprehensive evaluations, conducted by regulators and authorities, have consistently resulted in "Full Conformance" acknowledgments. This signifies that Allied Corp. meets the regulatory standards and requirements governing the cannabis industry.
The commitment to transparency and compliance demonstrated during these audits reinforces Allied's dedication to operating at the highest industry standards. Successfully navigating these regulatory assessments positions the Company as a trustworthy and responsible player in the cannabis sector. As Allied continues to uphold rigorous compliance measures, it establishes a solid foundation for sustained success and growth, ensuring that the Company's operations align seamlessly with regulatory expectations.
Strains Registration
Allied Colombia has varieties of cannabis in various stages of the registration process. Each strain, whether high or low in THC, must undergo an agronomic evaluation by the agricultural health entity - Instituto Colombiano Agropecuario (ICA). For the strains to be included in the National Registry of Cultivars, the following steps must be completed: (i) Genetic Stabilization; (ii) Agronomic Test; (iii) Phase 1 strain registry (legal document that allows the license to enter a strain in the registry); and (iv) Strain registration phase 2 (registration that allows the licensee to market any cannabis product derived from the specific strain in the registry). The harvest is also in the process of agronomic evaluation of additional strains.
Based on the yields of each strain, as determined by agronomic testing, Allied Colombia may decide to register fewer strains than available. The decision to complete the registration process of a strain depends on several factors, such as biomass yields, cannabinoid profile, average cannabinoid content, resistance to pests among others as determined by agronomic tests, and the intended uses by the Company.
In 2021, Allied Colombia had twenty varieties of medicinal cannabis registered strains with the ICA and had the registration as a producer of selected seeds granted by the ICA. Upon receiving the ICA Permit, Allied Colombia commenced commercial cultivation.
In compliance with its international obligations, Colombia establishes an annual limit for the production volume of cannabis plants and derivatives, which is monitored by the International Narcotics Control Board. Based on this limit, the Colombian government established a quota system, in order to control the amount of psychoactive cannabis production per license. This means that for the Psychoactive Cannabis License, licensees must first apply for a specific crop or manufacturing quota, before beginning production.
Protection of Environment and Human Health and Safety
We are subject to various Colombian federal, state and local and regulations relating to the protection of the environment and human health and safety, including those governing the management and disposal of hazardous substances and wastes, the cleanup of contaminated sites and the maintenance of a safe workplace. Some of our operations include the use, generation and disposal of hazardous materials. We also plan to acquire ownership in new facilities and properties, some of which may have had a history of commercial or other operations. We may, in the future, incur liability under environmental statutes and regulations with respect to contamination of sites we own or operate, including contamination caused by prior owners or operators of such sites, abutters or other persons, and the off-site disposal of hazardous substances. Violations of these laws and regulations may result in substantial civil penalties or fines.
United States
Allied is ready to supply the US market from its facility in Colombia if and when the United States federally legalizes the use and sale of cannabinoids. The United States health care industry is subject to extensive regulation by federal, state and local governments. Government regulation affects our businesses in several ways, including requiring licensure or certification of facilities. Our ability to conduct our business and to operate profitability depends in part upon obtaining and maintaining all necessary licenses and other approvals; and complying with applicable healthcare laws and regulations.
Legalization of CBD (Medical Cannabidiol Product)
The United States Agricultural Improvement Act of 2018 (the “2018 Farm Act”) removed hemp, defined as cannabis with less than 0.3% of THC, from Schedule 1 status under the Controlled Substances Act (“CSA”), and Federally legalized the cultivation and sale of hemp, subject to compliance with certain federal requirements and state laws. THC is the psychoactive component of plants in the cannabis family generally identified as marihuana or marijuana. Our medical CBD products are Federally legal in the United States in that they contain less than 0.3% THC in compliance with the 2018 Farm Act guidelines and have no psychoactive effects on our patients and customers. However, there can be no assurance that the 2018 Farm Act will not be repealed or amended such that our products containing hemp-derived CBD would once again be deemed illegal under Federal law in the United States.
The 2018 Farm Act also shifted regulatory authority from the Drug Enforcement Administration to the Department of Agriculture. The 2018 Farm Act did not change the United States Food and Drug Administration’s (“FDA”) oversight authority over CBD products. The 2018 Farm Act delegated authority to regulate and limit the production of hemp and hemp derived products to the state governments. Although many states have adopted laws and regulations that allow for the production and sale of hemp and hemp derived products under certain circumstances, no assurance can be given that such laws of the several states will not be repealed or amended such that our intended products containing hemp-derived CBD would once again be deemed illegal, which in turn would render such intended products illegal in those states under federal law even if the federal law is unchanged. In the event of either repeal of Federal or State laws and regulations, or amendments thereto that are adverse to our intended medical CBD products, we may be restricted or limited with respect to those products that we may sell or distribute, which could adversely impact our intended business plan with respect to such intended products.
Additionally, the FDA has indicated its view that certain types of products containing CBD may not be permissible under the United States Federal Food, Drug and Cosmetic Act (“FDCA”). The FDA’s position is related to its approval of Epidiolex, a marijuana-derived prescription medicine to be available in the United States. The active ingredient in Epidiolex is CBD. On December 20, 2018, after the passage of the 2018 Farm Bill, FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA’s position that, among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce and that the FDCA prohibits introducing into interstate commerce food products containing added CBD, and marketing products containing CBD as a dietary supplement, regardless of whether the substances are hemp-derived. Although we believe our existing and planned CBD product offerings comply with applicable federal and state laws and regulations, legal proceedings alleging violations of such laws could have a material adverse effect on our business, financial condition and results of operations.
Cannabis
In the United States cannabis is regulated at the both the Federal and State levels. Notwithstanding the permissive regulatory environment of cannabis in some states, cannabis continues to be categorized as a Schedule I controlled substance under the Controlled Substances Act (“CSA”), making it illegal under Federal law in the United States to cultivate, distribute, or possess cannabis. Certain states may have enacted statutes and regulations take a permissive approach to medical and/or recreational use of cannabis, the CSA may still be enforced by U.S. Federal law enforcement officials against citizens and businesses of those states for activity that is legal under state law.
As a result of the conflicting views between state legislatures and the U.S. federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation. The response to this inconsistency was first addressed in August 2013 when then Deputy Attorney General James Cole authored a memorandum (the “Cole Memorandum”), addressed to all U.S. district attorneys acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several U.S. states have enacted laws relating to cannabis.
The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Cole Memorandum standard.
In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority. On January 4, 2018, then U.S. Attorney General Jeff Sessions issued a memorandum (the “Sessions Memorandum”) that rescinded the Cole Memorandum. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of U.S. attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principles require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution and the cumulative impact of particular crimes on the community.
As a result of the Sessions Memorandum, federal prosecutors are now free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and therefore it is uncertain how active federal prosecutors will be in relation to such activities. Due to the ambiguity of the Sessions Memorandum, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.
On January 15, 2019, U.S. Attorney General nominee William P. Barr suggested a different approach to cannabis regulation than Sessions (his predecessor) during his confirmation hearing before the Senate Judiciary Committee. Mr. Barr stated that his approach to cannabis regulation would be not to upset settled expectations that have arisen as a result of the Cole Memorandum, that it would be inappropriate to upset the current situation as there has been reliance on the Cole Memorandum and that he would not be targeting companies that have relied on the Cole Memorandum and are complying with state laws with respect to the distribution and production of cannabis. While he did not offer support for cannabis legalization, Mr. Barr did emphasize the need for the U.S. Congress to clarify federal laws to address the untenable current situation which has resulted in a backdoor nullification of federal law.
Additionally, under U.S. federal law it may, under certain circumstances, be a violation of federal money laundering statutes for financial institutions to accept any proceeds from cannabis sales or any other Schedule I controlled substances. Certain Canadian banks are similarly reluctant to transact business with U.S. cannabis companies, due to the uncertain legal and regulatory framework characterizing the industry at present. Banks and other financial institutions could be prosecuted and possibly convicted of money laundering for providing services to U.S. cannabis businesses. Under U.S. federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan or any other service could be found guilty of money laundering or conspiracy. Despite these laws, in February 2014, the Financial Crimes Enforcement Network (“FCEN”) of the U.S. Treasury Department issued a memorandum (the “FCEN Memo”) providing instructions to banks seeking to provide services to cannabis-related businesses. The FCEN Memo states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. It refers to supplementary guidance that Deputy Attorney General Cole issued to federal prosecutors relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA. It is unclear at this time whether the Biden administration will follow the guidelines of the FCEN Memo.
As previously discussed herein, we plan on expanding our activities to include cannabis product sales and distribution in the United States if and when such activities are legalized by the Federal Government of the United States.
If federally legalized in the United States, we expect that our cannabis products will be specifically focused on cannabis for use (i) as a treatment aid; (ii) to provide relief for a large array of neurological and musculoskeletal system disorders; and (iii) as an alternative option for healthcare providers in place of prescribing opioids to patients. Offering our patients access to non-hallucinogenic and non-addictive natural remedies, under required clinical oversight policies and procedures as they relate to medicinal cannabis, combined with our existing clinic-based treatment protocols may allow us to provide a unique model that we do not believe is readily available in the United States.
Other Medical Practice Regulation
The United States healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we may provide cannabis products, our contractual relationships with our providers, vendors and clients, our marketing activities, and other aspects of our planned operations in the event such activities become Federally legal in the United States, of which there can be no assurance. Of particular importance are:
●
The Federal Anti-Kickback Statute that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration for referring an individual, in return for ordering, leasing, purchasing or recommending or arranging for, or to induce the referral of an individual or the ordering, purchasing or leasing of items or services covered, in whole or in part, by any federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
●
The criminal healthcare fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and their implementing regulations (collectively, “HIPAA”), and related rules which prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing or covering up a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent, to violate it to have committed a violation.
●
Similar state law provisions pertaining to anti-kickback, and false claims issues.
●
State laws that prohibit general business corporations, such as us, from practicing medicine, controlling physicians’ medical decisions, or engaging in certain practices such as splitting fees with physicians.
●
Laws that regulate debt collection practices as applied to our debt collection practices.
Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment, recoupment, imprisonment, and loss of status. The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with applicable regulatory requirements could impose liability on us and negatively affect our business. Any action against us for violation of these laws or regulations could cause us to incur significant legal expenses, divert our management’s attention from business operations, and result in adverse publicity.
Packaging, Labeling and Advertising
The processing, formulation, manufacturing, packaging, labeling, advertising and distribution of our products are subject to federal laws and regulation by one or more federal agencies, including the FDA, the FTC, HHS, the USDA and the United States Environmental Protection Agency (the “EPA”). These activities are also regulated by various state, local and international laws and agencies of the states and localities in which our products are sold. Regulations may prevent or delay the introduction, or require the reformulation, of our products, which could result in lost sales and increased costs to the Company. A regulatory agency may not accept the evidence of safety for any new ingredients that we may want to market, or may determine that a particular product or product ingredient presents an unacceptable health risk. Regulatory agencies may also determine that a particular statement of nutritional support on our products, or a statement that we want to use on our products, is an unacceptable drug claim or an unauthorized version of a food “health claim,” or that particular claims are not adequately supported by available scientific evidence. Any such regulatory determination could prevent us from marketing particular products or using certain statements on those products, which could adversely affect our sales and results of operations.
Canada
On October 17, 2018 marijuana in Canada became Federally legal.
According to Canadian Federal law, adults are legally permitted to purchase, use, possess, and grow recreational cannabis. The legal age and cultivation laws vary depending on the province. The minimum legal age is 19 in Canada except in the provinces of Alberta and Quebec where it is 18.
The maximum amount one is allowed to possess from a recreational source is 30 grams in all Canadian provinces, but in most locations, one is allowed to have larger amounts at home. In British Columbia for example, a person may possess up to 1,000 grams of marijuana at home. There is no limit to home possession in Manitoba. Those with a prescription are authorized to possess up to a five-day amount of their prescribed amount of medical cannabis.
Peru
We have been authorized to export our cannabis products from Colombia to Peru. Medical marijuana possession is legal, although recreational possession is not. In October 2017, Peru’s Congress passed a bill to legalize medical marijuana allowing cannabis oil to be produced, imported and commercialized. Additionally, although the cultivation and sale of cannabis remains illegal, the possession of small amounts of cannabis for personal usage has been decriminalized in Peru. According to Article 299 of the Peruvian Penal Code, one may legally carry eight grams of marijuana or two grams of its derivatives, for “your own and immediate consumption”.
Europe
The state of cannabis legalization in Europe varies widely among countries, with different nations adopting diverse approaches ranging from strict prohibition to varying degrees of decriminalization and medical cannabis legalization. It's important to note that the legal landscape is constantly changing.
Several European countries have legalized medical cannabis to some extent. Countries such as Germany, the United Kingdom, Italy, and the Netherlands have established medical cannabis programs, allowing patients access to cannabis-based medicines under certain conditions. Some European countries have decriminalized the possession of small amounts of cannabis for personal use. This means that while it remains illegal, the focus is often on treatment or education rather than criminal penalties. Portugal is often cited as a notable example of a country that decriminalized the possession of drugs, including cannabis, for personal use. Generally speaking, recreational cannabis use is generally illegal in most European countries. However, attitudes toward recreational use are evolving, and several countries are engaged in discussions about potential reforms. Luxembourg, for example, has announced plans to legalize recreational cannabis, becoming the first European country to do so. Hemp cultivation is legal in many European countries, with some nations having a long history of hemp cultivation for industrial purposes. Hemp-derived products, such as CBD (cannabidiol), have gained popularity and are widely available. Cannabis laws and regulations can vary significantly from one European country to another. Some countries have taken a more progressive stance, while others maintain strict prohibition. It's crucial to stay updated on the latest developments as attitudes and regulations regarding cannabis are subject to change. Countries across Europe are continually reevaluating their policies, and some may have made significant changes since my last update in January 2022. It is also interesting to note that most countries in Europe have now followed the German footsteps in requiring EU-GMP and EU-GACP certifications standards to allow for imports.
Australia
Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another.
Furthermore, regardless of the legal status of the plant in Australia, it is by far the most popular illicit drug, and past year use in Australia (10.6 percent) remains far higher than the world average (3.9 percent), according to the United Nations World Drug Report for 2020. In addition, a survey published in July 2020 found that 41% of Australians support cannabis legalization, and 37% are opposed. This represents nearly double the level of support found in a 2007 survey (21%).
The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions.
A major move in the direction of legalization took place in September 2019, when the Australian Capital Territory legalized cannabis possession (up to 50 grams) and the cultivation of up to two cannabis plants. And while voters in nearby New Zealand voted down a legalization initiative in late 2020, the cause of cannabis reform in the region is clearly gaining prominence.
Legal Proceedings
In 2020, Allied signed a purchase agreement to acquire a Nevada state license and had a 9800 sq ft. modular building built in Nevada as well. Allied signed a 25 year lease with a publicly listed company called FIORE cannabis. In December 2022, FIORE cannabis went insolvent so the business assets were seized by the debt holders of that company. The Allied building was on that land. Needless to say the lease was cancelled and Allied submitted an application to gain possession of the building back and have it be excluded from the bankruptcy proceedings of FIORE. This is now the subject of litigation in the state of Nevada. The property was sold at auction to the debt holder who has claimed that the building is part of the acquisition. We filed to have the court determine that the building belongs to the Company and/or the business that funded the acquisition of the building. This has become the subject of extensive negotiations between the parties which is continuing as of the date of this Report.
We are not aware of any other legal proceedings contemplated by any governmental authority or any other party involving us or our properties.
Employees
As of the date of this Offering Circular, the Company has approximately 15 contracted employees. Our wholly-owned subsidiary Allied Colombia, S.A.S. has a fluctuating casual labor compliment in Colombia depending on harvest cycles. This can be anywhere from 12-150 employees who farm and produce our cannabis products. The Company does not intend to pay a full salary to any of its executives or management at this time, but has entered into certain consulting agreements. (See “Executive Compensation”). The Company believes that its relations with its employees are good.
In the later part of 2024 the Executives conducted some actions to show a sign of confidence in the company and reduce significantly the accounts payable of the company by a total of $644,475 USD. These included:
·
Calum Hughes granted back to the Company 2,500,000 million of his shares.
·
Paul Bullock converted $178,000USD of accounts payable into Allied Shares at a share price of 0.87 cents, representing a significant multiple to the market share price at the time of conversion.
·
Jim Smeeding converted $150,000 USD of accounts payable into Allied Shares at a share price of 0.87 cents, representing a significant multiple to the market share price at the time of conversion.
·
Calum Hughes converted $126,500 USD of accounts payable into Allied Shares at a share price of 0.87 cents, representing a significant multiple to the market share price at the time of conversion.
·
Calum Hughes forgave $75,000USD of accounts payable.
·
Michael Moses $114,975 USD of accounts payable amount into Allied Shares at a share price of 0.87 cents, representing a significant multiple to the market share price at the time of conversion.
·
To add all of this up, the Company’s accounts payables amount was reduced by $644,475 USD.

---

ITEM 1A. RISK FACTORS
Item 1A. Risk Factors.
An investment in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below. Our business, financial condition, results of operations and cash flows could be materially adversely affected by any of these risks, and the market or trading price of our securities could decline due to any of these risks. In addition, please read “Disclosure Regarding Forward-Looking Statements” in this Annual Report, where we describe additional uncertainties associated with our business and the forward-looking statements included or incorporated by reference in this Annual Report. Please note that additional risks not presently known to us or that we currently deem immaterial may also impair our business and operations. In this Section, the terms the “Company,” “we”, “our” and “us” refer to Allied Corp. as well as its subsidiaries AM (Advanced Micro) Biosciences, Inc., Allied Colombia S.A.S., Allied U.S., Products, LLC and Tactical Relief LLC.
Below is a summary of material risks, uncertainties and other factors that could have a material effect on the Company and its operations:
·
We have a history of operating losses;
·
Public health epidemics or outbreaks (such as COVID-19) could adversely impact our business;
·
We may not be able to obtain sufficient additional capital to continue our operations;
·
We recently launched our cannabis products and have limited sales and marketing experience;
·
The cannabis industry is heavily regulated in the United States, Canada and Colombia, and if we fail to comply with these laws and governmental regulations, we could incur penalties or be required to make significant changes to our operations or even face criminal or civil sanctions;
·
There are conflicts in the United States between Federal and State regulations related to marijuana;
·
There are also provincial variations in cannabis regulation in Canada that could restrict certain of our operations;
·
Past and future cannabis reform legislation and other changes in the health care industry could adversely affect our business, financial condition and results of operations;
·
We are subject to the Canada Health Act, Canada’s National Health Insurance Program and Food and Drugs Act and analogous provisions of applicable federal, provincial, state and local laws and could face substantial penalties if we fail to comply with such laws;
·
Our products may not be accepted in the marketplace or achieve sales sufficient to provide sufficient profitability;
·
In the United States in particular and also elsewhere we are required to rely on third parties to perform many necessary services for our products, including services related to cultivation, distribution, invoicing, storage and transportation of our products;
·
We may be unable to consistently retain or hire third-party manufacturers, suppliers or other service providers to produce our products;
·
We will depend on a limited number of customers for the majority of our revenue;
·
There may be unanticipated delays in the development and introduction of our current and future products and/or our inability to control costs;
·
Significant competition;
·
Potential third-party infringement claims;
·
Risks associated with our current and potential acquisitions related to costs and integration into our product line;
·
We are subject to significant regulatory requirements in the United States, Canada and Colombia;
·
Our stock is subject to dilution through future sale of shares or conversion of existing convertible securities;
·
A significant portion of our stock is held by our officers and directors;
·
We depend on our management and key personnel for our success;
·
The market price for our common stock has and may continue to be volatile;
·
Adequate protection of confidential information;
·
Potential litigation from competitors and claims from customers;
·
Our ability to adequately protect the intellectual property used to produce our products; and
·
Our ability to stay abreast of modified or new laws and regulations applying to our business.
Risks Related to Our Operations
We have a history of operating losses and our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to its ability to continue as a going concern in their audit report for the years ended August 31, 2024 and 2023.
We are a relatively newly formed company focused on cultivating, processing and supplying natural, medicinal-grade cannabis well-being products to large channel distributors, and have limited operating history. We have limited financial resources and minimal operating cash flow. In addition, we do not currently have significant revenues and for the year ended August 31, 2024, had a loss of $3,800,994, and an accumulated deficit of $49,409,330. There is no guarantee that we will ever become profitable. The costs for research, product development, machinery adaptation to create our product candidates and cannabis products and/or technologies, along with marketing and selling expenses, and the general and administrative expenses, will be principal causes of our costs and/or potential losses. We may never become profitable and if we do not become profitable your investment could be harmed or lost completely.
We anticipate that we will continue to report losses and negative cash flow for the foreseeable future. We have concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the years ended August 31, 2024 and 2023.
The consolidated financial statements of the Company do not include any adjustments that might result from the outcome of this uncertainty. These adjustments would likely include substantial impairment of the carrying amount of our assets and potential contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition, the value of our securities, including common stock issued in this offering, would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient cash flow from operations and obtaining additional capital and financing, including funds to be raised in this offering. If our ability to generate cash flow from operations is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business even if this offering is successful. For further discussion about our ability to continue as a going concern and our plan for future liquidity, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Going Concern.”
We may need additional capital in the future in order to continue our operations.
We conducted private placements totaling $11,995,918 since 2019 of shares of common stock and/or warrants to fund acquisitions and operations in transactions that are exempt from the registration requirements of the Securities Act pursuant to Regulation 506(c) of common stock, which we are using for acquisitions and operations. However, if in the future we do not turn profitable or generate cash from operations and additional capital is needed to support operations, economic and market conditions may make it difficult or impossible to raise additional funds through debt or equity financings. If funds are not sufficient to support operations, we may need to pursue a financing or reduce expenditures to meet our cash requirements. If we do obtain such financing, we cannot assure that the amount or the terms of such financing will be as attractive as we may desire, and your equity interest in the Company may be diluted considerably. If we are unable to obtain such financing when needed, or if the amount of such financing is not sufficient, it may be necessary for us to take significant cost saving measures or generate funding in ways that may negatively affect our business in the future. To reduce expenses, we may be forced to make personnel reductions or curtail or discontinue development programs. To generate funds, it may be necessary to monetize future royalty streams, sell intellectual property, divest of technology platforms or liquidate assets. However, there is no assurance that, if required, we will be able to generate sufficient funds or reduce spending to provide the required liquidity. Long-term capital requirements will depend on numerous factors, including, but not limited to, the status of collaborative arrangements, the progress of research and development programs and the receipt of revenues from sales of products. Our ability to achieve and/or sustain profitable operations depends on a number of factors, many of which are beyond our control, including:
·
our ability to successfully sell our cannabis products;
·
Government legislation changes
·
our ability to successfully develop and obtain necessary national, federal, provincial, and/or state regulatory approval(s) for our own product candidates such as hemp cigarettes;
·
the success of our partners and distributors in selling our products;
·
our ability to successfully sell future products if we choose not to partner the product;
·
our ability to manufacture, or have manufactured, products efficiently, at the appropriate commercial scale, and with the required quality, and our ability to source and purchase from third party hemp cultivators that supplies required to produce our products;
·
timing of our partners’ development, regulatory and commercialization plans;
·
the demand for our products from current and future distribution and/or wholesale and/or retails partners;
·
our ability to increase and continue to outsource our raw materials, quality cannabis, and our manufacturing capacity to allow for new product introductions;
·
the level of product competition and of price competition;
·
consumer acceptance of our current and future products;
·
our ability to obtain reimbursement for our products from third-party payers;
·
our ability to develop additional commercial applications for our products;
·
our ability to attract the right personnel to execute our plans;
·
our ability to develop, maintain or acquire patent positions;
·
our ability to procure quality industrial hemp flowers and control these costs; and
·
general economic conditions in the USA and the hemp industry.
The occurrence or resurgence of global or regional health events, such as the COVID-19 outbreak or similar pandemics could adversely affect our operations.
The Company’s operations could be significantly adversely affected by the effects of a widespread global or regional outbreak of a contagious disease such as the COVID-19 pandemic and other unforeseen events and the related economic repercussions. A significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company’s operations and ability to finance its operations.
We launched our cannabis products in 2019 in an initially limited fashion and as a company, we have limited sales and marketing experience.
We launched marketing for our cannabis products in 2019, and although we have hired highly qualified personnel with specialized expertise, as a company, we have limited experience commercializing cannabis products on our own. In order to commercialize the cannabis products business, we have to build our sales, marketing, distribution, managerial and other non-technical capabilities and make arrangements with third parties to perform these services when needed. We may have to hire sales representatives and district managers to fill sales territories. To the extent we are relying on third parties to commercialize our business, we may receive less revenues or incur more expenses than if we had commercialized the products ourselves. In addition, we may have limited control over the sales efforts of any third parties involved in our commercialization efforts. If we are unable to successfully implement our commercial plans and drive adoption by patients and physicians of our products through our sales, marketing and commercialization efforts, or if our partners fail to successfully commercialize our products, then we may not be able to generate sustainable revenues from product sales which will have a material adverse effect on our business and future product opportunities. Similarly, we may not be successful in establishing the necessary commercial infrastructure, including sales representatives, wholesale distributors, legal and regulatory affairs teams. The establishment and development of commercialization capabilities to market our products has been and will continue to be expensive and time-consuming. As we continue to develop these capabilities, we will have to compete with other hemp companies to recruit, hire, train and retain sales and marketing personnel. If we have underestimated the necessary sales and marketing capabilities or have not established the necessary infrastructure to support successful commercialization, or if our efforts to do so take more time and expense than anticipated, our ability to market and sell our products may be adversely affected.
Recent and future acquisitions and strategic investments could be difficult to integrate, divert the attention of key management personnel, disrupt our business, dilute shareholder value, and harm our results of operations and financial condition.
We acquired Medicolombia S.A.S. (renamed Allied Colombia S.A.S.), and we may in the future seek to acquire or invest in, businesses, products, or technologies that we believe could complement our operations or expand our breadth, enhance our capabilities, or otherwise offer growth opportunities. Our diversity of product offerings may not be successful. While our growth strategy includes broadening our service and product offerings, implementing an aggressive marketing plan and employing product diversification, there can be no assurance that our systems, procedures and controls will be adequate to support our operations as they expand. We cannot assure you that our existing personnel, systems, procedures or controls will be adequate to support our operations in the future or that we will be able to successfully implement appropriate measures consistent with our growth strategy. As part of our planned growth and diversified product offerings, we may have to implement new operational and financial systems, procedures and controls to expand, train and manage our employee base, and maintain close coordination among our staff. We cannot guarantee that we will be able to do so, or that if we are able to do so, we will be able to effectively integrate them into our existing staff and systems. Additionally, the integration of our acquisitions and pursuit of potential future acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. Any acquisition, investment or business relationship may result in unforeseen operating difficulties and expenditures. In addition, we have limited experience in acquiring other businesses. Specifically, we may not successfully evaluate or utilize the acquired products, assets or personnel, or accurately forecast the financial impact of an acquisition transaction, including accounting charges. Moreover, the anticipated benefits of any acquisition, investment, or business relationship may not be realized, or we may be exposed to unknown risks or liabilities of our acquisitions.
We may not be able to find and identify desirable acquisition targets or we may not be successful in entering into an agreement with any one target. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could harm our results of operations. In addition, if an acquired business fails to meet our expectations, our business, results of operations, and financial condition may suffer. In some cases, minority shareholders may exist in certain of our non-wholly-owned acquisitions (for businesses we do not purchase as an 100% owned subsidiary) and may retain minority shareholder rights which could make a future change of control or corporate approvals for actions more difficult to achieve and/or more costly.
We also make strategic investments in early-stage companies developing products or technologies that we believe could complement our business or expand our breadth, enhance our technical capabilities, or otherwise offer growth opportunities. These investments may be in early-stage private companies for restricted stock. Such investments are generally illiquid and may never generate value. Further, the companies in which we invest may not succeed, and our investments would lose their value.
Certain conditions or events could disrupt the Company’s supply chains, disrupt operations, and increase operating expenses.
Conditions or events including, but not limited to, the following could disrupt the Company’s supply chains and in particular its ability to deliver its products, interrupt operations at its facilities, increase operating expenses, resulting in loss of sales, delayed performance of contractual obligations or require additional expenditures to be incurred: (i) extraordinary weather conditions or natural disasters such as hurricanes, tornadoes, floods, fires, extreme heat, earthquakes, etc.; (ii) a local, regional, national or international outbreak of a contagious disease, including COVID-19, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, H1N1 influenza virus, avian flu, or any other similar illness could result in a general or acute decline in economic activity; (iii) political instability, social and labor unrest, war or terrorism; or (iv) interruptions in the availability of basic commercial and social services and infrastructure including power and water shortages, and shipping and freight forwarding services including via air, sea, rail and road.
We will depend on a limited number of customers for the majority of our revenue, and the loss of any one of these customers could substantially reduce our revenue and impact our liquidity.
The loss of any significant customers or partners or reduction in our business activities could cause our revenues to decrease significantly and increase our continuing losses from operations. If our cannabis products are not successful and we cannot broaden our customer base, we will continue to depend on a few customers for the majority of our revenues. Additionally, if we are unable to negotiate favorable business terms with these customers in the future, our revenues and gross profits may be insufficient to allow us to achieve and/or sustain profitability or continue operations.
Demand for cannabis and derivative products could be adversely affected and significantly influenced by scientific research or findings, regulatory proceedings, litigation, media attention or other research findings.
Consumer perceptions regarding legality, morality, consumption, safety, efficacy and quality of medicinal cannabis are mixed and evolving and can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medicinal cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medicinal cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity, could have a material adverse effect on the demand for medicinal cannabis and on our business, results of operations, financial condition and cash flows. Further, adverse publicity reports or other media attention regarding cannabis in general or associating the consumption of medicinal cannabis with illness or other negative effects or events, could have such a material adverse effect. Public opinion and support for medicinal cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. Our ability to gain and increase market acceptance of our business may require substantial expenditures on investor relations, strategic relationships and marketing initiatives. There can be no assurance that such initiatives will be successful and their failure to materialize into significant demand may have an adverse effect on our financial condition.
Damage to the Company’s reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether such publicity is accurate or not.
The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share opinions and views regarding the Company and its activities, whether true or not. Although the Company believes that it operates in a manner that is respectful to all stakeholders and that it takes pride in protecting its image and reputation, it does not ultimately have direct control over how it is perceived by others. Reputational loss may result in decreased ability to enter into new customer, distributor or supplier relationships, retain existing customers, distributors or suppliers, reduced investor confidence and access to capital, increased challenges in developing and maintaining community relations and an impediment to our overall ability to advance our projects, thereby having a material adverse effect on our financial performance, financial condition, cash flows and growth prospects.
We are subject to the inherent risks involved with product recalls.
Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of our products are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin, or at all. In addition, a product recall may require significant management attention. There can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if our products are subject to recall, our reputation could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses, and potential legal fees and other expenses.
The Company’s products could have unknown side effects.
If the products the Company sells are not perceived to have the effects intended by the end user, its business may suffer and the business may be subject to products liability or other legal actions. Many of the Company’s products contain innovative ingredients or combinations of ingredients. There is little long-term data available with respect to efficacy, unknown side effects and/or interaction with individual human biochemistry, or interaction with other drugs. Moreover, there is little long-term data available with respect to efficacy, unknown side effects and/or its interaction with individual animal biochemistry. As a result, the Company’s products could have certain side effects if not taken as directed or if taken by an end user that has certain known or unknown medical conditions.
The Company may be unable to anticipate changes in its potential client requirements that could make the Company’s existing products and services obsolete. The Company’s success will depend, in part, on its ability to continue to enhance its product and service offerings so as to address the increasing sophistication and varied needs of the market and respond to technological and regulatory changes and emerging industry standards and practices on a timely and cost-effective basis.
Research regarding the medical benefits, viability, safety, efficacy, use and social acceptance of cannabis remains in early stages.
There have been relatively few clinical trials on the benefits of cannabis. Although the Company believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, investors should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated herein or reach negative conclusions related to medical cannabis, which could have a material adverse effect on the demand for the Company’s products, which could result in a material adverse effect on our business, financial condition and results of operations or prospects.
The seasonal trends in our business create variability in our financial and operating results.
Our financial and operating results are subject to seasonal and quarterly variations in our net revenue and operating income and, as a result, our quarterly results may fluctuate and could be below expectations.
We anticipate that our business will realize a disproportionate amount of net revenue and earnings in the third and fourth quarter as a result of the holiday season. If we experience lower than expected net revenue during any third or fourth quarter, it may have disproportionately large effects on our operating results and financial condition for that year. Any factors that harm our third or fourth quarter operating results, including disruptions in our brands or our supply chains or unfavorable economic conditions, could have a disproportionate effect on our results of operations and our financial condition for our entire fiscal year.
The Company may not be able to maintain effective quality control systems.
The Company may not be able to maintain an effective quality control system. The Company ascribes its early successes, in part, on its commitment to product quality and its effective quality control system. The effectiveness of the Company’s quality control system and its ability to obtain or maintain regulatory certification with respect to its manufacturing, processing and testing facilities depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure that its employees adhere to the Company’s policies and procedures. The Company also depends on service providers such as toll manufacturers and contract laboratories to manufacture, process or test its products, that are subject to regulatory certification requirements.
We expect that regulatory agencies will periodically inspect our and our service providers’ facilities to evaluate compliance with applicable requirements. Failure to comply with these requirements may subject us or our service providers to possible regulatory enforcement actions. Any failure or deterioration of the Company’s or its service providers’ quality control systems, including loss of any required certification, may have a material adverse effect on the Company’s business, results of operations and financial condition.
Energy prices and supply may be subject to change or curtailment due to new laws or regulations, imposition of new taxes or tariffs, interruptions in production by suppliers, imposition of restrictions on energy supply by government, worldwide price levels and market conditions.
The Company requires diesel and electric energy and other resources for its cultivation and harvest activities and for transportation of cannabis. the Company relies upon third parties for its supply of energy resources used in its operations. The prices for and availability of energy resources may be subject to change or curtailment, respectively, due to, among other things, new laws or regulations, imposition of new taxes or tariffs, interruptions in production by suppliers, imposition of restrictions on energy supply by government, worldwide price levels and market conditions. Although the Company attempts to mitigate the effects of fuel shortages, electricity outages and cost increases, the Company’s operations will continue to depend on external suppliers of fuel and electricity. If energy supply is cut for an extended period and the Company is unable to find replacement sources at comparable prices, or at all, the Company’s business, financial condition and results of operations could be materially and adversely affected.
There are risks associated with the regulatory regime and permitting requirements of our operations.
Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of our products. We may not be able to obtain or maintain the necessary licenses, permits, quotas, authorizations or accreditations to operate our business, or may only be able to do so at great cost. We cannot predict the time required to secure all appropriate regulatory approvals for our products, or the extent of testing and documentation that may be required by local governmental authorities.
Our officers and directors must rely, to a great extent, on Colombian legal counsel and local consultants retained in order to keep abreast of material legal, regulatory and governmental developments as they pertain to and affect our business operations, and to assist us with governmental relations. We must rely, to some extent, on those members of management and the Board who have previous experience working and conducting business in Colombia in order to enhance our understanding of and appreciation for the local business culture and practices in Colombia.
We also rely on the advice of local experts and professionals in connection with any current and new regulations that develop in respect of banking, financing and tax matters in Colombia. Any developments or changes in such legal, regulatory or governmental requirements or in local business practices in Colombia are beyond our control and may adversely affect our business.
We will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. We may be required to compensate those suffering loss or damage by reason of our operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on our business, results of operations and financial condition.
The cannabinoid industry faces strong opposition and may face similar opposition in other jurisdictions in which we operate.
Many political and social organizations oppose hemp and cannabis and their legalization, and many people, even those who support legalization, oppose the sale of hemp and cannabis in their geographies. Our business will need support from local governments, industry participants, consumers and residents to be successful. Additionally, there are large, well-funded businesses that may have a strong opposition to the cannabis industry. For example, the pharmaceutical and alcohol industries have traditionally opposed cannabis legalization. Any efforts by these or other industries opposed to cannabis would make in halting or impeding the cannabis industry could have detrimental effects on our business.
We are subject to the risks inherent in an agricultural business.
Our business involves the growing of cannabis, which is an agricultural product. The occurrence of severe adverse weather conditions, especially droughts, fires, storms or floods is unpredictable and may have a potentially devastating impact on agricultural production and may otherwise adversely affect the supply of cannabis. Adverse weather conditions may be exacerbated by the effects of climate change and may result in the introduction and increased frequency of pests and diseases. The effects of severe adverse weather conditions may reduce our yields or require us to increase our level of investment to maintain yields. Additionally, higher than average temperatures and rainfall can contribute to an increased presence of insects and pests, which could negatively affect cannabis crops. Future droughts could reduce the yield and quality of our cannabis production, which could materially and adversely affect our business, financial condition and results of operations.
The occurrence and effects of plant disease, insects and pests can be unpredictable and devastating to agricultural production, potentially rendering all or a substantial portion of the affected harvests unsuitable for sale. Even when only a portion of the production is damaged, our results of operations could be adversely affected because all or a substantial portion of the production costs may have been incurred. Although some plant diseases are treatable, the cost of treatment can be high and such events could adversely affect our operating results and financial condition. Furthermore, if we fail to control a given plant disease and the production is threatened, we may be unable to adequately supply our customers, which could adversely affect our business, financial condition and results of operations. There can be no assurance that natural elements will not have a material adverse effect on production.
Our operations could be materially and adversely affected if the supply of cannabis seeds is ceased or delayed and we do not find replacement suppliers and obtain all necessary authorizations.
If for any reason the supply of cannabis seeds is ceased or delayed, we would have to seek alternate suppliers and obtain all necessary authorization for the new seeds. If replacement seeds cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, our business, financial condition and results of operations would be materially and adversely affected.
Many of our competitors have greater resources that may enable them to compete more effectively than us in the cannabis industry.
The industry in which we operate is subject to intense and increasing competition. Some of our competitors have a longer operating history and greater capital resources and facilities, which may enable them to compete more effectively in this market. We expect to face additional competition from existing licensees and new market entrants who are granted licenses in Colombia, who are not yet active in the industry. If a significant number of new licenses are granted in the near term, we may experience increased competition for market share and may experience downward pricing pressure on our products as new entrants increase production. Such competition may cause us to encounter difficulties in generating revenues and market share, and in positioning our products in the market. If we are unable to successfully compete with existing companies and new entrants to the market, our lack of competitive advantage will have a negative effect on our business and financial condition.
The legalization of adult-use, recreational cannabis may reduce sales of medical cannabis.
Legalization of the sale to adults of recreational, non-medical cannabis in any country may increase competition in the medical cannabis market. We may not be able to achieve our business plan in a highly competitive market where recreational, adult-use cannabis is legal, or the market may experience a drop in the price of cannabis and cannabis products over time, decreasing our profit margins.
The Company is reliant on third party transportation services and importation services to deliver its products to customers.
The Company relies on third party transportation services and importation services to deliver its products to its customers. The Company is exposed to the inherent risks associated with relying on third party transportation service-providers, including logistical problems, delays, loss or theft of product and increased shipping and insurance costs. Any delay in transporting the product, breach of security or loss of product, could have a material adverse effect on the Company’s business, financial performance and results of operations. Further, any breach of security and loss of product during transport could affect the Company’s status as a licensed producer in Colombia.
The Company is dependent on suppliers to supply equipment, parts and components for the operation of its business.
The Company’s ability to compete and grow will be dependent upon having access, at a reasonable cost and in a timely manner, to equipment, parts and components. No assurances can be given that the Company will be successful in maintaining the required supply of equipment, parts and components. It is also possible that the final costs of the major equipment contemplated by capital expenditure programs may be significantly greater than anticipated or available, in which circumstance there could be a materially adverse effect on the Company’s financial results.
We may not be able to establish and maintain bank accounts in certain countries.
There is a risk that banking institutions in countries where we operate will not open accounts for us or will not accept payments or deposits from proceeds related to the cannabis industry. Such risks could increase our costs or prevent us from expanding into certain jurisdictions. Banks in the United States frequently refuse to do business with cannabis related companies because of the current federal law prohibiting cannabis sales.
The Company may be subject to cyber-security and privacy risks that could disrupt its operations and expose the Company to financial losses, contractual losses, liability, reputational damage and additional expense.
The Company may be subject to risks related to our information technology systems, including cyber-attacks, malware, ransomware and phishing attacks that could target our intellectual property, trade secrets, financial information, personal information of our employees, customers and patients, including sensitive personal health information. The occurrence of such an attack could disrupt our operations and expose the Company to financial losses, contractual damages, liability under labor and privacy laws, reputational damage and additional expenses. We have implemented security measures to protect our data and information technology systems; however, such measures may not be effective in preventing cyber-attacks. We may be required to allocate additional resources to implement additional preventative measures including significant investments in information technology systems. A serious cyber-security breach could have a material adverse effect on our business, financial condition and results of operations.
The Company may collect and store certain personal information about customers and is responsible for protecting such information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. In addition, theft of data is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such privacy breach or theft could have a material adverse effect on the Company’s business, financial condition and results of operations. If the Company were found to be in violation of privacy or security rules or other laws protecting the confidentiality of information, the Company could be subject to sanctions and civil or criminal penalties, which could increase its liabilities, harm its reputation and have a material adverse effect on the Company’s business, financial condition and results of operations.
The Company may incur significant costs to defend its intellectual property and other proprietary rights.
The ownership and protection of trademarks, patents, trade secrets and intellectual property rights are significant aspects of the Company’s future success. Unauthorized parties may attempt to replicate or otherwise obtain and use the Company’s products and technology. Policing the unauthorized use of the Company’s current or future trademarks, patents, trade secrets or intellectual property rights could be difficult, expensive, time-consuming and unpredictable, as may be enforcing these rights against unauthorized use by others.
In addition, other parties may claim that the Company’s products infringe on their proprietary and perhaps patent protected rights. Such claims, regardless of their merit, may result in the expenditure of significant financial and managerial resources, legal fees, injunctions, temporary restraining orders and/or require the payment of damages. As well, the Company may need to obtain licenses from third parties who allege that the Company has infringed on their lawful rights. Such licenses may not be available on terms acceptable to the Company or at all. In addition, the Company may not be able to obtain or utilize on terms that are favorable to it, or at all, licenses or other rights with respect to intellectual property that it does not own.
Risks Related to Operations in Colombia
We are reliant on certain licenses and authorizations to operate in Colombia.
Our ability to grow, store and sell cannabis in Colombia is dependent on our ability to sustain and/or obtain the necessary licenses and authorizations by certain authorities in Colombia. To date, we have received the licenses we need to operate our facilities in Colombia. The effects of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impair the development of markets, products and sales initiatives and could have a material adverse effect on our business, results of operations and financial condition.
The licenses and authorizations are subject to ongoing compliance and reporting requirements and our ability to obtain, sustain or renew any such licenses and authorizations on acceptable terms is subject to changes in regulations and policies and to the discretion of the applicable authorities or other governmental agencies in Colombia and potentially in other foreign jurisdictions. Failure to comply with the requirements of the licenses or authorizations or any failure to maintain the licenses or authorizations would have a material adverse effect on our business, financial condition and operating results.
Although we believe that we will meet the requirements to obtain, sustain or renew the necessary licenses and authorizations, there can be no guarantee that the applicable authorities will issue these licenses or authorizations. Should the authorities fail to issue the necessary licenses or authorizations, we may be curtailed or prohibited from the production and/or distribution of cannabis or from proceeding with the development of our operations as currently proposed and our business, results of operations and financial condition may be materially adversely affected.
Restrictions or regulations concerning changes in corporate structure may discourage transactions that otherwise could involve payment of a premium over prevailing market process for our securities.
Colombian cannabis licenses are granted on a non-transferable, non-exchangeable and non-assignable basis. Any breach of this restriction may result in the revocation of the license. While there are no specific regulations or restrictions regarding the effects of a change in control, modification of the corporate structure, issuance of shares, or any changes in holders or final beneficiaries on the cannabis licenses, these restrictions may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.
Our cultivation operations are located in Colombia, which may make it more difficult for investors to understand and predict how changing market and economic conditions will affect our financial results.
Our cultivation operations are located in Colombia and, consequently, are subject to the economic, political and tax conditions prevalent in that country. The economic conditions in Colombia are subject to different growth expectations, market weaknesses and business practices than economic conditions in other markets. We may not be able to predict how changing market conditions in Colombia will affect our financial results.
Currently Colombia’s long-term foreign currency sovereign credit ratings were affirmed “BB+” by S&P and “BB+” by Fitch, two of the main rating agencies worldwide. The Colombian economy is expected to experience some modest recovery in growth, along with a decrease in the current account deficit and a marginal increase in debt in the coming years. The stable outlook reflects their expectation that Colombia’s established political institutions and track record of consensus on key economic policies will contribute to economic stability and continuity over the coming two to three years.
Colombia’s economy, like most Latin-American countries, continues to suffer from the effects of lower commodity prices, mainly oil, reflected in its elevated level of external debt. Even though the country has taken measures to stabilize the economy, it is uncertain how these measures will be perceived and if the intended goal of increasing investor’s confidence will be achieved.
Economic and political conditions in Colombia may have an adverse effect on our financial condition and results of operations.
Our cultivation operations are located in Colombia. Consequently, our financial condition and results of operations depend significantly on macroeconomic and political conditions prevailing in Colombia. Decreases in the growth rate, periods of negative growth, increases in inflation, changes in law, regulation, policy, or future judicial rulings and interpretations of policies involving exchange controls and other matters such as (but not limited to) currency depreciation, inflation, interest rates, taxation, banking laws and regulations and other political or economic developments in or affecting Colombia may affect the overall business environment and may, in turn, adversely affect our financial condition and results of operations in the future. The Colombian government frequently intervenes in Colombia’s economy and from time to time makes significant changes in monetary, fiscal and regulatory policy. Our business and results of operations or financial condition may be adversely affected by changes in government or fiscal policies, and other political, diplomatic, social and economic developments that may affect Colombia. We cannot predict what policies the Colombian government will adopt and whether those policies would have a negative effect on the Colombian economy or on our business and financial performance in the future.
We cannot assure you whether current stability in the Colombian economy will be sustained. If the condition of the Colombian economy were to deteriorate, we would likely be adversely affected.
Colombia is experiencing substantial inflation resulting in the Company’s costs in the Colombian peso increasing significantly.
Colombia has in the past experienced double-digit rates of inflation. Colombia’s inflation rate is currently 6.12% and is expected to be 5.7% by the end of calendar 2024. If Colombia experiences substantial inflation in the future, the Company’s costs in Colombian peso terms will increase significantly, subject to movements in applicable exchange rates. Inflationary pressures may also curtail the Company’s ability to access global financial markets in the longer term and its ability to fund planned capital expenditures, and could materially adversely affect the Company’s business, financial condition and results of operations. The Colombian government’s response to inflation or other significant macro-economic pressures may include the introduction of policies or other measures that could increase the Company’s costs, reduce operating margins and materially adversely affect its business, financial condition and results of operations.
Colombia has experienced and continues to experience internal security issues that have had or could have a negative effect on the Colombian economy and our financial condition.
Colombia is subject to sustained internal security issues, primarily due to the activities of guerrilla groups, such as dissidents from the former Revolutionary Armed Forces of Colombia (Fuerzas Armadas Revolucionarias de Colombia), or “FARC,” the National Liberation Army (Ejército de Liberación Nacional), or “ELN,” paramilitary groups, drug cartels and criminal gangs (Bacrim). In remote regions of the country with minimal governmental presence, these groups have exerted influence over the local population and funded their activities by protecting and rendering services to drug traffickers and participating in drug trafficking activities. Even though the Colombian government’s policies have reduced guerilla presence and criminal activity, particularly in the form of terrorist attacks, homicides, kidnappings and extortion, such activity persists in Colombia, and possible escalation of such activity and the effects associated with them have had and may have in the future a negative effect on the Colombian economy and on us, including on our employees, results of operations and financial condition. The Colombian government commenced peace talks with the FARC in August 2012, and peace negotiations with the ELN began in November 2016. The Colombian government and the FARC signed a peace deal on September 26, 2016, which was amended after voters rejected it in the referendum held on October 2, 2016. The new agreement was signed on November 24, 2016 and was ratified by the Colombian Congress on November 30, 2016 and is being implemented after four years of negotiations. Pursuant to the peace agreements negotiated between the FARC and the Colombian government in 2016, the FARC occupies five seats in the Colombian Senate and five seats in the Colombian House of Representatives. The deal clarifies protection to private property, is expected to increase the government’s presence in rural areas and bans former rebels from running for office in certain newly created congressional districts in post-conflict zones. Colombia may experience an increase in internal security issues, drug-related crime and guerilla and paramilitary activities, which may have a negative effect on the Colombian economy. Our business or financial condition could be adversely affected by rapidly changing economic or social conditions, including the Colombian government’s response to implementation of the agreement with FARC and ongoing peace negotiations, if any, which may result in legislation that increases the tax burden of Colombian companies.
Despite efforts by the Colombian government, drug-related crime, guerrilla paramilitary activity and criminal bands continue to exist in Colombia, and allegations have surfaced regarding members of the Colombian congress and other government officials having ties to guerilla and paramilitary groups. On January 17, 2019, a car with explosives burst through the gates at a police academy in Bogotá resulting in 21 people dead and many injured. The Colombian Defense Minister confirmed that the terrorist attack was perpetrated by the ELN. Any possible escalation in the violence associated with this terrorist attack and/or these activities may have a negative effect on the Colombian economy. In addition, the current administration has not honored the peace protocols to be applied in the event of a suspension of peace negotiations entered into by the prior administration, on the grounds that these protocols are only binding to the administration that agreed to them. This situation could result in escalated violence by the ELN and may have a negative effect on the credibility of the Colombian government which could in turn have a negative effect on the Colombian economy. Any terrorist activity in Colombia generally may disrupt supply chains and discourage qualified individuals from being involved with our operations.
Political and economic instability in the region may affect the Colombian economy and, consequently, our results of operations and financial condition.
Some of Colombia’s neighboring countries, particularly Venezuela, have experienced and continue to experience periods of political and economic instability. According to figures from the United Nations, more than two million Venezuelans have emigrated amid food and medicine shortages and profound political divisions in their country. Approximately half of those migrants have opted to live in Colombia, and many have arrived with only what they could carry. Providing migrants with access to healthcare, utilities and education may have a negative effect on Colombia’s economy if the Colombian government is not able to respond adequately to legalize migrants, generate programs to help them find formal jobs, and increase tax revenue and consumption.
Moreover, diplomatic relations with Venezuela and Ecuador have from time to time been tense and affected by events surrounding the Colombian military forces’ confrontations with guerilla groups, particularly on Colombia’s borders with each of Venezuela and Ecuador. More recently, the Colombian government joined an international campaign against Nicolás Maduro asking him to relinquish power, which has further increased diplomatic tensions with Venezuela.
On November 19, 2012, the International Court of Justice placed a sizeable area of the Caribbean Sea within Nicaragua’s exclusive economic zone, which until then had been deemed by Colombia as part of its own exclusive economic zone. A worsening of diplomatic relations between Colombia and Nicaragua involving the disputed waters could result in the Nicaraguan government taking measures, or a reaction among the Nicaraguan public, which would be detrimental to Colombian-owned interests in that country.
Further economic and political instability in Colombia’s neighboring countries or any future deterioration in relations with Venezuela, Ecuador, Nicaragua and other countries in the region may result in the closing of borders, the imposition of trade barriers and a breakdown of diplomatic ties, or a negative effect on Colombia’s trade balance, economy and general security situation, which may adversely affect our results of operations and financial condition.
Finally, political conditions such as changes in the United States policies related to immigration and remittances could affect the regions in which we operate. Economic conditions in the United States and the region generally may be affected by the new United States-Mexico-Canada Agreement. This could have an indirect effect on the Colombian economy and other countries in which we may operate.
Any additional taxes resulting from changes to tax regulations or the interpretation thereof in Colombia or other countries where we operate, could adversely affect our consolidated results.
Uncertainty relating to tax legislation poses a constant risk to us. Colombian national authorities have levied new taxes in recent years. Changes in legislation, regulation and jurisprudence can affect tax burdens by increasing tax rates and fees, creating new taxes, limiting stated expenses and deductions, and eliminating incentives and non-taxed income.
Additional tax regulations could be implemented that could require us to make additional tax payments, negatively affecting our financial condition, results of operation, and cash flow. In addition, either national or local taxing authorities may not interpret tax regulations in the same way that we do. Differing interpretations could result in future tax litigation and associated costs.
Risks Related to Our Regulatory Framework
United States Federal regulation and enforcement may adversely affect the implementation of medical Cannabis and/or Cannabis adult use laws and regulations may negatively impact our revenues and profits.
Legislation in the United States continues to evolve throughout 2023 relative to laws regulating marijuana. Subsequent to the 2023 elections, there are currently 46 states in the United States, plus the District of Columbia that have laws and/or regulations that recognize in one form or another legitimate medical uses for cannabis and consumer use of cannabis in connection with medical treatment. More states are considering permitting cannabis use. Although it has not been passed, Congress recently presented legislation which would decriminalize marijuana use federally and relegate legalization to state law.
Around the world there are countries who are enacting medical and/or adult use cannabis regulations almost weekly. Conversely, currently under the Controlled Substance Act (the “CSA”), the policy and regulations of the Federal government and its agencies is that cannabis has no medical benefit and a range of activities including cultivation and use of cannabis for personal use is prohibited. Until Congress amends the CSA with respect to medical marijuana or there is an outcome of the current lawsuit against the un-constitutional application of cannabis in the CSA, there is a risk that federal authorities may enforce current federal law, and we may be deemed to be facilitating the selling or distribution of drug paraphernalia in violation of federal law. Active enforcement of the current federal regulatory position on cannabis may thus indirectly and adversely affect revenues and profits of the Company. The risk of strict enforcement of the CSA in light of congressional activity, judicial holdings and stated federal policy remains uncertain.
The DOJ (Department of Justice) has not historically devoted resources to prosecuting individuals whose conduct is limited to possession of small amounts of marijuana for use on private property but relied on state and local law enforcement to address marijuana activity. In the event the DOJ reverses stated policy and begins strict enforcement of the CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there may be a direct and adverse impact to our revenue and profits.
There are conflicts in the United States between Federal and State regulations related to marijuana.
Federal regulation and enforcement may adversely affect the implementation of adult use/medical Cannabis laws and regulations may negatively impact our revenues and profits. As of the date of this Annual Report, 46 states and the District of Columbia allow its citizens to use medical marijuana. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. Each of the Obama, Trump and Biden administrations effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state designated laws allowing the use and distribution of medical cannabis. In October 2022, Biden pardoned all persons convicted of minor marijuana infractions. In May 2017, Congress unveiled their new budget bill and as such, lawmakers included a provision, known as the Rohrabacher-Farr amendment, that allows states to carry on with crafting their own medical marijuana policies without fear of federal intervention. This bill was passed and as a result, no federal monies have been approved or appropriated to be used to enforce federal law in these cannabis program participating states.
In 2020, the Democrats through President Biden called for decriminalizing and rescheduling marijuana through executive action, with support for legalizing medical marijuana and expunging past criminal convictions for cannabis-related offenses all on the table.
Investors should understand that there is no guarantee that current or future administrations will not attempt to change this again in the future. Additionally, any new administration that follows could change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to the Company and its shareholders. While we will not harvest, distribute, or sell cannabis directly, we may be irreparably harmed by a change in enforcement by the Federal or state governments.
Cannabis remains illegal under United States federal law. It is a schedule-I controlled substance. Even in those jurisdictions in which the use of medical marijuana has been legalized at the state level, its prescription is a violation of federal law. The United States Supreme Court has ruled in United States v. Oakland Cannabis Buyers’ Coop. and Gonzales v. Raich that it is the federal government that has the right to regulate and criminalize cannabis, even for medical purposes. Therefore, federal law criminalizing the use of marijuana trumps state laws that legalize its use for medicinal purposes. At present, the states are standing tall against the federal government, maintaining existing laws and passing new ones in this area. A change in the federal attitude towards enforcement could have a negative effect on the industry, potentially ending it entirely. While we are not insulated from economic risk if such a change were to occur, we believe that by virtue of the fact that we do not sell, or produce Cannabis or Cannabis related products, our shareholders and we should be insulated from federal prosecution or harassment. However, the growers and sellers of adult use and medical cannabis are our primary customers, and if this industry were unable to operate, we would lose substantially all of our potential clients, which would have a negative impact on our business, operations, and financial condition.
Laws and regulations affecting the Cannabis industry are constantly changing, which could detrimentally affect our proposed operations. Local, state, and federal Cannabis laws and regulations are broad in scope and subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. In addition, it is possible that regulations may be enacted in the future that will be directly applicable to our business. We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.
Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.
Our business activities are heavily regulated in all jurisdictions where we do business. Our operations are subject to various laws, regulations and guidelines by governmental authorities relating to the cultivation, processing, manufacture, marketing, management, distribution, transportation, storage, sale, packaging, labelling, pricing and disposal of cannabis and cannabis products. In addition, we are subject to laws and regulations relating to employee health and safety, insurance coverage and the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services.
Any failure by us to comply with the applicable regulatory requirements could
·
require extensive changes to our operations;
·
result in regulatory or agency proceedings or investigations;
·
result in the revocation of our licenses and permits, increased compliance costs;
·
result in damage awards, civil or criminal fines or penalties;
·
result in restrictions on our operations;
·
harm our reputation; or
·
give rise to material liabilities.
There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management’s attention and resources or other adverse consequences to our business.
Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all necessary regulatory approvals for the cultivation, processing, production, storage, distribution, transportation, sale, import and export, as applicable, of our products. Any failure to comply with the regulatory requirements applicable to our operations may lead to possible sanctions, including:
·
the revocation or imposition of additional conditions on licenses to operate our business;
·
the suspension or expulsion from a particular market or jurisdiction or of our key personnel;
·
the imposition of additional or more stringent inspection, testing and reporting requirements;
·
product recalls or seizures; and
·
the imposition of fines and censures.
In addition, changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities or a revocation of our licenses and other permits. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely affect our ongoing regulatory compliance costs. There is no assurance that we will be able to comply or continue to comply with applicable regulations.
The legal cannabis market is a relatively new industry. As a result, the size of our target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.
Because the cannabis industry remains in a relatively nascent stage, there is a lack of information about comparable companies available for potential investors to review in deciding about whether to invest in us and, few, if any, established companies whose business model we can follow or upon whose success we can build. Accordingly, investors should rely on their own estimates regarding the potential size, economics and risks of the cannabis market in deciding whether to invest in our Common Shares. We are an early-stage company that has not generated net income. There can be no assurance that our growth estimates are accurate or that the cannabis market will be large enough for our business to grow as projected.
Although we are committed to researching and developing new markets and products and improving existing products, there can be no assurances that such research and market development activities will prove profitable or that the resulting markets or products, if any, will be commercially viable or successfully produced and marketed. We must rely largely on our own market research to forecast sales and design products as detailed forecasts and consumer research are not generally obtainable from reliable third-party sources in Canada and in other international jurisdictions.
In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management’s expectations and assumptions. We could also be subject to other events or circumstances that that adversely affect the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets.
We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar international anti-bribery and anti-kickback laws with respect to our activities outside the United States.
We anticipate distributing our products to locations in Canada and United States as well as operate our business in Canada and United States. The U.S. Foreign Corrupt Practices Act, and other similar anti-bribery and anti-kickback laws and regulations, generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that we will be successful in preventing our agents from taking actions in violation of these laws or regulations. Such violations, or allegations of such violations, could disrupt our business and result in a material adverse effect on our financial condition, results of operations and cash flows.
Risks Related to Financials and Accounting
Assumptions, estimates and judgments related to critical accounting matters could significantly affect our reported financial results or financial condition.
The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the notes to our financial statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. Our operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of our Common Shares. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, fair value of biological assets, as well as revenue and cost recognition.
There are tax risks the Company may be subject to in carrying on business in multiple jurisdictions.
We and our subsidiaries will operate and, accordingly, will be subject to income tax and other forms of taxation in multiple jurisdictions. We may be subject to income taxes and non-income taxes in a variety of jurisdictions and our tax structure may be subject to review by both domestic and foreign taxation authorities. Those tax authorities may disagree with our interpretation and/or application of relevant tax rules. A challenge by a tax authority in these circumstances might require us to incur costs in connection with litigation against the relevant tax authority or reaching a settlement with the tax authority and, if the tax authority’s challenge is successful, could result in additional taxes (perhaps together with interest and penalties) being assessed on us, and as a result an increase in the amount of tax payable by us. In addition, we may be subject to different taxes imposed by the Colombian government, and changes within such tax, legal and regulatory framework may have an adverse effect on our financial results.
Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates are also subject to change. Therefore, our earnings may be affected by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The determination of our provision for income taxes and other tax liabilities will require significant judgment (including based on external advice) as to the interpretation and application of these rules. We may have exposure to greater than anticipated tax liabilities or expenses.
Additionally, dividends and other intra-group payments made by our subsidiaries or international branches may expose the recipients of such payments to taxes in their jurisdictions of organization and operation and such dividends and other intra-group payments may also be subject to withholding taxes imposed by the jurisdiction in which the entity making the payment is organized or tax resident. Unless such withholding taxes are fully creditable or refundable, dividends and other intra-group payments may increase the amount of tax paid by us. Although the Company and its subsidiaries arrange themselves and their affairs with a view to minimizing the incurrence of such taxes, there can be no assurance that we will succeed.
Restrictions on Deduction of Certain Expenses for U.S. Federal Income Tax Purposes
Section 280E of the Internal Revenue Code of 1986, as amended (the “Code”), prohibits businesses from deducting certain expenses associated with trafficking controlled substances for United States federal income tax purposes. The IRS has invoked Code Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Section 280E of the Code prohibits cannabis businesses that are deemed to be trafficking in controlled substances from deducting certain ordinary and necessary business expenses, forcing them to pay higher effective federal tax rates than similar companies in other industries. The effective tax rate on a cannabis business depends on how large its ratio of non-deductible expenses is to its total revenues. Therefore, businesses in the legal cannabis industry may be less profitable than they would otherwise be.
Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative bodies and federal courts challenging these restrictions, there is no guarantee that these authorities will issue an interpretation of Code Section 280E favorable to cannabis businesses.
Failure to develop our internal controls over financial reporting as we grow could have an adverse effect on our operations.
As our Company matures we will need to continue to develop and improve our current internal control systems and procedures to manage our growth. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls, or any failure of those controls once established, could adversely affect our public disclosures regarding our business, financial condition or results of operations. In addition, management’s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting, disclosure of management’s assessment of our internal controls over financial reporting or disclosure of our public accounting firm’s attestation to or report on management’s assessment of our internal controls over financial reporting may have an adverse effect on the price of our Common Shares.
Risks Related to Our Common Shares
We will need, but may be unable to, obtain additional funding on satisfactory terms, which could dilute our shareholders or impose burdensome financial restrictions on our business.
In the future, we hope to rely on revenues generated from operations to fund all of the cash requirements of our activities. However, there can be no assurance that we will be able to generate any significant cash from our operating activities in the future. Future financings may not be available on a timely basis, in sufficient amounts or on terms acceptable to us, if at all. Any debt financing or other financing of securities senior to the Common Shares will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a material adverse effect on our business, prospects, financial condition and results of operations because we could lose our existing sources of funding and impair our ability to secure new sources of funding. There can be no assurance that we will be able to generate any investor interest in our securities. If we do not obtain additional financing, our business may never commence, in which case you would likely lose the entirety of your investment in the Company.
Holders of our Common Shares are subject to dilution resulting from the issuance of equity-based compensation by us.
We award warrants or restricted stock units to management to incentivize their performance and retention. Any additional equity grants and any exercise of existing warrants or restricted stock units will cause our shareholders to be diluted and may negatively affect the price of the Common Shares.
Ownership of our Common Shares may be considered unlawful in some jurisdictions and holders of our Common Shares may consequently be subject to liability in such jurisdictions.
Cannabis-related financial transactions, including investment in the securities of cannabis companies and receipt of any associated benefits, such as dividends, are currently subject to anti-money laundering and a variety of other laws that vary by jurisdiction, many of which are unsettled and still developing. While the interpretation of these laws is unclear, in some jurisdictions, financial benefit directly or indirectly arising from conduct that would be considered unlawful in such jurisdiction may be viewed to be within the purview of these laws, and persons receiving any such benefit, including investors in an applicable jurisdiction, may be subject to liability under such laws. Each prospective investor should therefore contact his, her or its own legal advisor regarding the ownership of our Common Shares and any related potential liability.
Our executive officers and directors and their respective affiliates may continue to exercise significant control over our Company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.
As of the date of this 10-K, our executive officers and directors currently represent beneficial ownership, in the aggregate, of approximately 27.3% of our outstanding Common Shares. As a result, these shareholders may be able to influence our management and affairs and control the outcome of matters submitted to our shareholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These shareholders may have interests, with respect to their Common Shares, that are different from other shareholders, and the concentration of voting power among one or more of these shareholders may have an adverse effect on the price of our Common Shares. In addition, this concentration of ownership might adversely affect the market price of our Common Shares by:
·
delaying, deferring or preventing a change of control of the Company;
·
impeding a merger, consolidation, takeover or other business combination involving the Company; or
·
discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company.
The Company’s directors and officers may have conflicts of interest in conducting their duties.
We may be subject to various potential conflicts of interest because of the fact that some of our officers and directors may be engaged in a range of business activities. In addition, our executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, our executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to our business and affairs and that could adversely affect our operations. These business interests could require significant time and attention of our executive officers and directors.
The regulated nature of our business may impede or discourage a takeover, which could reduce the market price of our Common Shares.
We require and hold various government licenses to operate our business. These licensing requirements could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer for our Common Shares, which, under certain circumstances, could reduce the market price of our Common Shares.
We do not intend to pay dividends on our Common Shares in the near future, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our Common Shares.
We have never declared or paid any cash dividend on our Common Shares and do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Therefore, the success of an investment in the Common Shares will depend upon any future appreciation in their value. There is no guarantee that the Common Shares will appreciate in value or even maintain the price at which you purchased them.
Future issuances of debt securities, which would rank senior to our Common Shares upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our Common Shares for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be able to achieve from an investment in our Common Shares.
In the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders of our Common Shares. Moreover, if we issue preferred stock, the holders of such preferred stock could be entitled to preferences over holders of Common Shares in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to issue debt or preferred stock in any future offering, or borrow money from lenders, will depend in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders of our Common Shares must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return, if any, they may be able to achieve from an investment in our Common Shares.
General Risk Factors
The Company is at this point and is in a protracted legal proceeding and may in the future become involved in legal proceedings from time to time, which could adversely affect the Company.
We are currently in litigation in Nevada related to a building on land which was leased from FIORE who became insolvent. See “Litigation.” From time to time, we may be a party to other legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. We will evaluate our exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with generally accepted accounting principles. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on our financial results.
Our participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against us. Litigation, complaints, and enforcement actions involving us could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on our future cash flows, earnings, results of operations and financial condition.
The Company’s success will depend, in part, on its ability to continue to enhance its product and service offerings to respond to technological and regulatory changes and emerging industry standards and practices.
Rapidly changing markets, technology, emerging industry and regulatory standards and frequent introduction of new products characterize the Company’s business. The introduction of new products embodying new technologies and regulatory developments may render the Company’s equipment obsolete and its products and services less competitive or less marketable. The process of developing the Company’s products and services is complex and requires significant continuing costs, development efforts, third-party commitments and regulatory approvals. The Company may not be successful in developing or effectively commercializing such new products and services, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of developing such products and services, may have a material adverse effect on the Company’s business, financial condition and operating results.
We are dependent upon our management and key employees, and the loss of any member of our management team or key employees could have a material adverse effect on our operations.
The Company’s success is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management and key employees. The loss of any member of our management team or key employees could have a material adverse effect on our business and results of operations. While employment agreements and incentive programs are customarily used as primary methods of retaining the services of key employees, these agreements and incentive programs cannot assure the continued services of such employees. Any loss of the services of such individuals, or an inability to attract other suitably qualified persons when needed, could have a material adverse effect on the Company’s business, operating results or financial condition. We do not currently maintain key-person insurance on the lives of any of our key employees. Competition for qualified technical, sales and marketing staff, as well as officers and directors can be intense, and no assurance can be provided that the Company will be able to attract or retain key employees in the future, which may adversely affect the Company’s operations.
Our inability to retain and acquire skilled personnel could impair our business and operations.
The loss of any member of our management team could have a material adverse effect on our business and results of operations. In addition, the inability to hire or the increased costs of hiring new personnel, including members of executive management, could have a material adverse effect on our business and operating results. The expansion of marketing and sales of our products will require us to find, hire and retain additional capable employees who can understand, explain, market and sell our products. There is intense competition for capable personnel in all of these areas and we may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take a significant amount of time before they achieve full productivity. As a result, we may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses issued in connection to equity awards, and we may lose new employees to our competitors or other companies before we realize the benefit of our investment in recruiting and training them. In addition, as we move into new jurisdictions, we will need to attract and recruit skilled employees in those new areas.
We will need to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.
As our development and commercialization plans and strategies develop, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal and other resources. Future growth would impose significant added responsibilities on members of management. In order to manage growth and changes in strategy effectively, the Company must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities, and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth and successfully growing our Company.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us, our share price and trading volume could decline.
The trading market for our Common Shares will depend, in part, on the research and reports that securities or industry analysts publish about us or our operations. We do not have any control over these analysts and their research and reports. Securities and industry analysts do not currently, and may never, publish research on our business. If no security or industry analysts commence coverage of our Company, the trading price for our Common Shares would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about our business, our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.
We expect to incur significant ongoing costs and obligations related to our investment in infrastructure, growth, regulatory compliance and operations.
We expect to incur significant ongoing costs and obligations related to our investment in infrastructure and growth and regulatory compliance, which could have a material adverse effect on our results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on our business, results of operations and financial condition. Our efforts to grow our business may be costlier than we expect, and we may not be able to generate sufficient revenue to offset such higher operating expenses. We may incur significant losses in the future for a number of reasons, including unforeseen expenses, difficulties, complications and delays, and other unknown events.
There is no assurance that the Company’s will have insurance coverage sufficient to cover all claims to which the Company may become subject.
Our production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labor disputes, changes in the legal and regulatory framework applicable to us and environmental contingencies.
We currently do not maintain insurance coverage over our production and facilities. We may not be able to maintain insurance of the type and amount desired at a reasonable cost. If we were to incur significant liability for which we were not fully insured, it could have an adverse effect on our business, financial condition and results of operations.
We do not currently maintain key-person insurance on the lives of any of our key employees.
We may be unable to implement our business strategy, which could have negative financial and reputational effects on our business.
The growth and expansion of our business is heavily dependent upon the successful implementation of our business strategy. There can be no assurance that we will be successful in the implementation of our business strategy. A failure to do so could have negative financial and reputational effects on us. Future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis.
The Company could be subject to a security breach that could result in significant damage or theft of products and equipment.
Breaches of security at our facilities may occur and could result in damage to or theft of products and equipment. A security breach at our facilities could result in a significant loss of inventory or work in process, expose us to liability under applicable regulations and increase expenses relating to the investigation of the breach and implementation of additional preventative security measures, any of which could have an adverse effect on our business, financial condition and results of operations.

---

ITEM 1B. UNRESOLVED STAFF COMMENTS
Item 1B. Unresolved Staff Comments
Not applicable.

---

ITEM 2. PROPERTIES
Item 2. Properties.
Bucamaranga, Colombia
The Company’s 100% owned subsidiary, Allied Colombia, S.A.S., has secured vast agricultural land extension in Bucamaranga, a key production farming region of Colombia. Both areas have the benefit of having 12 hours of sunlight year-round, temperatures oscillating between 20-30 degrees celsius, with constant humidity. This environment and situation ideal to growing cannabis at low cost. The Ibague land has an area of 1,400 hectares (about 3,450 acres), all with water rights, an electrical substation, and great paved access to the property. This is situated in close proximity to the free trade zone. The Company currently has a lease arrangement for 5 hectares and a cost of $1,600 per month with an option to purchase. Further, the Company has the ability to expand its leased land footprint to the adjacent 24-hectare property.
Kelowna, British Columbia, Canada
We have office space available at 200-460 Doyle Ave, Kelowna, British Columbia, V1Y OC2, Canada. At that location Allied leases an office space within which executives of the Company can host virtual meetings via zoom, host team days and operate general corporate affairs. There is working space for Allied corporate personnel and several meeting rooms that can be rented from $10.00 per hour to a large hall that can be rented for $50.00 per hour.

---

ITEM 3. LEGAL PROCEEDINGS
Item 3. Legal Proceedings.
Other than the legal proceedings in Nevada involving retrieving our asset from the bankruptcy proceedings of another company as described under “Business”, we are not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties.
As of the date of this report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. We are not aware of any other legal proceedings pending or that have been threatened against us or our properties.
From time to time the Company may be named in claims arising in the ordinary course of business. Currently, no legal proceedings or claims, other than those disclosed above, are pending against or involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on its business and financial condition. The company doesn’t have any material updates on this matter beyond what is stated.

---

ITEM 4. MINE SAFETY DISCLOSURE
Item 4. Mine Safety Disclosures.
Not applicable.
PART II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock is quoted on the OTC Bulletin Board under the symbol “ALID”. Our symbol was changed to ALID effective August 3, 2019 upon notice to and review by FINRA. Prior to such date the Company had minimal trading under its previous symbol. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.
Below is a table indicating the range of high and low closing price information for the common stock as reported by the OTC Markets Group for the periods listed. These prices do not necessarily reflect actual transactions.
Fiscal 2024
Low
High
First Quarter
$ 0.08
$ 0.24
Second Quarter
$ 0.03
$ 0.11
Third Quarter
$ 0.04
$ 0.19
Fourth Quarter
$ 0.07
$ 0.19
Fiscal 2023
Low
High
First Quarter
$ 0.23
$ 0.65
Second Quarter
$ 0.20
$ 0.41
Third Quarter
$ 0.14
$ 0.35
Fourth Quarter
$ 0.17
$ 0.28
Holders
As of August 31, 2024, there were approximately 156 record holders of our common stock. This does not include the holders of our common stock who held their shares in street name as of that date.
Dividends
We have never paid or declared any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future but rather intend to retain future earnings, if any, for reinvestment in our future business. Any future determination to pay cash dividends will be in compliance with our contractual obligations and otherwise at the discretion of the board of directors and based upon our financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant.
Transfer Agent
Our registrar and transfer agent is ClearTrust LLC., 16540 Pointe Village Dr., Suite 205, Lutz, FL 33558.
Recent Sales of Unregistered Securities
During the year ended August 31, 2024, the Company obtained gross proceeds of $2,039,343 through the sale of shares at $0.20 per share.
On October 23, 2024, the Company entered into a Securities Purchase Agreement with an independent private banking institution wherein the Company agreed to sell 3,900,000 shares of common stock to the independent private banking institution at the purchase price of $0.20 per share for an aggregate of $780,000 in two tranches. On October 28, 2024, the Company completed the first tranche and sold 1,950,000 shares for $390,000. The second tranche is scheduled for completion on or before December 27, 2024, at which time the Company expects to receive an additional $390,000.

---

ITEM 6. SELECTED FINANCIAL DATA
Item 6. [Reserved]

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion relates to the historical operations and financial statements of Allied Corp. for the fiscal years ending August 31, 2024 and 2023.
Forward-Looking Statements
The following Management’s Discussion and Analysis should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this Annual Report. The Management’s Discussion and Analysis contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Annual Report. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risks Factors” in our various filings with the Securities and Exchange Commission. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report.
As a result of the Reorganization Agreement and the change in business and operations of the Company, a discussion of the past financial results of the Company, formally known as Cosmo Ventures, Inc., is not pertinent, and, under generally accepted accounting principles in the United States the historical financial results of AM Biosciences, the acquirer for accounting purposes, prior to the Reorganization Agreement are considered the historical financial results of the Company.
The following discussion highlights the Company’s results of operations and the principal factors that have affected its consolidated financial condition as well as its liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the Company’s consolidated financial condition and results of operations presented herein. The following discussion and analysis are based Allied Corp’s audited and unaudited financial statements contained in this Current Report, which have been prepared in accordance with generally accepted accounting principles in the United States. You should read the discussion and analysis together with such financial statements and the related notes thereto.
RESULTS OF OPERATIONS
We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.
Results for the year ended August 31, 2024 compared to the year ended August 31, 2023
Net revenues
For the fiscal year ended August 31, 2024, the Company had revenue of $96,180. For the fiscal year ended August 31, 2023, the Company had revenue of $72,096. The Company entered into multiple sales contracts leading to an increase in total revenue in 2024.
Gross loss
For the fiscal year ended August 31, 2024, the Company had a gross loss of $323,132 compared to a gross loss of $1,461,767 for the fiscal year ended August 31, 2023. The higher gross loss in the previous year was primarily driven by an inventory write-off of $1,463,157 to adjust inventory to net realizable value. Following the acquisition of Allied Colombia, the Company has generated revenue over the past few fiscal years as compared to other companies in the same industry, which have not yet started generating revenues.
Operating expenses
Operating expenses for the fiscal year ended August 31, 2024 totaled $3,653,052, compared to $6,380,166 for the fiscal year ended August 31, 2023. The decrease in operating expenses was primarily due to a reduction in stock-based compensation, which was $500,627 in the current year, compared to $3,047,156 in the prior year. In the year ended August 31, 2023, the Company granted 6,140,000 stock options to certain officers and consultants, all of which vested immediately. For the year ended August 31, 2024, the Company granted 500,000 options which will fully vest by February 13, 2026.
Net loss
For the fiscal year ended August 31, 2024, the Company recorded a net loss of $3,976,184, compared to a net loss of $10,675,671 for the fiscal year ended August 31, 2023. The larger net loss in the prior year was primarily due to a higher inventory write-off of $1,463,157 to net realizable value in 2023 compared to inventory write-off of $417,863 to net realizable value in 2024. The decrease in the net loss was further driven by loss on deposit impairment of $2,656,695 in 2023 and a higher consulting fees of $4,189,953 in 2023 compared to $1,577,148 in 2024.
LIQUIDITY AND CAPITAL RESOURCES
The following table sets forth the major components of the consolidated statements of cash flows for the years ended August 31, 2024 and 2023:
Net cash used in operating activities
$ (2,000,300 )
$ (1,956,779 )
Net cash used in investing activities
2,159,762
2,068,160
Net cash provided by financing activities
(9,892 )
(87,795 )
Effect of exchange rate on cash
(203 )
90,107
Net change in cash
149,570
23,586
Cash, beginning of period
209,736
96,043
Cash, end of period
$ 359,103
$ 209,736
As at August 31, 2024, the Company had a working deficit of $8,834,739, compared to a working deficit of $8,379,055 for the fiscal year ended August 31, 2023. The Company’s primary cash flow needs are for the development of cannabis products, operating costs, administrative expenses and for general working capital.
As at August 31, 2024, the Company had $713,559 in current assets, consisting principally of $359,103 in cash and $261,016 in inventory, as compared to $470,580 in current assets, consisting principally of $209,736 in cash and $107,510 in inventory as at August 31, 2023.
The Company continues to seek funding to meet operational needs. Historically, the Company has been financing its operations primarily through issuance of equity and convertible notes. However, there can be no assurance that future financing will be available or on favorable terms.
a) Secured Convertible Notes
As of August 31, 2023, the Company issued multiple tranches of convertible notes with attached warrants, raising total proceeds of $4,024,891. Of this amount, $543,004 was allocated to the warrants and recorded as additional paid-in capital.
These notes have undergone several amendments, setting an interest rate of 10% per annum and extending their maturity dates. By September 30, 2023, $300,000 of the principal had been repaid, and the remaining notes had matured, prompting the Company to enter into negotiations with the noteholders to further extend the maturity dates.
On March 15, 2024, a new amendment was finalized, extending the maturity of all defaulted convertible notes to December 31, 2024. The conversion prices were revised to the lesser of 80% of the 20-day average closing price per share (but no lower than $0.20 per share) or $0.50 per share. The interest rate remains 10% per annum.
Additionally, on December 4, 2023, the Company issued a convertible note with a face value of $50,000. This note bears interest at 10% per annum, matures on December 31, 2024, and is convertible into common shares at $0.20 per share prior to maturity.
As at August 31, 2024, the principal outstanding on the convertible notes totaled $3,774,891 (August 31, 2023 - $3,724,891), with accrued interest payable of $1,102,729 (August 31, 2023 - $725,721) recorded within accrued liabilities.
b) Equity Transactions
During the year ended August 31, 2024:
The Company issued a total of 10,181,990 shares of common stock at $0.2 per share and 42,000 shares of common stock at $0.072 per share, generating gross proceeds of $2,039,343, of which $50,000 had been received during the year ended August 31, 2023. Of the 10,181,990 shares of common stock issued, 6,000,000 shares were issued to a shareholder under a share purchase agreement, resulting in cash proceeds of $1,199,920 during the year ended August 31, 2024. As part of the agreement, the shareholder has the option to appoint a member to the Board of Directors. The Company incurred $50,000 in share issuance costs in connection with these transactions.
On August 16, 2024, the Company entered into an agreement with certain related parties to settle outstanding payables related to prior management and consulting services. Under the terms of the agreement, payables of $569,475 were settled through the issuance of 654,568 common shares, of which $65 was allocated to common stock and $569,410 was allocated to additional paid in capital. The difference between the settlement amount and the par value of the shares was recognized as an additional capital contribution from the related parties and recorded under additional paid-in capital.
During the year ended August 31, 2023:
On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022.
On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred a finder’s fee of $10,000 and share issuance costs of $2,792.
On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606.
On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437.
On August 21, 2023, the Company issued 1,525,000 shares of common stock at $0.20 per share for proceeds of $305,000.
On August 31, 2023, the Company issued 3,029,760 shares of common stock at $0.20 per share for proceeds of $605,952. In connection with the financing, the Company issued 1,000,000 warrants with a fair value of $204,452 as finder’s fees. Each warrant entitles the holder to acquire one common share at a price of $0.20 per share until July 30, 2025. The fair value of the finder’s warrants was calculated using the Black-Scholes option pricing model assuming the following weighted-average assumptions: a risk-free rate of 4.87%, no expected dividends or forfeiture rate, volatility of 160.87% and an expected life of 2 years.
As at August 31, 2023, the Company had received $80,000 in cash for shares subscriptions at $0.20 per share.
c) Use of funds
During the fiscal year ended August 31, 2024, the Company secured additional equity financing and received loans from related parties. These funds have supported the Company’s ongoing operations in Colombia and Canada, as well as efforts related to regulatory compliance, development of intellectual property, and strengthening working capital. The additional financing has also provided general corporate resources to sustain and grow operational capacity in key regions.
We continually assess our operational plans to determine the most effective use of our cash resources. The timeline for completing various aspects of our operations depends significantly on the availability of funds and other factors beyond our control. There is no assurance we will successfully secure the required capital or revenue, or if obtained, that the amounts will fully fund our ongoing operations.
d) Capital Expenditures
As of August 31, 2024, the Company’s carrying value of property, plant and equipment was $1,218,111 (August 31, 2023 - $1,417,192).
MediColombias Acquisition (Colombia Licensed Producer)
On August 29, 2019, the Company entered into a Share Purchase Agreement (“Purchase Agreement”) with Dorson Commercial Corp. (“Dorson”) as the sole owner of Baleno Ltd. to purchase all of the issued and outstanding shares of Baleno Ltd., the sole owner of Medicolombia Cannabis S.A.S. (“Medicolombia”). Medicolombia is based in Colombia with a full set of licenses and a lease agreement in place to begin production on a 5-hectare parcel of land. We have the ability to scale production to over hundreds of hectares. This is located in the area of Bucamaranga, Colombia.
Pursuant to the agreement the Company acquired all of the issued and outstanding shares of Medicolombia in exchange for $700,000 and 4,500,000 shares of Allied. The Company closed and completed the acquisition on February 17, 2020. Medicolombia has subsequently changed its name to Allied Colombia S.A.S.
Natural Health Products Acquisition
In May 2019 the management team of AM Biosciences were able to negotiate the inclusion of a natural health products catalogue of products. This includes 50 products in the natural health vertical market. Three of these products are of particular interest as they have Natural Health Products registration numbers with Health Canada. AM Biosciences can add these to the product offerings both in Canada and the United States.
Since the Board of Directors of the Company has determined to currently focus on the cannabis product, this project is currently on hold.
COMMITMENTS AND CONTRACTUAL OBLIGATIONS
As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.
OFF-BALANCE SHEET ARRANGEMENTS
The Company has no undisclosed off-balance sheet arrangements.
GOING CONCERN
As reflected in the accompanying financial statements, the Company had an accumulated deficit of $49,584,520 at August 31, 2024 and a net loss of $3,976,184 for the fiscal year ended August 31, 2024.
The Company does not yet have a history of financial stability. Historically, the principal source of liquidity has been the issuance of convertible notes and equity securities. In addition, the Company has generated minimal revenues since inception. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The ability of the Company to continue operations is dependent on the success of management’s plans, which include the raising of capital through the issuance of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements.
The Company will require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives. The Company believes its current available cash will be sufficient to meet its cash needs for the near future. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all.
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide this information.

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Item 8. Financial Statements and Supplementary Data.
ALLIED CORP.
CONSOLIDATED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firms (PCAOB ID #2738)
Consolidated balance sheets at August 31, 2024 and 2023
Consolidated statements of operations and comprehensive loss for the years ended August 31, 2024 and 2023
Consolidated statements of stockholders’ deficit for the years ended August 31, 2024 and 2023
Consolidated statements of cash flows for the years ended August 31, 2024 and 2023
Notes to the consolidated financial statements
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Allied Corp.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Allied Corp. (the Company) as of August 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for each of the two years in the period ended August 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended August 31, 2024, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered net losses from operations, has a net capital deficiency, and has minimal revenue which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are discussed in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Black Scholes Calculations
As discussed in Note 13 to the Consolidated Financial Statements, the Company utilizes Black Scholes calculations to determine fair value of the Company’s stock options.
Auditing management’s calculations of fair value of stock options involves significant judgements and estimates to determine the proper value. Volatility and expected term are the major assumptions used by management in determining the value of the stock options.
To evaluate the appropriateness of fair value calculation, we evaluated management’s significant judgements and estimates in what inputs were utilized within the Black Scholes calculations. We also reperformed the Black Scholes using independently determined inputs to determine the reasonableness of the fair value.
/s/M&K CPAS, PLLC
We have served as the Company’s auditor since 2022.
The Woodlands, TX
December 16, 2024
ALLIED CORP.
Consolidated Balance Sheet
(Expressed in US dollars)
August 31,
August 31,
ASSETS
Current assets
Cash
$ 359,103
$ 209,736
Inventory (Note 4)
261,016
107,510
Accounts receivable (Note 5)
47,955
134,482
Prepaid expenses
45,485
18,852
Total current assets
713,559
470,580
Non-current assets
Deposits and advances (Note 6)
20,668
26,354
Right-of-use assets (Note 10)
131,865
109,301
Property, plant and equipment (Note 7)
1,218,111
1,417,192
Intangible assets (Note 8)
30,638
40,301
Total assets
$ 2,114,841
$ 2,063,728
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable and accrued liabilities (Note 9)
$ 2,703,163
$ 2,393,359
Due to related parties (Note 14)
353,513
693,292
Current portion of lease liabilities (Note 10)
17,090
10,745
Loans payable (Note 11)
2,699,641
2,027,348
Secured convertible notes payable (Note 12)
3,774,891
3,724,891
Total current liabilities
9,548,298
8,849,635
Non-current liability
Lease liabilities, non-current portion (Note 10)
115,007
98,556
Total liabilities
$ 9,663,305
$ 8,948,191
STOCKHOLDERS’ DEFICIT
Common stock - 300,000,000 shares authorized, $0.0001 par value; 112,471,472 shares issued and outstanding (August 31, 2023 - 101,592,914)
11,248
10,160
Additional paid in capital
42,613,696
39,404,667
Common stock issuable
30,000
80,000
Accumulated deficit
(49,584,520 )
(45,608,336 )
Accumulated other comprehensive loss
(618,888 )
(770,954 )
Total stockholders’ deficit
$ (7,548,464 )
$ (6,884,463 )
Total liabilities and stockholders’ deficit
$ 2,114,841
$ 2,063,728
Nature of operations and going concern (Note 1)
Commitments and contingencies (Note 17)
Subsequent events (Note 21)
The accompanying notes form an integral part of these consolidated financial statements.
ALLIED CORP.
Consolidated Statements of Operations and Comprehensive Loss
(Expressed in US dollars, except number of shares)
For the year ended
August 31,
Sales
$ 96,180
$ 72,096
Cost of sales
(419,312 )
(1,533,863 )
Gross loss
(323,132 )
(1,461,767 )
Operating expenses:
Amortization and depreciation
139,769
137,046
Consulting fees (Note 14)
1,577,148
4,189,953
Foreign exchange loss
288,278
147,722
Office and miscellaneous
499,396
564,328
Professional fees
276,448
439,603
Travel
5,652
12,265
Convertible note interest expense
377,173
385,453
Loan interest expense
471,693
477,750
Operating lease cost
17,495
26,046
Total operating expenses
3,653,052
6,380,166
Operating loss
(3,976,184
)
(7,841,933 )
Other income (expenses):
Loss on deposit impairment (Note 17(c))
-
(2,656,695 )
Loss on license acquisition advance (Note 17(c))
-
(150,000 )
Loss on debt extinguishment
-
(27,043 )
Net loss
$ (3,976,184
)
$ (10,675,671 )
Foreign currency translation adjustment
152,066
127,265
Comprehensive loss
$ (3,824,118
)
$ (10,548,406 )
Loss per share - basic and diluted
$ (0.04 )
$ (0.11 )
Weighted average number of shares outstanding - basic and diluted
105,640,700
96,797,714
The accompanying notes form an integral part of these consolidated financial statements.
ALLIED CORP.
Consolidated Statements of Stockholders’ Deficit
(Expressed in US dollars, except number of shares)
Common stock
Additional
Common
Accumulated other
Total
Number of shares
Par Value
paid-in
capital
stock
issuable
Accumulated deficit
comprehensive
loss
stockholders'
deficit
Balance, August 31, 2022
93,967,594
$ 9,397
$ 33,999,090
$ 540,000
$ (34,932,665 )
$ (898,219 )
$ (1,282,397 )
Shares issued for cash
7,479,760
2,080,204
(540,000 )
-
-
1,540,952
Share issuance costs
-
-
191,660
-
-
-
191,660
Shares subscribed
-
-
-
80,000
-
-
80,000
Shares issued to settle debts
145,560
86,557
-
-
-
86,572
Stock-based compensation
-
-
3,047,156
-
-
-
3,047,156
Comprehensive loss for the year
-
-
-
-
(10,675,671 )
127,265
(10,548,406 )
Balance, August 31, 2023
101,592,914
10,160
39,404,667
80,000
(45,608,336 )
(770,954 )
(6,884,463 )
Shares issued for cash
10,223,990
1,023
2,038,320
(50,000 )
-
-
1,989,343
Share issuance costs
-
-
(50,000 )
-
-
-
(50,000 )
Shares issued to settled related party debts
654,568
569,410
-
-
-
569,475
Related party debt forgiveness
-
-
150,672
-
-
-
150,672
Stock-based compensation
-
-
500,627
-
-
-
500,627
Comprehensive loss for the year
-
-
-
-
(3,976,184
)
152,066
(3,824,118
)
Balance, August 31, 2024
112,471,472
$ 11,248
$ 42,613,696
$ 30,000
$ (49,584,520
)
$ (618,888
)
$ (7,548,464
)
The accompanying notes form an integral part of these consolidated financial statements
ALLIED CORP.
Consolidated Statements of Cash Flows
(Expressed in US dollars)
For the year ended
August 31,
Operating activities:
Net loss for the year
$ (3,976,184 )
$ (10,675,671 )
Adjustments for non-cash items:
Accrued interest expense
848,866
857,146
Amortization and depreciation
139,769
137,046
Inventory write-down to net realizable value
-
1,507,018
Fair value of finder's warrants
-
204,452
Loss on deposit impairment
-
2,656,695
Loss on license acquisition advance
-
150,000
Loss on debt extinguishment
-
27,043
Stock-based compensation - options
500,627
3,047,156
Adjustments for changes in working capital:
Inventory
(76,818 )
(447,175 )
Accounts receivable
86,527
(15,692 )
Prepaid expenses
(26,633 )
6,335
Deposits and advances
5,686
37,162
Accounts payable and accrued liabilities
837,639
212,686
Due to related parties
(339,779 )
339,020
Net cash used in operating activities
(2,000,300 )
(1,956,779 )
Investing activities:
Purchases of property, plant and equipment
(2,049 )
(83,170 )
Purchases of intangible assets
(7,843 )
(4,625 )
Net cash used in investing activities
(9,892 )
(87,795 )
Financing activities:
Advance from related party
-
70,000
Proceeds of convertible notes payable
50,000
390,000
Proceeds from loans payable
200,600
-
Proceeds from the issuance of common stock
1,939,343
1,528,160
Proceeds for subscriptions of stock issuable
-
80,000
Payments of lease liabilities
(30,181 )
-
Net cash provided by financing activities
2,159,762
2,068,160
Effect of exchange rate on cash
(203 )
90,107
Net change in cash
149,570
23,586
Cash, beginning of period
209,736
96,043
Cash, end of period
$ 359,103
$ 209,736
Cash paid for:
Income taxes
$ -
$ -
Interest expense
$ 17,495
$ -
The accompanying notes form an integral part of these consolidated financial statements.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
1. NATURE OF OPERATIONS AND GOING CONCERN
a) Nature of operations
Allied Corp. (the “Company” or “Allied”) was incorporated in the State of Nevada on February 3, 2013, and officially adopted its current name on July 1, 2019. The Company's head office and registered office are located at 200-460 Doyle Ave, Kelowna, British Columbia, V1Y OC2, Canada. The Company’s common shares trade on the OTCQB under the symbol “ALID”.
On February 18, 2020, the Company acquired all issued and outstanding share capital of Allied Colombia, a Colombian entity. Allied Colombia’s assets, liabilities, and results have been consolidated into these financial statements from the date of acquisition. As of August 31, 2024, Allied Colombia operates a licensed cannabis farm in Colombia.
Allied’s business plan includes the discovery of new medical technologies, some of which are cannabis-derived, aimed at providing comprehensive therapy and support for trauma survivors, military veterans, and first responders. However, the Company has not yet begun such operations or obtained the necessary permits. Its current revenue is derived from the sale of cannabis products through Allied Colombia.
b) Going concern
The consolidated financial statements for the years ended August 31, 2024 and 2023 (the “financial statements”) have been prepared on a going concern basis. For the year ended August 31, 2024, the Company incurred a net loss of $3,976,184 (2023 - $10,675,671), generated minimal revenue, and did not achieve positive operating cash flows. As at August 31, 2024, the Company had a working capital deficit of $8,834,739 (August 31, 2023 - $8,379,055). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not reflect any adjustments related to the potential recoverability and classification of recorded assets, or the amounts and classifications of liabilities, which could be required if the Company is unable to continue as a going concern. The Company’s ability to continue relies on raising sufficient financing to acquire or develop a profitable business. Management plans to fund operations and future development primarily through equity sales, supplemented by related party loans, until future operations can generate sufficient funds to meet working capital needs.
c) Business Risks
While some states in the United States have authorized the use and sale of cannabis, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against cannabis is subject to change. The Company plans to engage in cannabis-related activities in the United States, only if and when cannabis operations are federally legalized.
Given the federal illegality of cannabis, changes in U.S. federal enforcement policies could materially affect the Company’s operations and financial position. Although no federal legal actions have been taken against state-compliant cannabis businesses since the 2018 Sessions Memorandum, a policy shift could cause significant harm. Additionally, the Company’s access to U.S. public and private capital is limited, as certain federally regulated financial institutions are restricted from financing cannabis-related activities. The Company may seek alternative financing from non-federally regulated sources in the U.S., Canada, and other jurisdictions to support operations.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
2. BASIS OF PREPARATION
a) Principles of presentation
These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars. The Company’s fiscal year end is August 31.
b) Principles of consolidation
These financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.
3. SIGNIFICANT ACCOUNTING POLICIES
a) Foreign currency translation
Foreign currency transactions are translated into U.S. dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rate at the reporting date. All differences are recorded in the consolidated statements of income and comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.
Assets and liabilities of foreign operations are translated into U.S. dollars at year-end exchange rates and any revenue and expenses are translated at the average exchange rate for the year. The resulting exchange differences are recognized in other comprehensive income.
b) Cash
Cash is comprised of cash on hand, cash held in trust accounts and demand deposits.
c) Taxes receivable
Taxes receivable represent payments of VAT and are presented as part of other receivables. On a periodic basis, the Company assess recoverability of these balances based on the probability of the Colombian government to reimburse these amounts.
d) Inventory
Inventory includes work-in-progress and finished goods. Work-in-progress comprises raw materials, supplies, pre-harvest cannabis plants, and diluted crude. Finished goods consist of dried flower, CBD isolates available for sale, and purchased cannabis products.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
The costs of inventory include but are not limited to labor, utilities, nutrition and irrigation, overhead and the depreciation of manufacturing equipment and production facilities, and amortization of licenses determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and rent of grow facility. The Company began production in Colombia in late 2020, when the Company obtained approval for its strains of products. During the current period, certain costs were determined based on the actual usage of production space as compared to the normal predetermined operational production of the facility based on capacity as the Company gradually started to grow products and prepared the facility ready.
Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows.
e) Property, plant and equipment
Property, plant, and equipment are recorded at cost, net of accumulated depreciation and impairment losses. Depreciation is calculated on a straight-line basis over the assets’ estimated useful lives, which are as follows:
Category
Useful life
Farm facility and equipment
1 - 10 years
Office and computer equipment
5 - 10 years
Land equipment
10 years
f) Intangible assets
Intangible assets consist of licenses, amortized on a straight-line basis over the shorter of their estimated economic life of 10 years or their legal life. Amortization of licenses begins from the acquisition date.
The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.
For long-lived assets, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
g) Impairment of long-lived assets
Long-lived assets include property and equipment, right-of-use assets, and intangible assets with finite useful lives.
At each balance sheet date or when triggering events arise, the Company assesses long-lived assets for potential impairment. Assets are grouped at the lowest level of separately identifiable cash flows, or asset groups. Circumstances that may trigger an impairment review include significant declines in the asset's market price, adverse changes in business climate or legal factors, substantially higher than expected acquisition or construction costs, current period or projected operating losses associated with the asset, and expectations of early asset disposal.
If impairment indicators are present, the Company conducts an undiscounted cash flow analysis to assess recoverability. Impairment losses are recognized in profit or loss to the extent that an asset’s carrying amount exceeds its fair value.
h) Leases
At the start of a contract containing a lease, the Company classifies leases other than short-term leases as either operating or finance leases, following the criteria outlined in ASU 2016-02 Leases. Lease classification is only reassessed when: (a) the contract is modified and not treated as a separate contract, or (b) there is a change in the lease term or a reassessment of whether the lessee is likely to exercise a purchase option for the underlying asset. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases with terms of 12 months or less.
For both finance and operating leases, right-of-use assets and lease liabilities are initially measured as the present value of future lease payments plus initial direct costs, discounted at the lease's implicit interest rate, or, if not available, the Company’s incremental borrowing rate.
Subsequent measurements differ by lease type:
·
For finance leases, lease liabilities are measured at amortized cost using the effective interest rate method, and right-of-use assets are measured at cost less accumulated amortization, depreciated on a straight-line basis over the lease term.
·
For operating leases, lease liabilities are measured at the present value of unpaid lease payments, discounted at the original discount rate. Right-of-use assets are adjusted by accumulated amortization, calculated as the difference between the straight-line lease cost (including amortization of initial direct costs) and the periodic accretion of the lease liability.
As at August 31, 2024, the Company has one lease which is classified as an operating lease.
i) Stock-based compensation
The Company measures equity-settled share-based payments at fair value on the grant date, recognizing share-based compensation expense over the vesting period based on the estimated number of equity instruments expected to vest and uses Plain Vanilla for calculating the expected terms of options. Any consideration received from stock option exercises is recorded as an increase to common stock and additional paid-in capital.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
j) Share issuance costs
Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.
k) Secured convertible notes payable
Under the simplified guidance of ASU 2020-06, the Company accounts for convertible debt instruments, including its secured convertible notes payable as a single unit of account unless the conversion feature requires bifurcation in accordance with derivative accounting under ASC 815. Secured convertible notes payable are initially recorded at fair value adjusted for issuance costs and subsequently measured at amortized cost using the effective interest method. Convertible note interest expense includes the stated interest rate and any applicable amortized discounts. Upon conversion, the debt's carrying amount is reclassified to equity with no gain or loss recognized.
l) Financial instruments
Financial instruments represent contracts that create a financial asset for one party and a financial liability or equity instrument for another. Initially, financial instruments are recorded at fair value, reflecting the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Subsequent measurement depends on the classification of the financial instrument, with values measured at either fair value or amortized cost. For instruments measured at fair value, the Company uses quoted market prices when available to determine fair value.
Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy, based on the reliability of the lowest level of inputs used in estimating fair values. The three levels of the fair value hierarchy are as follows:
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
Level 3 - Inputs that are not based on observable market data.
The Company’s financial instruments comprise cash, trade receivables, accounts payable, accrued liabilities, loans payable, and secured convertible notes payable. There are no financial assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet. As of August 31, 2024, the carrying values of the Company’s financial instruments approximate their fair values, primarily due to their short-term maturities.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
m) Revenue recognition
The Company’s revenue is comprised of sales of cannabis products.
The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product.
Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.
n) Net income (loss) per common share
Net income (loss) per share is calculated in accordance with ASC 260 Earnings per Share. The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding to the extent the effect would not be antidilutive. Dilutive potential common shares are additional common shares assumed to be exercised.
Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.
o) Income taxes
The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.
A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
p) Related party transactions
Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.
q) Significant accounting estimates and judgments
The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.
Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1.
r) Recent accounting pronouncements
Issuance of ASU 2020-06:
In August 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-06 - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging and Contracts in Entity’s Own Equity (Subtopic 815-40), aimed at simplifying the accounting for certain financial instruments. ASU 2020-06 eliminates the existing models that require the separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the guidance on the derivative scope exception related to the equity classification of contracts in an entity’s own equity.
Additionally, the new standard introduces enhanced disclosures for convertible debt and freestanding instruments indexed to and settled in an entity’s own equity. It also amends the diluted earnings per share guidance, mandating the use of the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2022, and must be applied on a full or modified retrospective basis, with early adoption allowed starting January 1, 2021. The Company adopted ASU 2020-06 effective September 1, 2022.
Issuance of ASU 2023-07:
In November 2023, the FASB issued ASU 2023-07, which introduces improvements to the information that a public entity discloses about its reportable segments and addresses investor requests for more information about reportable segment expenses. The ASU does not change the current guidance related to the identification of operating segments, the determination of reportable segments, or the aggregation criteria. Rather, the new guidance introduces additional disclosure requirements and expands those requirements to entities with a single reportable segment, not just entities with multiple reportable segments.
ASU 2023-07 enhances interim disclosure requirements, clarifies the circumstances in which an entity can disclose multiple segment measures of profit or loss, and introduces the significant expense principle, which requires additional disclosure of segment expenses. In addition, the ASU provides new segment disclosure requirements for entities with a single reportable segment and contains other disclosure requirements.
ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The Company will adopt ASU 2023-07 for effective September 1, 2024 and the effects will be present in the Company’s financial statements the fiscal year ended August 31, 2025 and all interim periods following.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
3. SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company has not early-adopted any new accounting standard, interpretation or amendment that has been issued but is not yet effective other than ASU 2020-06. The adoption of ASU 2020-06 did not have a material impact.
4. INVENTORY
Inventory is comprised of the following items:
August 31,
August 31,
Work in progress
$ 132,508
$ 80,094
Finished goods
128,508
27,416
$ 261,016
$ 107,510
Inventory as at August 31, 2024 is presented net of a net realizable value adjustment of $417,862 (August 31, 2023 - $1,507,018). During the year ended August 31, 2024, the Company recognized an inventory write-off of $417,862 due to obsolescence (2023 - $1,507,018), recorded within cost of sales.
5. ACCOUNTS RECEIVABLE
A summary of the Company’s accounts receivable is as follows:
August 31,
August 31,
Trade receivables
$ 47,955
$ 2,570
Due from related party
-
2,446
Tax receivables
-
129,466
$ 47,955
$ 134,482
During the year ended August 31, 2024, the Company recognized a tax receivable write-off of $169,326 due to lack of recoverability of the balances (2023 - $nil).
6. DEPOSITS AND ADVANCES
As at August 31, 2024 and 2023, deposits and advances were $20,668 and $26,354, respectively, representing payments made to vendors for the construction of farm facilities in Colombia.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
7. PROPERTY, PLANT AND EQUIPMENT
A summary of the Company’s property, plant and equipment during the year ended August 31, 2024 is as follows:
Construction in process
Farm facility and equipment
Office and computer equipment
Transport equipment
Total
COST
August 31, 2023
$ 429,749
$ 1,346,373
$ 29,952
$ 29,525
$ 1,835,599
Additions
-
2,049
-
-
2,049
Effect of currency translation
(10,157 )
(16,207 )
(708 )
(698 )
(27,770 )
August 31, 2024
$ 419,592
$ 1,332,215
$ 29,244
$ 28,827
$ 1,809,878
ACCUMULATED DEPRECIATION
August 31, 2023
$ -
$ 404,559
$ 7,700
$ 6,148
$ 418,407
Additions
-
177,564
3,245
5,899
186,708
Effect of currency translation
-
(12,581 )
(338 )
(429 )
(13,348 )
August 31, 2024
$ -
$ 569,542
$ 10,607
$ 11,618
$ 591,767
NET BOOK VALUE
August 31, 2023
$ 429,749
$ 941,814
$ 22,252
$ 23,377
$ 1,417,192
August 31, 2024
$ 419,592
$ 762,673
$ 18,637
$ 17,209
$ 1,218,111
As at August 31, 2024, depreciation of $74,814 was included in inventory.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
8. INTANGIBLE ASSETS
A summary of the Company’s intangible assets during the year ended August 31, 2024 is as follows:
Licenses
COST
August 31, 2023
$ 4,535,696
Additions
7,843
Effect of currency translation
(97,920 )
August 31, 2024
$ 4,445,619
ACCUMULATED AMORTIZATION
August 31, 2023
$ 1,022,926
Additions
17,118
Effect of currency translation
(15,459 )
August 31, 2024
$ 1,024,585
ACCUMULATED IMPAIRMENT
August 31, 2023
$ 3,472,469
Effect of currency translation
(82,073 )
August 31, 2024
$ 3,390,396
NET BOOK VALUE
August 31, 2023
$ 40,301
August 31, 2024
$ 30,638
9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
A summary of the Company’s accounts payable and accrued liabilities is as follows:
August 31,
August 31,
Trade payable
$ 832,870
$ 822,447
Accrued liabilities
1,870,293
1,570,912
$ 2,703,163
$ 2,393,359
10. LEASES
The Company accounts for leases under ASC 842, Leases, which establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet.
As at August 31, 2023, the Company had one active lease for a 12.5-hectare plot of land in Los Santos Municipality, Colombia, designated for cultivation activities. The lease was set to expire on February 1, 2030. This lease was classified as an operating lease.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
10. LEASES (continued)
On August 1, 2024, the Company and the lessor amended the lease, increasing the base rent and adjusting the lease term to expire on July 31, 2029. As a result of the amendment, the carrying amounts of right-of-use assets and lease liabilities were remeasured, resulting in an increase of $39,050 in the right-of-use asset and lease liabilities.
ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the ROU asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. At August 31, 2023, the Company did not have any finance leases.
A summary of the Company’s weighted average discount rate used in calculating lease liabilities and weighted average remaining lease term is as follows:
August 31, 2024
August 31, 2023
Weighted average discount rate
15 %
15 %
Weighted average remaining lease term
4.92 years
6.00 years
The components of lease expenses were as follows:
Operating lease cost:
Amortization of right-of-use assets
$ 12,631
Interest expense on lease liabilities
17,495
Total operating lease cost
$ 30,126
As at August 31, 2024, depreciation of $1,874 from right-of-use asset was included in inventory.
For the year ended August 31, 2024, the Company incurred total operating lease cost of $30,126 (2023 - $50,125). Lease payments on the Company’s operating lease for the year ended August 31, 2024 were $30,181 (2023 - $50,125).
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
10. LEASES (continued)
A summary of the maturity of contractual undiscounted liabilities associated with the Company’s operating leases as at August 31, 2024 is as follows:
Year ending August 31,
$ 35,331
37,301
38,757
38,728
36,695
Total minimum lease payments
186,812
Less: amount of lease payments representing effects of discounting
(54,715 )
Present value of minimum lease payments
132,097
Less current portion of lease liability
(17,090 )
Lease liabilities, non-current portion
$ 115,007
11. LOANS PAYABLE
A summary of the Company’s loans payable during the year ended August 31, 2024 is as follows:
Loan for prefabricated buildings financing
Loan for equipment purchase financing
Related party loans
Other cash advance
Total
August 31, 2023
$ 1,742,648
$ 284,700
$ -
$ -
$ 2,027,348
Additions
-
-
100,600
100,000
200,600
Interest expense
451,358
20,335
-
-
471,693
August 31, 2024
$ 2,194,006
$ 305,035
$ 100,600
$ 100,000
$ 2,699,641
a) Loan for prefabricated buildings financing
In June 2020, the Company secured a financing agreement to fund the purchase of prefabricated buildings intended for potential cannabis operations.
Under the agreement, the Company borrowed $1,253,772, with an original maturity date of November 20, 2020. This date was extended through several amendments, with the most recent in June 2022, establishing a current maturity date of September 1, 2024. The revised payment terms require monthly payments of $37,613 for the first three months starting July 1, 2022, followed by monthly payments of $66,288 for the remaining period. These payments include interest at a monthly rate of 3%. For the year ended August 31, 2024, no interest was paid and the loan accrued interest payable of $451,358 (2023 - $451,358).
b) Loan for equipment purchase financing
On December 17, 2021, the Company entered into a financing agreement to fund an equipment purchase. The Company borrowed $295,543 at an interest rate of 8% per annum. The equipment financing loan required the Company to make monthly payments of $15,000 with a final balloon payment of $633 due in September 2023, however, during the year ended August 31, 2024, the Company defaulted on its monthly payments. During the year ended August 31, 2024, the Company incurred interest of $20,335 (2023 - $20,335). As of August 31, 2024, the loan is due on demand and the balance owing, including accrued interest was $305,035 (2023 - $284,700).
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
11. LOANS PAYABLE (continued)
c) Related party loans
During the year ended August 31, 2024, the Company received loans totaling $100,600 from its key management personnel. The loans bear no interest and are due on demand (Note 14(d)).
d) Other cash advance
During the year ended August 31, 2024, the Company received a cash advance of $100,000 from a third party. The loan does not bear interest and is due on demand.
12. SECURED CONVERTIBLE NOTES PAYABLE
As of August 31, 2023, the Company issued multiple tranches of convertible notes with attached warrants, raising total proceeds of $4,024,891. Of this amount, $543,004 was allocated to the warrants using the relative fair value method and recorded as additional paid-in capital. Bifurcation of the conversion feature is not required and the secured convertible notes payable are classified as a single financial liability.
These notes have undergone several amendments, setting an interest rate of 10% per annum and extending their maturity dates. By September 30, 2023, $300,000 of the principal had been repaid, and the remaining notes had matured, prompting the Company to enter into negotiations with the noteholders to further extend the maturity dates.
On March 15, 2024, a new amendment was finalized, extending the maturity of all defaulted convertible notes to December 31, 2024. The conversion prices were revised to the lesser of 80% of the 20-day average closing price per share (but no lower than $0.20 per share) or $0.50 per share. The interest rate remains 10% per annum.
Additionally, on December 4, 2023, the Company issued an additional convertible note with a face value of $50,000. This note bears interest at 10% per annum, matures on December 31, 2024, and is convertible into common shares at $0.20 per share prior to maturity.
As at August 31, 2024, the principal outstanding on the convertible notes totaled $3,774,891 (August 31, 2023 - $3,724,891), with accrued interest payable of $1,102,729 (August 31, 2023 - $725,721) recorded within accrued liabilities.
13. EQUITY
a) Common share transactions
During the year ended August 31, 2024:
The Company issued a total of 10,181,990 shares of common stock at $0.20 per share and 42,000 shares of common stock at $0.072 per share, generating gross proceeds of $2,039,343, of which $50,000 had been received during the year ended August 31, 2023. Of the 10,181,990 shares of common stock issued, 6,000,000 shares were issued to a shareholder under a share purchase agreement, resulting in cash proceeds of $1,199,920 during the year ended August 31, 2024. As part of the agreement, the shareholder has the option to appoint a member to the Board of Directors. The Company incurred $50,000 in share issuance costs in connection with these transactions.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
13. EQUITY (continued)
On August 16, 2024, the Company entered into an agreement with certain related parties to settle outstanding payables related to prior management and consulting services. Under the terms of the agreement, payables of $569,475 were settled through the issuance of 654,568 common shares, with a fair value of $65,457, of which $65 was allocated to common stock and $569,410 was allocated to additional paid in capital. The difference between the settlement amount and the par value of the shares was recognized as an additional capital contribution from the related parties and recorded under additional paid-in capital.
During the year ended August 31, 2023:
On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022.
On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred a finder’s fee of $10,000 and share issuance costs of $2,792.
On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606.
On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437.
On August 21, 2023, the Company issued 1,525,000 shares of common stock at $0.20 per share for proceeds of $305,000.
On August 31, 2023, the Company issued 3,029,760 shares of common stock at $0.20 per share for proceeds of $605,952. In connection with the financing, the Company issued 1,000,000 warrants with a fair value of $204,452 as finder’s fees. Each warrant entitles the holder to acquire one common share at a price of $0.20 per share until July 30, 2025. The fair value of the finder’s warrants was calculated using the Black-Scholes option pricing model assuming the following weighted-average assumptions: a risk-free rate of 4.87%, no expected dividends or forfeiture rate, volatility of 160.87% and an expected life of 2 years.
As at August 31, 2023, the Company had received $80,000 in cash for shares subscriptions at $0.20 per share.
b) Share purchase warrants
The following table summarizes the continuity of share purchase warrants:
Number of warrants
Weighted average exercise price
#
$
August 31, 2023
5,459,000
1.06
Expired
(4,459,000 )
1.25
August 31, 2024
1,000,000
0.20
As at August 31, 2024, there were 1,000,000 warrants outstanding. These warrants have exercise price of $0.20 and will expire on July 30, 2025.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
13. EQUITY (continued)
c) Stock options
The Company measures equity-settled share-based payments at fair value on the grant date, recognizing share-based compensation expense over the vesting period based on the estimated number of equity instruments expected to vest and uses Plain Vanilla for calculating the expected terms of options. Any consideration received from stock option exercises is recorded as an increase to common stock and additional paid-in capital.
A summary of the Company’s stock option activity is as follows:
Number of options
Weighted average exercise price
Weighted average remaining contractual term
Aggregate Intrinsic Value
#
$
Years
$
August 31, 2023
12,140,000
0.25
3.70
55,900
Granted
500,000
0.12
1.64
-
Outstanding, August 31, 2024
12,640,000
0.21
3.74
-
Exercisable, August 31, 2024
11,756,667
0.22
3.70
-
A summary of the Company’s outstanding stock options is as follows:
Expiry date
Number of options
Weighted average exercise price
Weighted average remaining contractual term
#
$
Years
February 1, 2026
1,750,000
0.27
1.42
September 2, 2026
100,000
0.42
2.01
March 1, 2027
300,000
0.22
2.50
May 1, 2027
1,000,000
0.27
2.67
October 1, 2028
200,000
0.20
4.09
January 1, 2029
8,990,000
0.20
4.34
March 1, 2029
300,000
0.06
4.50
12,640,000
0.21
3.74
During the year ended August 31, 2024, the Company incurred stock-based compensation of $500,627 from the vesting of stock options (2023 - $3,047,156). All stock-based compensation was recorded within consulting fees on the consolidated statements of operations and comprehensive loss.
Granting of new stock options
On March 1, 2024, the Company granted 300,000 options to a consultant with an exercise price of $0.06, expiring on March 1, 2029. The options vest in two equal tranches over six-month intervals. The fair value of these options was estimated at $27,573, using the Black-Scholes model with the following assumptions: stock price of $0.10, expected life of 5 years, risk-free interest rate of 4.17%, volatility of 179%, and no dividend yield.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
13. EQUITY (continued)
Granting of performance-based options
On January 1, 2024, the Company entered into a performance-based option agreement with a consultant, allowing for the potential vesting of up to 500,000 options upon meeting specified performance conditions. The options vest over a two-year period from the date each milestone is achieved. During the year ended August 31, 2024, 200,000 options were granted following the achievement of performance conditions. These options have an exercise price of $0.20, expire on October 1, 2028, and are scheduled to fully vest by February 13, 2026.
The fair value of these options was $15,765 and was estimated using the Black-Scholes option pricing model, applying the following weighted average inputs: stock price of $0.085, expected life of 4.75 years calculated based on Plain Vanilla, risk-free interest rate of 3.93%, expected volatility of 178%, and no dividend yield.
Modification of options
On January 1, 2024, the Company modified the exercise price and vesting terms for 300,000 previously granted and unexercised options as follows:
Number of
stock options
Original
exercise price
Original
vesting terms
Modified
exercise price
Modified
vesting terms
300,000
$0.22
100,000 on October 1, 2024
100,000 on October 1, 2025
100,000 on October 1, 2026
$0.20
150,000 on January 1, 2024
150,000 on September 30, 2024
The adjustment was treated as a modification, requiring a remeasurement of the options’ fair value as of the modification date. The fair value was determined using the Black-Scholes option pricing model with the following inputs: stock price of $0.085, expected life of 4.75 years calculated based on Plain Vanilla, risk-free interest rate of 3.93%, expected volatility of 178%, and no dividend yield. This remeasurement resulted in an incremental stock-based compensation expense of $28,129.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
14. RELATED PARTY TRANSACTIONS AND BALANCES
a) Key management compensation through consulting services
The Company has identified its key management personnel to include its directors and senior officers. A summary of the compensation provided to key management during the years ended August 31, 2024 and 2023 is as follows:
Compensation to the Chief Executive Officer (“CEO”)
$ 109,767
$ 112,311
Compensation to the Chief Financial Officer (“CFO”)
92,627
84,249
Compensation to the Chief Operations Officer (“COO”)
92,627
93,592
Compensation to the Chief Business Development Officer (“CBDO”)
150,029
-
Compensation to the directors
74,500
105,900
$ 519,550
$ 396,052
All compensation provided to key management personnel is made in the normal course of business and is included in consulting fees.
b) Stock-based compensation
A summary of stock-based compensation from vesting options granted to related parties during the years ended August 31, 2024 and 2023 is as follows:
Stock-based compensation to the CFO
$ 15,683
$ 494,499
Stock-based compensation to the directors
74,698
730,105
$ 90,381
$ 1,224,604
All stock-based compensation is recorded within consulting fees.
c) Debt settlements with related parties
During the year ended August 31, 2024, the Company entered into a debt waiver agreement with its CEO and COO, under which each officer forgave $75,336 in payables related to past management services. As a result, the Company wrote off a total payable amount of $150,672 and recognized this as a capital contribution from the officers, which was recorded in additional paid-in capital.
On August 16, 2024, the Company entered into a debt settlement agreement with certain directors and senior officers. Under the agreement, outstanding payables owed to these individuals were settled through the issuance of the Company’s common shares. The table below summarizes the amounts settled and the number of shares issued to each related party:
Settlement with CEO
Settlement with COO
Settlement with CBDO
Settlement with director
Total
Settlement amount
$ 126,500
$ 178,000
$ 114,975
$ 150,000
$ 569,475
Number of shares issued (#)
145,402
204,597
132,155
172,414
654,568
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
14. RELATED PARTY TRANSACTIONS AND BALANCES (continued)
The settlement amount of $569,475 was recognized as capital contribution from the officers and was recorded as equity.
d) Amounts due to related parties
In the normal course of operations, the Company shares certain administrative resources with entities related by common management and directors. These administrative resources and services are measured at their exchange value. All amounts payable and receivable from related parties are non-interest bearing, unsecured, and due on demand.
During the year ended August 31, 2024, the Company received short-term loans totaling $20,600 from its CBDO and $80,000 from one of its directors. These loans are due on demand and bear no interest.
The following table summarizes the amounts due to related parties:
August 31, 2024
August 31, 2023
Trade payables to the CEO
$ 17,428
$ 156,028
Trade payables to the COO
4,371
201,612
Trade payables to the CFO
129,309
84,962
Trade payable to the CBDO
7,718
-
Trade payable to a director
-
159,690
Trade payable to a former director
194,687
91,000
Outstanding short-term loan from the CBDO
20,600
-
Outstanding short-term loan from a director
80,000
-
$ 454,113
$ 693,292
15. FINANCIAL RISK FACTORS
The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:
a) Credit risk
Credit risk arises when one party to a financial instrument fails to meet its obligations, potentially causing financial loss to the other party. The Company’s main exposure to credit risk lies in its cash holdings and trade receivables. Cash is securely held with major Canadian banks, and trade receivables remain minimal. Management considers the overall credit risk to be low.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
15. FINANCIAL RISK FACTORS (continued)
b) Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. As at August 31, 2024, the Company had a working capital deficiency of $8,834,739 (August 31, 2023 - $8,379,055). To address this risk, the Company has implemented a planning and budgeting process to assess the funding required to support its operations. Limited cash resources have impacted the Company’s ability to meet some obligations as they fall due, including accounts payable, loans payable, and secured convertible notes. Loans payable totaling $2,699,641 are due on demand. During the year ended August 31, 2024, the Company negotiated an extension of its convertible notes’ maturity to December 31, 2024. The Company continues to seek funding through equity offerings or debt financing to meet operational needs, while carefully managing existing cash resources. However, there can be no assurance that future financing will be available or on favorable terms and as a result, liquidity risk is high.
c) Interest rate risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to interest rate risk is minimal, as it does not hold any variable-rate financial liabilities.
d) Foreign exchange risk
Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate risk but manages the risk my minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Canadian dollars:
August 31, 2024
August 31, 2023
Accounts payable and accrued liabilities
$ (1,023,380 )
$ (947,214 )
Net exposure in Canadian dollars
$ (1,023,380 )
$ (947,214 )
Balance in US dollars
$ (758,452 )
$ (700,032 )
As at August 31, 2024, a 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company’s net loss by approximately $75,845 (August 31, 2023 - $70,003).
The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Colombian Pesos:
August 31, 2024
August 31, 2023
Cash
$ 238,480,051
$ 415,100,982
Accounts receivable
200,766,822
539,704,008
Accounts payable and accrued liabilities
(496,725,947 )
(3,669,893,803 )
Net exposure in Columbian Pesos
$ (57,479,074 )
$ (2,715,088,813 )
Balance in US dollars
$ (13,730 )
$ (664,234 )
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
15. FINANCIAL RISK FACTORS (continued)
As at August 31, 2024, a 10% change in the US dollar to the Colombian Peso exchange rate would impact the Company’s net loss by approximately $1,373 (August 31, 2023 - $66,423).
16. CAPITAL MANAGEMENT
The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the business and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business. The Company has a working capital deficit and requires additional capital to finance its future business plans. The Company is not subject to any externally imposed capital requirements.
17. COMMITMENTS AND CONTINGENCIES
The Company is involved in various claims, litigation and other matters in the ordinary course and conduct of business. Some of these pending matters may take a number of years to resolve. While it is not possible to determine the ultimate outcome of such actions at this time, and inherent uncertainties exist in predicting such outcomes, it is the Company’s belief that the ultimate resolution of such actions is not reasonably likely to have a material adverse effect on its consolidated financial position or results of operations.
a) As of August 31, 2023 and 2024, the Company recorded a contingent liability of $547,190 (CAD$700,000) for expenses in connection with Allied Colombia acquisition, which is included in the balance of accounts payable and accrued liabilities on the consolidated balance sheet.
b) The Company has entered into binding lease agreement for agricultural land in Colombia (Note 9).
c) In June 2019, AM Biosciences, a subsidiary of the Company, contracted to manufacture a building initially intended for Canadian operations but later designated for potential U.S. operations in Nevada, pending federal legalization of cannabis. On March 30, 2021, Allied US Products LLC, another subsidiary, agreed to purchase two Nevada cannabis cultivation licenses for $150,000, with a $1,350,000 promissory note and assumed liabilities. Tactical Relief LLC, a subsidiary, also signed a 25-year lease with Fiore Subsidiary for a Nevada property to house these buildings. By August 31, 2022, the Company had paid deposits totaling $2,656,695 for the buildings and $150,000 for the licenses, though the buildings were not yet delivered.
In December 2022, the Fiore Subsidiary became insolvent, and the leased property was scheduled for a trustee’s sale. The Company filed a lawsuit in Nevada court seeking to halt the sale or obtain damages, filing a lis pendens to assert its claim on the buildings as personal property. Despite these efforts, the sale proceeded, and the buyer claimed ownership of the buildings as part of the property. The Company is currently awaiting a court decision to affirm its ownership. Due to uncertainty in recoverability, a loss on deposit impairment of $2,656,695 and a $150,000 loss on the license advance were recorded for the year ended August 31, 2023, as the purchase agreement was effectively terminated.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
18. NON-CASH ACTIVITIES
A summary of the Company’s non-cash transactions during the years ended August 31, 2024 and 2023 is as follows:
Fair value of warrants issued as finder fees
$ -
$ 204,452
Common stock issuable applied to shares issued in the year
$ 50,000
$ -
Shares issued to settle accounts payable and accrued liabilities
$ 569,475
$ -
Related party debt forgiveness of accounts payable and accrued liabilities
$ 150,672
$ -
19. SEGMENT INFORMATION
The Company has two operating segments including:
·
Allied Colombia, a Colombian based company through which the Company intends to commence commercial production in Colombia. (Allied Colombia)
·
Allied Corp. which consists of the rest of the Company’s operations (Allied)
Factors used to identify the Company’s reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company’s operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates the Allied reporting segment in one geographical area (Canada), and the Allied Colombia reporting segment in one geographical area (Colombia).
A summary of the Company’s segment information is as follows:
Allied
Allied Columbia
Total
Gross margin
$ -
$ (323,132 )
$ (323,132 )
Net loss
$ (2,659,406 )
$ (1,316,778 )
$ (3,976,184 )
Depreciation and amortization
$ 76,392
$ 63,377
$ 139,769
Total asset
$ 836,262
$ 1,278,579
$ 2,114,841
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
20. INCOME TAXES
As at August 31, 2024, the Company has a net operating loss carryforward of approximately $20,292,000 (August 31, 2023 - $20,588,000). A summary of the significant components of deferred income tax assets is as follows:
August 31, 2024
August 31, 2023
Net operating loss carryforward
$ 5,223,000
$ 5,095,000
Less: valuation allowance
(5,223,000 )
(5,095,000 )
Net deferred tax asset
$ -
$ -
The amount taken into income as deferred income tax assets must reflect that portion of the income tax loss carry forwards that is more likely-than-not to be realized from future operations. The Company has chosen to provide a full valuation allowance against all available income tax loss carry forwards. The Company has recognized a valuation allowance for the deferred income tax asset since the Company cannot be assured that it is more likely than not that such benefit will be utilized in future years. The valuation allowance is reviewed annually. When circumstances change and which cause a change in management’s judgment about the realizability of deferred income tax assets, the impact of the change on the valuation allowance is generally reflected in current income.
As at August 31, 2024 and 2023, the Company has no recognized income tax benefits. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items as tax expense. No interest or penalties have been recorded during the years ended August 31, 2024 and 2023. No interest or penalties have been accrued as at August 31, 2024 and 2023. As at August 31, 2024 and 2023, the Company did not have any amounts recorded pertaining to uncertain tax positions.
A reconciliation of the provision for income taxes at the combined statutory rate for the years ended August 31, 2024 and 2023 is as follows:
August 31, 2024
August 31, 2023
Income tax benefit
$ 1,028,000
$ 1,970,000
Non-deductible expenditures and other
(53,000 )
-
Adjustment to prior years provision versus statutory tax returns
760,000
-
Change in valuation allowance
(128,000 )
(1,970,000 )
Income tax expense
$ -
$ -
As at August 31, 2024, the Company had approximately $11,014,000 (August 31, 2023 - $11,942,000) of US federal net operating losses that may be available to offset future taxable income. In accordance with Section 382 of the Internal Revenue Code, deductibility of the Company’s U.S. net operating carryovers may be subject to an annual limitation in the event of a change of control as defined the regulations. A Section 382 analysis has not been prepared and the Company’s NOLs could be subject to limitation. The Company also had as at August 31, 2024 approximately $4,056,000 (August 31, 2023 - $3,601,000) of Canadian non-capital losses which will begin to expire in 2043. In addition, the Company had Colombian net operating losses of $5,222,000 as at August 31, 2024 (August 31, 2023 - $5,045,000) which will begin to expire in 2035.
ALLIED CORP.
Notes to the consolidated financial statements
For the year ended August 31, 2024 and 2023
(Expressed in US dollars)
21. SUBSEQUENT EVENTS
On September 27, 2024 and October 1, 2024, the Company settled outstanding liabilities with two former employees through the issuance of 638,912 and 435,000, respectively.
On October 1, 2024, the Company amended its agreement with a consultant to provide for the grant of up to 700,000 performance-based options between October 1, 2024 and March 31, 2025. Pursuant to the amendment, the consultant will be granted a maximum of 100,000 options each time a sales contract with an annual value of $100,000 is signed. For any contracts with an annual value exceeding $1,500,000, the consultant will be awarded 200,000 options. Options granted pursuant to achievement of performance targets will vest over a two-year period from the date the contract is signed.
On October 21, 2024, the Company appointed Abdul Musoke Nnyenje to the Company’s Board of Directors. As part of his appointment, the Company issued 918,750 options at an exercise price of $0.20 per share to Mr. Nnyenje. The options are exercisable 7 years from the issuance date.
On October 23, 2024, the Company entered into a Securities Purchase Agreement with an independent private banking institution wherein the Company agreed to sell 3,900,000 shares of common stock to the independent private banking institution at the purchase price of $0.20 per share for an aggregate of $780,000 in two tranches. On October 28, 2024, the Company completed the first tranche and sold 1,950,000 shares for $390,000. The second tranche is scheduled for completion on or before December 27, 2024, at which time the Company will receive an additional $390,000.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Effective August 1, 2022, we engaged M&K CPAS, LLLC (“M&K”) to serve as our independent registered public accounting firm for our fiscal years ending August 31, 2024 and 2023. During our most recent fiscal year ending August 31, 2024 and 2023 we did not consult with M&K regarding (i) the application of accounting principles to a specific transaction, either completed or contemplated, or the type of audit opinion that might be rendered on our financial statements, and no written report or oral advice was provided to us that was an important factor to be considered by us in reaching a decision as to an accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

---

ITEM 9A. CONTROLS AND PROCEDURES
Item 9A. Controls and Procedures.
Management’s Annual Report on Internal Control over Financial Reporting.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.
Our management evaluated the effectiveness of the Company’s internal control over financial reporting as of August 31, 2024. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. While our initial assessment, completed on August 31, 2024 deemed internal controls effective, based upon a further evaluation of legal proceedings during our annual audit, which was conducted subsequent to August 31, 2024, we modified management’s initial estimates used in our asset impairment in a manner that caused audit adjustments. Accordingly, management concluded there was a material weakness in our internal control over financial reporting at August 31, 2024, based on the COSO framework criteria, since management lacked a formal policy of testing for impairment resulting in adjusting journal entries.
This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permits us to provide only management’s report in this annual report.
Changes in Internal Control over Financial Reporting.
There were no changes in our internal control over financial reporting that occurred during the fiscal year ended August 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

---

ITEM 9B. OTHER INFORMATION
Item 9B. Other Information.
None.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Item 10. Directors, Executive Officers and Corporate Governance.
The table below reflects the Company’s executive officers and directors. There is no agreement or understanding between the Company and each current or proposed director or executive officer pursuant to which he was selected as an officer or director. The address for each such officer and director is 200-460 Doyle Ave, Kelowna, British Columbia, V1Y OC2, Canada.
Name
Intended Positions and Offices
Calum Hughes
Chairman of the Board, Chief Executive Officer and Director
Michael Moses
Chief Business Development Officer
Paul Bullock
Chief Operating Officer, Interim Chief Financial Officer and Director (1)
Jim Smeeding
Vice President of Pharmaceuticals and Director
Ryan Maarschalk
Chief Financial Officer (1)
Abdul Musoke
Director (2)
(1)
Ryan Maarschalk presented his resignation on August 19, 2024 and on October 11, 2024, Paul Bullock was named as interim CFO.
(2)
On October 21, 2024, Abdul Musoke was appointed as Director of the Company.
The Directors and Officers named above will serve until the next annual meeting of the stockholders or until their respective resignation or removal from office. Thereafter, Directors are anticipated to be elected for one-year terms at the annual stockholders’ meeting. Officers will hold their positions at the pleasure of the Board of Directors, absent any employment agreement, of which none currently exists or is contemplated.
Calum Hughes, Chairman of the Board, Chief Executive Officer, Director
Calum Hughes has been responsible for leading activities relating to large scale Quality Assurance and Evaluation of Health Programs. He is skilled in the Project Management Institute’s Methodology© for managing projects through mitigating risk, maximizing communication and ensuring project success.
In the past, Calum has created and presented at top level educational presentations for Healthcare Executives, Business Professionals, Psychiatrists, Nursing staff, General Practitioners, Internal Medicine, ObGyn, and Cardiologists. He has worked as an Adjunct Professor for the UBC Faculty of Health and Social Development, as a Consultant to several large for-profit and non-profit Health Organizations and Nutraceutical companies.
Calum, has held an appointment of Adjunct Professor for the University of British Columbia Faculty of Health and Social Development, and is a Registered Kinesiologist with the British Columbia Association of Kinesiologists. He has also completed a Post Baccalaureate Diploma in Gerontology. Calum holds certification in designation of Project Management Professional (PMP) from the Project Management Institute (Pennsylvania, USA). He achieved a 98% (certified with Gold Standing) in his studies towards a LEAN Greenbelt in 2009, and is also working towards his Doctorate Degree with Royal Roads University.
Calum’s past clinical experience includes functioning as a health care provider for patients with co-morbid chronic diseases, acute disability and workplace health & wellness. Working as a clinician, Calum has created Physical & Functional Diagnostic Tools and Chronic Disease Management Protocols for Cardiovascular, Orthopedic, Obesity, Respiratory, Brain Injury, and Cerebrovascular disease. He has created teaching resources and presented at top-level educational presentations regarding Change Management, Quality Improvement, Personality & Communication, Project Management and Lean Manufacturing Method for Healthcare.
Michael Moses, Chief Business Development Officer
Entrepreneur with executional expertise in go to market, business strategy and partnership building with some of the largest philanthropy organizations in the UK. With experience in working with Engineering, Investment and Risk Management firms from across three continents, Michael brings a strong understanding of both the business needs to taking products to market. Masters in Electronic Engineering with Management from Imperial College London & Guest Lecturer at Imperial College Business School. His expertise, along with his network in the Cannabis industry, will be instrumental in identifying new opportunities and driving growth for the Company.
Paul Bullock, Chief Operating Officer and Director
Born and raised in Kelowna, BC, Canada, Paul Bullock comes from one of Kelowna’s oldest pioneer families, which possesses a rich history in both agricultural innovation and entrepreneurial spirit. Paul brings 10 years of experience to the Allied team from MMAR, MMPR, and ACMPR cannabis cultivation, genetics, compliance and facility design.
Previous to joining Allied, Paul owned and operated a company specializing in both personal and corporate finance for clients, which offered exportable services in overseas and offshore markets. Earlier, Paul worked in the oil and gas industry specializing in offshore construction. Paul also owned and operated an agricultural management and consulting firm, which renovated and replanted over 2,500 acres of orchard and vineyard in the Okanagan Valley. He was also the Kelowna site operations manager for Kettle Mountain Ginseng, one of the pioneers in the British Colombia ginseng industry.
Jim Smeeding, Vice President of Pharmaceuticals and Director
Jim Smeeding is a Registered Pharmacist (RPh) from the State University of New York, and also holds a Master’s degree in Business Administration (MBA) from the University of Texas (with an emphasis in pharmaceutical marketing, organizational strategies and pharma sales management). He is the Executive Vice President of CP Pharmaceutical International: a division of CP Global Health (Hong Kong and Texas).
Some of Mr. Smeeding’s past experience has included working as the Executive Director of the National Association of Specialty Pharmacy (NASP), a founder of the Center for Pharmacoeconomic Studies at the University of Texas College of Pharmacy and a founder and President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
Within Mr. Smeeding’s specialty pharmacy consultancy practice, Project Rx, Mr. Smeeding has offered management services to hospitals and pharmaceutical companies throughout the US. Mr. Smeeding has also been active in other Cannabis Based Medicines (CBM) research as a founder of CannaPharma Rx and has authored more than 85 peer-reviewed publications and has given hundreds of presentations.
Mr. Smeeding has worked with many major pharmaceutical companies and is aa founder and president of Indication Biosciences; an early-stage drug discovery company that is examining the use of CBD with statin agents to safely lower lipid anomalies. Mr. Smeeding also was the Executive VP and founder of Engaged Media; a technology driven patient engagement solution used in multiple pharmaceutical co-pay programs that was acquired in May of 2018.
As President of the National Payer Roundtable, Mr. Smeeding is in regular contact with the Chief Medical Officers and Chief Pharmacy Officers of national and regional health insurers, as well as, pharmaceutical executives.
Ryan Maarschalk, BSc, CPA, Chief Financial Officer
Mr. Maarschalk is a driven leader with multifaceted communication skills, and a proven track record of successfully working with senior leadership to achieve growth. Mr. Maarschalk uses his entrepreneurship experience to communicate financial information for real life decision making. Some of Mr. Maarschalk’s past experience includes merger and acquisition activities to successfully close the acquisition of IMPACT Radio Accessories to private equity for $23,000,000, building extraction and cultivation facilities in Las Vegas with 1933 Industries (TGIF.CSE). Mr. Maarschalk has worked with variety of companies since becoming a consulting CFO, including micro- mobility, wineries, cannabis and real estate. Mr Maarschalk has also worked as a Business Valuation Associate with MVI Valuations & Planning, Senior Accountant with Crowe MacKay LLP (accounting firm) and has been a Co-Founder / Board Member of various companies over the years.
Mr. Maarschalk is a Chartered Professional Accountant (CPA) Institute of Chartered Professional Accountants. He has a Bachelor of Biomedical Science BSc. (Hons) and is a Chartered Business Valuator (CBV) candidate (CICBV Canadian Institute of Business Valuators).
Abdul Musoke Nnyenje, Director
On October 21, 2024, the Company appointed Abdul Musoke Nnyenje to the Company’s board of directors.
Mr. Nnyenje currently serves as Chief Strategy Officer at Afri Digital Media Corp, a UAE-based pan-African media and lifestyle brand with operational assets across Uganda, Tanzania, Burundi, and Rwanda. In this role, Abdul is responsible for spearheading strategic acquisitions, overseeing market expansion initiatives, licensing & regulatory compliance, driving corporate governance as well as overall group commercial strategy. Mr. Nnyenje is a Director in Albertine Nuts Uganda Ltd a 500-acre macadamia orchard along the slopes of the East African Rift Valley in western Uganda where he leads the finance, partnerships and strategy functions. Previously, Mr. Nnyenje has served as a Regulatory Economist leading a regulatory competitions and market oversight department. This role included responsibilities in multinational negotiations, international settlement frameworks as well as reviewing industry Mergers and Acquisitions. Abdul remains a contributing member of the International Telecom Union’s Study Group 3 on Telecom Economics and Markets. Mr. Nnyenje holds a Bachelor in Statistics (Economics Major), Master of Business Administration, several postgraduate certifications and is a Fellow of the Tufts University FLPFI Program.
Involvement in Certain Legal Proceedings
No director, executive officer, promoter or control person of Allied has, during the last ten years: (i) been convicted in or is currently subject to a pending a criminal proceeding (excluding traffic violations and other minor offenses); (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to any federal or state securities or banking or commodities laws including, without limitation, in any way limiting involvement in any business activity, or finding any violation with respect to such law, nor (iii) any bankruptcy petition been filed by or against the business of which such person was an executive officer or a general partner, whether at the time of the bankruptcy or for the two years prior thereto.
Committees of the Board
Decisions of the Board of Directors are generally taken by written unanimous resolutions. The current Board comprises four members and is intending to hold regularly scheduled meetings. The entire board provides the functions of Audit, Compensation and Governance committees until such time as charters for these committees can be adopted and they can be populated by independent directors.
Family Relationships
No family relationships exist between any of our present directors and officers.
Compliance with Section 16(A) of The Exchange Act
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires that our directors and executive officers and persons who beneficially own more than 10% of our common stock (referred to herein as the “reporting persons”) file with the SEC various reports as to their ownership of and activities relating to our common stock. Such reporting persons are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file. Based solely upon a review of copies of Section 16(a) reports and representations received by us from reporting persons, and without conducting any independent investigation of our own during the fiscal year ended August 31, 2024, all forms required, if any, were filed with the SEC by such reporting persons.
Changes in Nominating Procedures
None

---

ITEM 11. EXECUTIVE COMPENSATION
Item 11. Executive Compensation.
Summary Compensation Table
The following table sets forth the total compensation paid to, or accrued by, the Named Executive Officers and any other employees earning over $100,000 per year from August 31, 2021 to date. No restricted stock awards, long-term incentive plan payout or other types of compensation were paid to these executive officers during those fiscal years.
Name
Year
Fees earned or paid in cash
($)
Stock awards
($)
Number of stock options granted
Non-equity incentive plan compensation
($)
Change in pension value and nonqualifed deferred compensation earnings
($)
All other compensation ($)
Total ($)
Calum Hughes
$ 109,767
-
-
-
-
-
$ 109,767
$ 112,311
-
-
-
-
-
$ 112,311
$ 119,205
-
-
-
-
-
$ 119,205
$ 118,756
-
-
-
-
-
$ 118,756
Paul Bullock
$ 92,627
-
-
-
-
-
$ 92,627
$ 93,592
-
-
-
-
-
$ 93,592
$ 99,337
-
-
-
-
-
$ 99,337
$ 101,563
-
-
-
-
-
$ 101,563
Jim Smeeding
$ 60,000
-
-
-
-
-
$ 60,000
$ 60,000
-
140,000
-
-
-
$ 60,000
$ 60,000
-
-
-
-
-
$ 60,000
$ 75,000
-
-
-
-
-
$ 75,000
Santiago Ribero
$ 14,500
-
-
-
-
-
$ 14,500
$ 45,900
-
1,900,000
-
-
-
$ 45,900
$ 42,000
-
-
-
-
-
$ 42,000
$ 42,000
-
-
-
-
-
$ 42,000
Ryan Maarschalk
$ 92,627
-
-
-
-
-
$ 92,627
$ 84,249
-
1,900,000
-
-
-
$ 84,249
$ 69,536
-
-
-
-
-
$ 69,536
$ 96,530
-
-
-
-
-
$ 96,530
Michael Moses
$ 150,029
-
-
-
-
-
$ 150,029
$ -
-
-
-
-
-
$ -
$ -
-
-
-
-
-
$ -
$ -
-
-
-
-
-
$ -
No stock options were granted to key management personnel during the year ended August 31, 2024.
Although compensation has been paid to our officers and directors on behalf of Advanced Biosciences, no compensation has been paid to date from Allied Corp. to any of our existing officers and directors.
Employment Agreements
The Company is not a party to any employment agreement with its Officers or its Directors currently. At present, the Company has entered into consulting agreements with entities controlled by Calum Hughes (Director & CEO), Paul Bullock (Director & COO), Jim Smeeding (Director & VP Pharmaceutical), Michael Moses (Chief Business Development Officer) and Ryan Maarschalk (CFO). At present these individuals are paid on a monthly basis in the amounts of CA$12,000, CA$10,500, US$5,000, CA$12,000 and CA$10,500, respectively. Total balances paid during the year included amounts paid to previous directors and officers of the Company.
Effective September 1, 2024, the Company revised the monthly payment amounts of Calum Hughes (Director & CEO), Paul Bullock (Director & COO) and Michael Moses (Chief Business Development Officer) to CA$6,000, $CA5,000 and $CA6,000, respectively and revised the monthly payment of Jim Smeeding (Director & VP Pharmaceutical) to a quarterly payment of US$2,500.
Equity Compensation Plans
During 2020, the Company’s board of directors approved the Allied Corp. 2020 Incentive Plan (“Plan”) which authorized the issuance of options, restricted stock units or other equity compensation to its employees directors, and consultants.
On February 1, 2021, the Company granted 4,900,000 stock options to directors, officers and employees of the Company. The options expire five years after the grant date and 1,200,000 options are exercisable at $0.825 per share and 3,700,000 options are exercisable at $0.75 per share. The options vest one third on the grant date and one third on the first and second years after the grant date. The weighted average grant date fair value of stock options granted was $0.77 per share. During the year ended August 31, 2021, the Company recorded stock-based compensation of $2,666,077 on the consolidated statement of operations and comprehensive loss.
During the year ended August 31, 2023, the Company granted 6,140,000 stock options to directors, officers and employees of the Company. The options expire five years after the grant date and 6,000,000 options are exercisable at $0.24 per share and 140,000 options are exercisable at $0.20 per share. All options vested immediately on the grant date. The weighted average grant date fair value of stock options granted was $0.23 per share. During the year ended August 31, 2023, the Company recorded stock-based compensation of $3,047,156 on the consolidated statement of operations. In addition, the Company granted 1,000,000 warrants as finder’s fees to the Chief Business Development Officer. The warrants expire five years after the grant date and are exercisable at $0.20 per share.
In January 2023, the Company modified the exercise prices for previously granted and unexercised options. The options held by current consultants and ambassadors were repriced to $0.22 per share and the options held by current directors and officers were repriced to $0.25 per share. As a result, 4,900,000 unexercised options originally granted to purchase common stock at prices ranging from $0.75 to $0.825 per share were repriced. The repricing resulted in incremental stock-based compensation expense of $80,739. Expense related to vested shares was expensed on the repricing date and expense related to unvested shares will be amortized over the remaining vesting period.
On May 16, 2023, the Company modified the exercise price of the 6,000,000 options to $0.24 per share. The repricing resulted in incremental stock-based compensation expense of $14,506. Expense related to vested shares was expensed on the repricing date.
During the year ended August 31, 2024, the Company granted 500,000 stock options to employees. These options expire five years from the grant date and will fully vest by February 13, 2026. The weighted average fair value at the grant date was $0.09 per option. As of August 31, 2024, 150,000 of the options granted were exercisable at an exercise price of $0.06 per share. The Company recorded $500,627 in stock-based compensation expense for these options in the consolidated statement of operations and comprehensive loss during the year ended August 31, 2024.
Subsequently to year end and as part of the departure of the former CFO and a Director, the Company settled $127,782 and $87,000, respectively, outstanding payables to them through the exercise of options at an exercise price of $0.20 for a total of 638,912 and 435,000 shares issued to them.
On January 1, 2024, the Company modified the exercise price and vesting schedule of 300,000 unexercised options granted to a consultant. The original terms set the exercise price at $0.22, with vesting in three equal tranches on October 1, 2024, 2025, and 2026. The modification adjusted the exercise price to $0.20 and changed the vesting schedule to two equal tranches on January 1, 2024 and September 30, 2024. This remeasurement resulted in minimal incremental stock-based compensation expense. Additionally, the consultant is eligible for up to 500,000 performance-based options between January 1, 2024 and September 30, 2024, with a maximum of 100,000 options granted for each sales contract valued at $100,000. Pursuant to this agreement, the Company issued 200,000 options based on the value of sales contracts signed.
On October 1, 2024, the agreement was amended to allow for up to 700,000 performance-based options between October 1, 2024 and March 31, 2025. Additionally, for any contracts with an annual value exceeding $1,500,000, the consultant will be awarded 200,000 options. Options granted based on performance targets will vest over two years from the contract date.
All compensation and stock option plans for executives and employees will be governed by the Compensation and Governance Committee.
Expense Reimbursement
We will reimburse our officers and directors for reasonable expenses incurred during the course of their performance.
Retirement Plans and Benefits
None.
Director Compensation
We do not have a standard compensation arrangement for directors.
Indemnification and Limitation on Liability of Directors
The Nevada Revised Statutes allows indemnification of directors, officers, employees and agents of a company against liabilities incurred in any proceeding in which an individual is made a party because he or she was a director, officer, employee or agent of the Company if such person conducted himself in good faith and reasonably believed his actions were in, or not opposed to, the best interests of the Company, and with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. A person must be found to be entitled to indemnification under this statutory standard by procedures designed to assure that disinterested members of the board of directors have approved indemnification or that, absent the ability to obtain sufficient numbers of disinterested directors, independent counsel or shareholders have approved the indemnification based on a finding that the person has met the standard. Indemnification is limited to reasonable expenses.
We do not have indemnification provisions in our articles or bylaws.
Insofar as indemnification for liabilities arising under the 1933 Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the 1933 Act and is, therefore, unenforceable.
Outstanding Stock Options or other Equity Awards
The following table summarizes the stock options and warrants we have issued during the fiscal year ended August 31, 2024.
Name
Issuance Date
Expiration Date
Exercise Price per Share ($)
Number of Stock Options or Warrants Granted
Juba Abdellaoui (1)
January 28, 2024
October 1, 2028
$ 0.20
100,000
Juba Abdellaoui (1)
February 13, 2024
October 1, 2028
$ 0.20
100,000
Mark Moses
March 1, 2024
March 1, 2029
$ 0.06
300,000
(1) Options granted pursuant to performance conditions being met during the year.
The fair value of each option and warrant granted was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: a stock price of $0.09, risk-free rate of 4.07%, no expected dividends or forfeiture rate, volatility of 178% and an expected life of 4.90 years.

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The following table sets forth as of August 31, 2024 the number of shares of common stock beneficially owned by (i) those persons or groups known to beneficially own more than 10% of the Company’s common stock, (ii) each current director and executive officer of the Company, and (iii) all the current executive officers and directors as a group.
Pursuant to Rule 13d-3 under the Exchange Act, a beneficial owner of securities is a person who directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has, or shares, voting power and/or investment power with respect to the securities, and any person who has the right to acquire beneficial ownership of the security within 60 days through any means, including the exercise of any option, warrant or right or the conversion of a security. Any shares that are not outstanding that a person has the right to acquire are deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of such person, but are not deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of any other person.
Title of Class
Name of Beneficial Owner
Amount of Beneficial Ownership (1)
Percentage
Common Stock
Calum Hughes, Chief Executive Officer and Director
18,135,430
14.3 %
Common Stock
Michael Moses, Chief Business Development Officer (2)
3,932,155
3.1 %
Common Stock
Paul Bullock, Chief Operating Officer and Director (3)
10,181,596
8.1 %
Common Stock
Jim Smeeding, Director (4)
1,079,081
0.8 %
Common Stock
Abdul Musoke Nnyenje, Director (5)
918,750
2.5 %
____________
(1)
Calculated pursuant to Rule 13d-3 under the Exchange Act, a beneficial owner of securities is a person who directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has, or shares, voting power and/or investment power with respect to the securities, and any person who has the right to acquire beneficial ownership of the security within 60 days through any means, including the exercise of any option, warrant or right or the conversion of a security. Any shares that are not outstanding that a person has the right to acquire are deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of such person, but are not deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of any other person. All of the foregoing shares are legally held of record by SECFAC Exchange Corp., which has an agreement with the shareholders to exchange shares of SECFAC Exchange Corp. for Allied Corp. shares on a one for one basis at the request of any such shareholder.
(2)
Mr. Moses holds 2,932,155 shares and an additional 1,000,000 shares pursuant to options.
(3)
All shares are held through Oceanus Consulting Ltd and 0994091 BC Ltd. Mr. Paul James Bullock is the principal of Oceanus Contracting Ltd. and 09940901 BC Ltd., and consequently may be deemed to be the beneficial owner of shares held by such entities.
(4)
Mr. Smeeding holds 740,000 shares pursuant to options and an additional 339,081 shares are held by Edjudicate LLC, a company beneficially owned by Mr. Smeeding.
(5)
Mr. Nnyenje holds 918,750 shares pursuant to options.
Holders of Common Stock
As of August 31, 2024, there were approximately 156 record holders of our common stock. This does not include the holders of our common stock who held their shares in street name as of that date.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Item 13. Certain Relationships and Related Transactions and Director Independence.
All transactions with related parties have occurred in the normal course of operations and are recorded at the exchange amount which is the amount agreed to by the Company and the related party.
Key management compensation and related party transactions
The Company has identified its directors and certain senior officers as its key management personnel. The compensation costs for key management personnel during the nine months ended were as follows:
August 31,
August 31,
Consulting fees and benefits
$ 519,550
$ 396,052
Amounts due to/from related parties
In the normal course of operations, the Company shares certain administrative resources with companies related by common management and directors. The administrative resources and services, which were provided in the normal course of operations, were measured at the exchange. All amounts payable and receivable are noninterest bearing, unsecured and due on demand. The following table summarizes the amounts were due from related parties:
August 31,
August 31,
Trade payables to the CEO
$ 17,428
$ 156,028
Trade payables to the COO
4,371
201,612
Trade payables to the former CFO
129,309
84,962
Trade payable to the CBDO
7,718
-
Trade payable to a director
-
159,690
Trade payable to a former director
194,687
91,000
Outstanding short-term loan from the CBDO
20,600
-
Outstanding short-term loan from a director
80,000
-
$ 454,113
$ 693,292
As of August 31, 2024, the Company had $454,113 (August 31, 2023 - $693,292) payable to related parties for fees or expenses incurred or expensed paid on behalf of the Company by the parties which has been presented in accounts payable and accrued liabilities.
Director Independence
The Company is not currently listed on any national exchange, or quoted on any inter-dealer quotation service, that imposes independence requirements on any committee of the Company’s directors, such as an audit, nominating or compensation committee. The Company currently does not currently have any independent directors on its Board.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
Item 14. Principal Accountant Fees and Services.
Audit Fees
The aggregate fees billed for the fiscal year ended August 31, 2024, for professional services rendered by the principal accountants for the audit of the registrant's annual financial statements and review of financial statements included in the registrant's Form 10-K or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements were: $100,000.
Audit-Related Fees
$nil was billed in the fiscal year ended August 31, 2024 for assurance and related services by the principal accountant that are reasonably related to the performance of the audit or review of the registrant's financial statements.
Tax Fees
$nil was billed for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning for the year ended August 31, 2024.
All Other Fees
Other than the services reported above, no other fees billed for professional services provided by the principal accountant.
Audit Committee Pre-Approval Policies
Our Board of Directors performing as the Audit Committee by their Chair has approved the principal accountant’s performance of services for the audit of the registrant’s annual financial statements and review of financial statements included in our Report on Form 10-K or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the fiscal year ending August 31, 2024. Audit-related fees, tax fees, and all other fees, if any, were approved by the Board of Directors.
PART IV

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Item 15. Exhibits and Financial Statement Schedules.
The following exhibits are filed as part of this Annual Report.
Exhibit
Description
3.1
Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1(i) of the Company’s Registration Statement filing on Form S-1 filed with the Securities and Exchange Commission on May 28, 2013)
3.2
Bylaws of Registrant (incorporated by reference to Exhibit 3.1(ii) of the Company’s Registration Statement filing on Form S-1 filed with the Securities and Exchange Commission on May 28, 2013)
3.3
Certificate of Amendment of Articles of Incorporation dated July 1, 2019 (incorporated by reference to Exhibit 3.3 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
3.4
Form of Underwriter Warrant (incorporated by reference to Exhibit 3.1 of the Company’s Offering Statement filing on Form 1-A filed with the Securities and Exchange Commission on June 11, 2021)
10.1
Reorganization Agreement among Allied Corp., Pacific Capital Investment Group, Inc., SECFAC Exchange Corp., AM (Advanced Micro) Biosciences, Inc. and shareholders of AM (Advanced Micro) Biosciences, Inc. Dated as of July 25, 2019 and as amended effective August 27, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s Registration Statement filing on Form 8-K filed with the Securities and Exchange Commission on September 10, 2019)
10.2
Assumption of contract of purchase and sale of 8999 Jim Bailey Rd. between the Company and 1185710 B.C. Ltd. Dated November 6, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.3
Share Purchase Agreement between AM (Advanced Micro) Biosciences, Inc. and Maryls Wolfe and Grant Wolfe dated May 24, 2019. (incorporated by reference to Exhibit 10.3 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.4
Escrow Agreement between AM (Advanced Micro) Biosciences, Inc., and Maryls Wolfe dated May 31, 2019 (incorporated by reference to Exhibit 10.4 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.5
Xtreme Cubes - Purchase Proposal dated May 14, 2019 (incorporated by reference to Exhibit 10.5 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.6
Vitalis Extraction Technology Sales Order dated August 30, 2019 (incorporated by reference to Exhibit 10.6 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.7
Purchase Agreement between AM (Advanced Micro) Biosciences, Inc. and 1150641 BC Ltd., doing business as Activated Nano, dated May 22, 2019 (incorporated by reference to Exhibit 10.7 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.8
Asset Purchase Agreement between AM (Advanced Micro) Biosciences, Inc. and Clifford Wade Lackie and Robin Dale Lackie for Bud’s Naturals dated February 13, 2019 (incorporated by reference to Exhibit 10.8 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.9
Consulting Agreement between AM (Advanced Micro) Biosciences, Inc. and John Saric dated May 31, 2019 (incorporated by reference to Exhibit 10.9 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2019)
10.10
Convertible Promissory Note issued to CA Indosuez (Switzerland) S.A. January 23, 2020 (incorporated by reference to Exhibit 10.10 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.11
Series A Warrant issued to CA Indosuez (Switzerland) S.A. January 23, 2020 (incorporated by reference to Exhibit 10.11 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020).
10.12
Security Agreement dated as of January 23, 2020 between the Company and CA Indosuez (Switzerland) S.A. (incorporated by reference to Exhibit 10.12 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.13
Convertible Promissory Note issued to Parkward Holding Ltd. January 23, 2020 (incorporated by reference to Exhibit 10.13 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16., 2020)
10.14
Series A Warrant issued to Parkward Holding Ltd. January 23, 2020 (incorporated by reference to Exhibit 10.14 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.15
Security Agreement dated as of January 23, 2020 between the Company and Parkward Holding Ltd. (incorporated by reference to Exhibit 10.15 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.16
Convertible Promissory Note issued to Allied Special Opportunities Limited February 25, 2020 (incorporated by reference to Exhibit 10.16 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.17
Series A Warrant issued to Allied Special Opportunities Limited February 25, 2020 (incorporated by reference to Exhibit 10.17 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.18
Security Agreement dated as of January 23, 2020 between the Company and Allied Special Opportunities Lit.. (incorporated by reference to Exhibit 10.18 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.19
Loan and Security Agreement dated May 14, 2020 between the Company and SLCI1, LLC. (incorporated by reference to Exhibit 10.19 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.20
Promissory Note issued May 14, 2020 from the Company to SLCI1, LLC. (incorporated by reference to Exhibit 10.20 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.21
2020 Long term Incentive Plan (incorporated by reference to Exhibit 10.21 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.22
Share Purchase Agreement between Dorson Commercial Corp. and AD (Advanced Micro) Biosciences, Inc. dated August 29, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.23
License for Medicolombia Cannabis A.S. from Republic of Columbia, Ministry of Justice and Law, dated August 3, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.24
License for Medicolombia Cannabis A.S. from Republic of Columbia, Ministry of Health and Social Protection, dated December 4, 2018 (incorporated by reference to Exhibit 10.3 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.25
License for Medicolombia Cannabis A.S. from Republic of Columbia, Ministry of Justice and Law, dated July 31, 2019 (incorporated by reference to Exhibit 10.4 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.26
License for Medicolombia Cannabis A.S. from Republic of Columbia, Ministry of Justice and Law, dated February 20, 2019 (incorporated by reference to Exhibit 10.5 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.27
License for Medicolombia Cannabis A.S. from Republic of Columbia, Ministry of Health and Social Protection, dated November 29, 2019 (incorporated by reference to Exhibit 10.6 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.28
License for Medicolombia Cannabis A.S. from Republic of Columbia, Minagricultura dated May 05, 2019 (incorporated by reference to Exhibit 10.7 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.29
License for Medicolombia Cannabis A.S. from Republic of Columbia, National Narcotics Fund U.A.E., Ministry of Health and Social Protection dated January 13, 2020 (incorporated by reference to Exhibit 10.8 of the Company’s Report filing on Form 8-K filed with the Securities and Exchange Commission on October 7, 2020)
10.30
Settlement and Release Agreement between the Company and Anthony Zelen dated September 17, 2020 (incorporated by reference to Exhibit 10.29 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.31
Settlement and Release Agreement between the Company and David Weinkauf dated September 21, 2020 (incorporated by reference to Exhibit 10.30 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.32
Settlement and Release Agreement between the Company and Malcolm Davidson dated September 16, 2020 (incorporated by reference to Exhibit 10.31 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.33
Convertible Promissory Note issued to Sawasawa Inc. September 30, 2020 (incorporated by reference to Exhibit 10.32 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.34
Convertible Promissory Note issued to Sawasawa Inc. November 7, 2020 (incorporated by reference to Exhibit 10.33 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.35
Convertible Promissory Note issued to Sawasawa, Inc. November 30, 2020 (incorporated by reference to Exhibit 10.34 of the Company’s Report filing on Form 10-K filed with the Securities and Exchange Commission on December 16, 2020)
10.36
Placement Agent Agreement between the Company and Boustead Securities, LLC dated as of May 7, 2021 (incorporated by reference to Exhibit 1.1 of the Company’s filing on Form 1-A filed with the Securities and Exchange Commission on August 23, 2021)
10.37
Amendment No. 1 to Placement Agent Agreement between the Company and Boustead Securities, LLC dated as of August 17, 2021 (incorporated by reference to Exhibit 1.2 of the Company’s filing on Form 1-A filed with the Securities and Exchange Commission on August 23, 2021)
10.38
Convertible Promissory Note issued to Stephen Moses on March 26, 2021 (incorporated by reference to Exhibit 10.36 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.39
Convertible Promissory Note issued to Tulip Enterprises LLC on March 26, 2021 (incorporated by reference to Exhibit 10.37 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.40
Convertible Promissory Note issued to Tulip Enterprises LLC on April 21, 2021 (incorporated by reference to Exhibit 10.38 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.41
Convertible Promissory Note issued to Stephen Moses on April 30, 2021 (incorporated by reference to Exhibit 10.39 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.42
Convertible Promissory Note issued to Tulip Enterprises LLC on July 25, 2021 (incorporated by reference to Exhibit 10.40 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.43
Convertible Promissory Note issued to Stephen Moses on July 25, 2021 (incorporated by reference to Exhibit 10.41 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.44
Convertible Promissory Note issued to Tulip Enterprises LLC on October 1, 2021 (incorporated by reference to Exhibit 10.42 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.45
Convertible Promissory Note issued to Tulip Enterprises LLC on October 25, 2021 (incorporated by reference to Exhibit 10.43 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.46
Convertible Promissory Note issued to Tulip Enterprises LLC on December 23, 2021 (incorporated by reference to Exhibit 10.44 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.47
Convertible Promissory Note issued to Stephen Moses on December 23, 2021 (incorporated by reference to Exhibit 10.45 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.48
Convertible Promissory Note issued to Tulip Enterprises LLC on January 11, 2022 (incorporated by reference to Exhibit 10.46 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.49
Convertible Promissory Note issued to Tulip Enterprises LLC on January 31, 2022 (incorporated by reference to Exhibit 10.47 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.50
Convertible Promissory Note issued to 0994091 BC Ltd. on March 29, 2022 (incorporated by reference to Exhibit 10.48 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.51
Convertible Promissory Note issued to Mulsane Ltd. on June 16, 2022 (incorporated by reference to Exhibit 10.49 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.52
Form of Amendment for all outstanding convertible promissory notes September 30, 2022 (incorporated by reference to Exhibit 10.50 of the Company’s filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2022).
10.53
SOL NDA Forward Purchase Agreement dated February 8, 2023. (incorporated by reference to Exhibit 10.1 of the Company’s filing on Form 8-K filed with the Securities and Exchange Commission on December 5, 2023)
10.54
Australian Cannabis Group Forward Purchase Agreement dated May 30, 2023. (incorporated by reference to Exhibit 10.3 of the Company’s filing on Form 8-K filed with the Securities and Exchange Commission on December 5, 2023)
10.55
One Life Labs Pty Ldt Forward Purchase Agreement dated November 13, 2023. (incorporated by reference to Exhibit 10.2 of the Company’s filing on Form 8-K filed with the Securities and Exchange Commission on December 5, 2023)
10.56
Term Sheet for Contract Manufacturing Services with Blossom Genetics Unipessoal Lda dated October 27, 2023. (incorporated by reference to Exhibit 10.1 of the Company’s filing on Form 8-K filed with the Securities and Exchange Commission on December 5, 2023)
10.57
Interim Operating Agreement dated September 1, 2023 (incorporated by reference to Exhibit 10.51 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.58
Consulting Agreement with Michael Moses (incorporated by reference to Exhibit 10.52 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.59
Certification by Calum Hughes (incorporated by reference to Exhibit 31.1 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.60
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 31.2 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.61
Certification by Calum Hughes (incorporated by reference to Exhibit 32.1 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.62
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 32.2 of the Company's filing on Form 10-K filed with the Securities and Exchange Commission on December 14, 2023)
10.63
Certification by Calum Hughes (incorporated by reference to Exhibit 31.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on January 16, 2024)
10.64
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 31.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on January 16, 2024)
10.65
Certification by Calum Hughes (incorporated by reference to Exhibit 32.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on January 16, 2024)
10.66
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 32.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on January 16, 2024)
10.67
Notification of Late Filing (incorporated by reference to Company's filing on Form NT 10-Q with the Securities and Exchange Commission on April 15, 2024)
10.68
Certification by Calum Hughes (incorporated by reference to Exhibit 31.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on April 19, 2024)
10.69
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 31.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on April 19, 2024)
10.70
Certification by Calum Hughes (incorporated by reference to Exhibit 32.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on April 19, 2024)
10.71
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 32.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on April 19, 2024)
10.72
Press Release dated May 29, 2024 (incorporated by reference to Exhibit 99.1 of the Company's filing on Form 8-K with the Securities and Exchange Commission on July 1, 2024)
10.73
Notification of Late Filing (incorporated by reference to Company's filing on Form NT 10-Q with the Securities and Exchange Commission on July 16, 2024)
10.74
Certification by Calum Hughes (incorporated by reference to Exhibit 31.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on July 18, 2024)
10.75
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 31.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on July 18, 2024)
10.76
Certification by Calum Hughes (incorporated by reference to Exhibit 32.1 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on July 18, 2024)
10.77
Certification by Ryan Maarschalk (incorporated by reference to Exhibit 32.2 of the Company's filing on Form 10-Q filed with the Securities and Exchange Commission on July 18, 2024)
10.78
Notice of Exempt Offering of Securities (incorporated by reference to Company's filing on Form D with the Securities and Exchange Commission on August 8, 2024)
10.79
Amendment on Notice of Exempt Offering of Securities (incorporated by reference to Company's filing on Form D with the Securities and Exchange Commission on August 9, 2024)
10.80
Press Release dated September 24, 2024 (incorporated by reference to Exhibit 99.1 of the Company's filing on Form 8-K with the Securities and Exchange Commission on September 24, 2024)
10.81
CanPoland Spółka Akcyjna Forward Purchase Agreement dated September 26, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s filing on Form 8-K filed with the Securities and Exchange Commission on October 15, 2024)
10.82
Press Release dated November 18, 2024 (incorporated by reference to Exhibit 99.1 of the Company's filing on Form 8-K with the Securities and Exchange Commission on November 18, 2024)
10.83
Notification of Late Filing (incorporated by reference of the Company's filing on Form 10-K with the Securities and Exchange Commission on November 29, 2024)
List of Subsidiaries.
31.1
Certification of Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
31.2
Certification of Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
32.1
Certification of Chief Executive Officer pursuant to Section 1350
32.2
Certification of Chief Financial Officer pursuant to Section 1350